<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J. Med. Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7489051</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.0c00626</article-id><article-categories><subj-group><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Chinese Therapeutic Strategy for Fighting COVID-19 and Potential
Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2)</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Choudhry</surname><given-names>Namrta</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes1" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Zhao</surname><given-names>Xin</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes1" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Xu</surname><given-names>Dan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Zanin</surname><given-names>Mark</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath5"><name><surname>Chen</surname><given-names>Weisan</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath6"><name><surname>Yang</surname><given-names>Zifeng</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath7"><name><surname>Chen</surname><given-names>Jianxin</given-names></name><xref rid="cor3" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Guangdong Provincial Key Laboratory of
Veterinary Pharmaceutics Development and Safety Evaluation, Guangdong
Laboratory for Lingnan Modern Agriculture, College of Veterinary
Medicine, <institution>South China Agricultural
University</institution>, Guangzhou 510642,
<country>China</country></aff><aff id="aff2"><label>&#x02021;</label><institution>Guangdong Institute of
Analysis (China National Analytical Center,
Guangzhou)</institution>, Guangzhou 510070,
<country>China</country></aff><aff id="aff3"><label>&#x000a7;</label>State Key Laboratory of Respiratory
Disease, National Clinical Research Center for Respiratory Disease,
Guangzhou Institute of Respiratory Health, <institution>First
Affiliated Hospital of Guangzhou Medical
University</institution>, Guangzhou 510120,
<country>China</country></aff><aff id="aff4"><label>&#x02225;</label>Department of Biochemistry and
Genetics, La Trobe Institute for Molecular Science, <institution>La
Trobe University</institution>, Melbourne, Victoria 3086,
<country>Australia</country></aff><aff id="aff5"><label>&#x022a5;</label>School of Public Health,
<institution>The University of Hong Kong</institution>, 7
Sassoon Road, Pokfulam, Hong Kong, SAR, <country>China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>W.C.: email,
<email>Weisan.Chen@latrobe.edu.au</email>.</corresp><corresp id="cor2"><label>*</label>Z.Y.: email,
<email>jeffyah@163.com</email>.</corresp><corresp id="cor3"><label>*</label>J.C.: email,
<email>jxchen@scau.edu.cn</email>.</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>08</month><year>2020</year></pub-date><elocation-id>acs.jmedchem.0c00626</elocation-id><history><date date-type="received"><day>16</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 American Chemical Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for
unrestricted RESEARCH re-use and analyses in any form or by any
means with acknowledgement of the original source. These
permissions are granted for the duration of the World Health
Organization (WHO) declaration of COVID-19 as a global
pandemic.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0008" id="ab-tgr1"/></p><p>The coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more
than 20 million people infected worldwide with an average
mortality rate of 3.6%. This virus poses major challenges to
public health, as it not only is highly contagious but also can
be transmitted by asymptomatic infected individuals. COVID-19 is
clinically difficult to manage due to a lack of specific
antiviral drugs or vaccines. In this article, Chinese therapy
strategies for treating COVID-19 patients, including current
applications of traditional Chinese medicine (TCM), are
comprehensively reviewed. Furthermore, 72 small molecules from
natural products and TCM with reported antiviral activity
against human coronaviruses (CoVs) are identified from published
literature, and their potential applications in combating
SARS-CoV-2 are discussed. Among these, the clinical efficacies
of some accessible drugs such as remdesivir (RDV) and
favipiravir (FPV) for COVID-19 are emphatically summarized. We
hope this review provides a foundation for managing the
worsening pandemic and developing antivirals against
SARS-CoV-2.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm0c00626</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm0c00626</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><sec id="sec1.1"><label>1.1</label><title>CoVs and Types</title><p>Coronaviruses (CoVs) represent a group of enveloped, positive-sense,
single-stranded RNA viruses with a genome size of 27&#x02013;33 kb.
They can cause diseases of the respiratory tract, intestinal tract,
liver, and nervous system of many animal species, including humans,
with varying degrees of severity.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup><italic>Coronaviridae</italic> in the order
<italic>Nidovirales</italic> is divided into four genera:
&#x003b1;-, &#x003b2;-, &#x003b3;-, and &#x003b4;-CoVs, of which only &#x003b1;-
and &#x003b2;-CoVs can infect humans. There are seven known types of
human CoVs. Four human CoVs are known to be prevalent: HCoV-229E,
HCoV-OC43, HCoV-HKU1, and HCoV-NL63, which are common and cause mild
to moderate respiratory infections, such as the common cold.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Two other &#x003b2;-CoVs, severe acute respiratory
syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV
(MERS-CoV), have zoonotic origins and have been linked to fatal
illness in past years.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> SARS-CoV was the causal
agent of SARS outbreaks in 2002 and 2003 in
China.<sup><xref ref-type="bibr" rid="ref3">3</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> The SARS outbreak was contained in 2004
following a highly effective public health response, with 8454
confirmed cases and 792 deaths.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> In 2012, Middle
East respiratory syndrome (MERS), caused by MERS-CoV, emerged in the
Kingdom of Saudi Arabia and subsequently spread to 27
countries.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> MERS presented as a severe
respiratory disease with frequent gastrointestinal and renal
complications. As of September 12, 2017, 2080 confirmed cases and 722
deaths have been reported.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> The seventh human CoV,
termed SARS-CoV-2, is a novel &#x003b2;-CoV that first emerged in Wuhan
city, Hubei Province, China.</p></sec><sec id="sec1.2"><label>1.2</label><title>The COVID-19 Pandemic</title><p>In December 2019, pneumonia cases caused by a novel pathogen emerged in
Wuhan, a city of 11 million people in Central China. The pathogen was
soon identified as the novel CoV SARS-CoV-2, which is closely related
to SARS-CoV.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Recently, Dorp et al. estimated that
the initial timing of human infection with SARS-CoV-2 may have been in
early December or even earlier in 2019 by analyzing the emergence of
genomic diversity of SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> However, the
native host(s) of SARS-CoV-2 and the place of origin of human
SARS-CoV-2 infections remain uncertain, even though Wuhan was the
first city in which this disease was detected and managed. As of March
30, 2020, COVID-19 has led to over 80&#x0202f;000 confirmed cases with
over 3000 deaths in China. Due to strict quarantines throughout China,
new cases have sharply decreased since mid-March, and the outbreak was
successfully contained in China. Unfortunately, as of August 14, 2020,
this virus has now spread to over 200 other countries and areas
worldwide and led to over 20 million people infected and over
750&#x0202f;000 deaths.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Currently, there are no
vaccines or drugs available.</p></sec></sec><sec id="sec2"><label>2</label><title>Chinese Therapeutic Strategy and the Application of TCMs as Treatments for
COVID-19</title><p>Developing a vaccine for a new pathogen needs at least 18 months, and thus,
vaccinations are unlikely to control emergent epidemics. Developing novel
drugs against this virus could take a longer time than developing a vaccine.
However, since SARS-CoV-2 shares high similarity in gene sequence and
pathogenic mechanism with previous human pathogenic CoVs, especially
SARS-CoV (82% sequence identity),<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> existing therapeutic strategies for
combating SARS might be effective for managing COVID-19. In
2002&#x02013;2003, the SARS outbreak first started in South China and
subsequently spread to 31 countries worldwide. Patients in mainland China
accounted for over 60% of the total cases. Interestingly, the average death
rate in mainland China (approximately 6.5%) was lower than the worldwide
average death rate (9.3%). The higher cure rate in China for SARS infections
was attributed to combining traditional Chinese medicine (TCM) with Western
medicine in China.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Since the outbreak of COVID-19 in
early January 2020, some therapeutic strategies for SARS, including the
application of TCM, have been repurposed for combating COVID-19 in
China.</p><sec id="sec2.1"><label>2.1</label><title>Chinese Therapeutic Strategy</title><p>On January 20, 2020, the National Health Commission (NHC) of China issued
the first edition of the Guidelines for the Diagnosis and Treatment of
COVID-19. Subsequently, these guidelines have been frequently revised,
and the seventh version was released on March 4, 2020. In the seventh
edition of the Guidelines for the Diagnosis and Treatment of COVID-19,
COVID-19 patients are classified into four groups based on the
severity of illness: mild, moderate, severe, and critical, and the
therapeutic regimen varies according to this classification (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> Among the recommended antiviral drugs, interferon &#x003b1;
(IFN-&#x003b1;) represents one of the broad-spectrum antiviral
interferons extensively and clinically used to induce the host innate
immune response. Lopinavir&#x02013;ritonavir, the anti-human
immunodeficiency virus (HIV) combination drugs, was shown to be
beneficial for MERS-CoV infections,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> while its
effect on COVID-19 is currently being assessed in clinical trials
along with umifenovir (also named Arbidol) and ribavirin. Chloroquine
(CQ), a widely used antimalarial and immunomodulatory drug, showed
<italic>in vitro</italic> activity against SARS-CoV-2 at low
micromolar concentrations.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> These findings led to
15 clinical trials of CQ or hydroxychloroquine (HCQ) in China to test
their efficacy and safety for COVID-19 patients. Results from more
than 100 patients so far have demonstrated reduced hospital stays and
improved the progression of COVID-19 pneumonia after CQ phosphate
treatment with no severe adverse reactions.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Given
these findings, CQ phosphate was included in the seventh edition of
the Guidelines for the Diagnosis and Treatment of COVID-19.</p><p>It has been thought that deaths induced by SARS-CoV-2 infection are due
to vigorous systemic inflammation caused by &#x0201c;cytokine
storms&#x0201d;, driven by proinflammatory cytokines such as tumor
necrosis factor-&#x003b1; (TNF-&#x003b1;), interleukin-1 (IL-1),
interleukin-6 (IL-6), and interferon &#x003b3; (IFN-&#x003b3;), similar to
those induced by SARS-CoV and highly pathogenic influenza A virus
(IAV) infections.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Tocilizumab, a monoclonal
antibody with interleukin 6 (IL-6)-neutralizing activity, has been
used to clinically treat rheumatoid arthritis. In a recent initial
clinical trial, tocilizumab was used in 21 severe COVID-19 cases. The
results showed that all patients had resolution of fever within 24 h,
with reported relief of clinical symptoms. All 21 patients were
discharged from the hospital within 2 weeks, although two were
readmitted to the hospital by the end of follow-up.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Glucocorticoids were extensively used to treat SARS patients in
2002&#x02013;2003 due to their significant suppression of exaggerated
systemic inflammation induced by SARS-CoV infections. However,
high-dose therapy with glucocorticoids could cause severe side effects
to SARS patients, including immunosuppression, delayed virus
clearance, and osteoporosis.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> In the Guidelines
for the Diagnosis and Treatment of COVID-19, glucocorticoid
methylprednisolone was prudently recommended to treat severe patients
at a low dose (&#x02264;1&#x02013;2 mg kg<sup>&#x02013;1</sup>
day<sup>&#x02013;1</sup>).</p></sec><sec id="sec2.2"><label>2.2</label><title>Application of TCMs in the Treatment of COVID-19</title><p>TCMs have been used for thousands of years to treat pandemic and endemic
diseases, and there is evidence of efficacy against SARS-CoV reported
in 2002&#x02013;2003,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> including marked improvement
of symptoms, shortened disease course, reduced side effects caused by
conventional therapeutics, and dramatically reduced
fatality.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Taking into account the
similarities between SARS-CoV-2 and SARS-CoV in epidemiology and
genomics, TCM is expected to have therapeutic value for
SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> Since the fourth edition of
the Guidelines for the Diagnosis and Treatment of COVID-19, different
TCMs have been recommended for the treatment of COVID-19.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> In the seventh edition of the Guidelines for the
Diagnosis and Treatment of COVID-19, 15 commercially available
proprietary Chinese medicines (formulas) and 10 TCM decoction
prescriptions were recommended for patients in different phases of the
disease and stages, including medical observation period, clinical
treatment period, and recovery period, as shown in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c00626/suppl_file/jm0c00626_si_001.pdf">Supplementary Table 1</ext-link>. As of March 23, 2020, 392
clinical trials aimed at evaluating the efficacy and safety of various
treatments for COVID-19 patients had been launched in China. Among
them, 78 trials (19.9%) utilized TCMs, including 21 (5.3%) examining
the effects of the combined treatment of TCM and Western
medicine.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> A total of 92% of COVID-19
patients in China received TCM treatment, with a total effective rate
of 90%.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Among the recommended TCM formulas and
prescriptions, three formulas, including Jinhua Qinggan granule
(JHQGG), Lianhua Qingwen capsule (LHQWC), and Xue Bi Jing injection
(XBJI), and three prescriptions, including Qingfei Paidu Tang (QFPDT),
Xuanfei Baidu Tang (XFBDT), and Huashi Baidu Tang (HSBDT) (shown in
<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>), were widely
used in the treatment of COVID-19 patients due to their significant
clinical efficacy. JHQGG and LHQWC were recommended to treat mild and
moderate COVID-19 patients. A comparative clinical trial showed that
among the recruited 80 COVID-19 patients, the average duration of
viral nucleic acid detection was 7 (&#x000b1;4) days in the JHQGG
administration group (44 patients) and 10 (&#x000b1;4) days in the
control group (36 patients).<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> In February 2020, Hu
and collaborators performed a prospective multicenter open-label
randomized controlled trial to determine the safety and efficacy of
LHQWC in COVID-19 patients. A total of 284 patients were randomized to
receive standard treatment alone or in combination with LHQWC (142
patients in each group) for 14 days. The results indicated that the
symptom (fever, fatigue, and coughing) recovery rate was significantly
higher in the combined treatment group than in the control group
(91.5% vs 82.4%), and no serious adverse events were reported.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> QFPDT, consisting of 21 components that included
both herbs and mineral drugs, was recommended as a basic prescription
for treating mild to severe cases of COVID-19. A clinical survey
evaluating the effect of QFPDT showed that among the 1263 recruited
COVID-19 patients from 66 hospitals in 10 cities in China, 1214
patients were cured and discharged, and none of the patients with mild
and moderate disease progressed to the severe stage. Among these
patients, out of the 49 severe patients who were treated with both
QFPDT and Western medicine, 42 were cured.<sup><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup></p><p>Unlike chemical drugs, which generally function on defined targets with
clearly understood mechanisms of action, TCM prescriptions consist of
multiple herbs with multiple targets. Recently, Yang and colleagues
comprehensively analyzed the chemical constituents of QFPDT using
liquid chromatography coupled with high-resolution mass spectrometry
(HRMS). A total of 129 compounds were identified or tentatively
characterized from QFPDT, including 58 flavonoids, 20 glycosides, 13
carboxylic acids, 7 saponins, 6 alkaloids, and 4 terpenes. <italic>In
silico</italic> approaches such as network pharmacology and
molecular networking revealed multiple constituents, such as
glycyrrhizic acid (glycyrrhizin, GL), saikosaponins (SSs),
scutellarein, and betulonic acid. Various compounds from different
herbs in QFPDT may interfere with the disease process of COVID-19
through multiple signaling pathways, such as Toll-like receptor
activation and IFN response induced by viral infection, thereby
reducing the secretion of inflammatory cytokines and inhibiting viral
replication to protect patients.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p><p>TCM was established on a different theoretical system than Western
medicine, emphasizing diagnosis and treatment based on the
patient&#x02019;s overall condition rather than targeting specific
etiologies or pathologies. Therefore, the prescription principle of
TCM treatment on COVID-19 includes strengthening body resistance and
eliminating pathogenic factors (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Most of the herbal medicines
included in the Guidelines for the Diagnosis and Treatment of COVID-19
fall into three categories: drugs for clearing heat and resolving
dampness plus detoxification, drugs for promoting blood circulation,
and drugs for enhancing host antiviral immune responses. For example,
in the QFPDT prescription, <italic>Gypsum Fibrosum</italic> and
<italic>Scutellaria Radix</italic> clear heat, and <italic>Citri
reticulatae pericarpium</italic> and <italic>Pogostemonis
herba</italic> clear dampness and detoxify; <italic>Ephedrae
herba, Cinnamomi ramulus</italic> and <italic>Zingiberis
rhizome</italic> promote blood circulation; <italic>Glycyrrhizae
radix, Polyporus, Atractylodis macrocephalae rhizoma</italic>,
and <italic>Poria</italic> enhance host antiviral immune
responses.<sup><xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup> Given that TCM theory has
widely appreciated clinical effects, it has been promoted by the
Chinese government in its campaign against SARS-CoV-2. The Health
Commissions in 26 provinces officially recommended TCM in combination
with Western medicine in the treatment of COVID-19.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Clinical Classification of COVID-19 Patients and the
Corresponding Therapeutic Regimen According to the Seventh
Edition of the Guidelines for the Diagnosis and Treatment
of COVID-19 Issued by the NHC of China<sup><xref ref-type="bibr" rid="ref14">14</xref></sup>,<xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">clinical&#x000a0;classification</th><th style="border:none;" align="center">criteria&#x000a0;for&#x000a0;classification</th><th style="border:none;" align="center">therapeutic&#x000a0;regimen</th></tr></thead><tbody><tr><td style="border:none;" align="center">Mild</td><td style="border:none;" align="left">Nonspecific clinical symptoms and no
manifestation of pneumonia based on medical
imaging.</td><td style="border:none;" align="left"><bold>General treatment:</bold></td></tr><tr><td style="border:none;" align="center">Moderate</td><td style="border:none;" align="left">Fever and respiratory tract symptoms, and
manifestation of pneumonia based on medical
imaging.</td><td style="border:none;" align="left">(1)&#x000a0;Stay&#x000a0;in&#x000a0;bed&#x000a0;to&#x000a0;rest,&#x000a0;strengthen&#x000a0;supportive&#x000a0;treatment,&#x000a0;keep&#x000a0;a
balanced diet and maintain the balance of water
and electrolytes.</td></tr><tr><td rowspan="6" style="border:none;" align="center" valign="middle">Severe</td><td style="border:none;" align="left">At least one of the following symptoms in
adults:</td><td style="border:none;" align="left">(2) Effective oxygen therapies, including
nasal catheter oxygen inhalation, oxygen
inhalation with a mask or high-flow nasal cannula
with a hydrogen and oxygen mixture
(H<sub>2</sub>/O<sub>2</sub>) of 66.6%/33.3%, if
possible.</td></tr><tr><td style="border:none;" align="left">(1) Respiratory distress, respiration rate
(RR) &#x0003e; 30/min;</td><td style="border:none;" align="left">(3) Antiviral therapies: IFN-&#x003b1;
nebulization (5 &#x000d7; 10<sup>6</sup> units or
equivalent per time, add 2 mL of sterile water,
aerosol inhalation, BID); lopinavir/ritonavir (200
mg/50 mg per capsule, 2 capsules each time, BID);
ribavirin (500 mg by venoclysis per time, BID,
combination treatment with IFN-&#x003b1; or
lopinavir/ritonavir are recommended); CQ phosphate
(500 mg per time, BID), Arbidol (200 mg per time,
TID). The above dosages are suitable only for
adults, and the course of treatment with above
antivirals should be &#x02264;10 days. Monitor side
effects such as diarrhea, nausea, vomiting, and
liver damage related to lopinavir/ritonavir as
well as harmful interactions with other drugs.
Simultaneous use of three or more types of
antiviral drugs is not recommended, and relevant
drug treatments should be stopped if unbearable
side effects occur.</td></tr><tr><td style="border:none;" align="left">(2) Pulse oxygen saturation
(SpO<sub>2</sub>) of &#x02264;93% at resting
state;</td><td style="border:none;" align="left">(4) Traditional Chinese medicine (TCM)
treatments, shown in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>.</td></tr><tr><td style="border:none;" align="left">(3) Arterial partial pressure of oxygen
(PaO<sub>2</sub>)/oxygen concentration
(FiO<sub>2</sub>) of &#x02264;300 mmHg.</td><td style="border:none;" align="left"><bold>Treatment of severe and critical
cases:</bold></td></tr><tr><td style="border:none;" align="left">For&#x000a0;high&#x000a0;altitude&#x000a0;regions&#x000a0;(above&#x000a0;1000&#x000a0;m),&#x000a0;PaO<sub>2</sub>/FiO<sub>2</sub>&#x000a0;should&#x000a0;be
adjusted based on equation of
PaO<sub>2</sub>/FiO<sub>2</sub> &#x000d7;
(atmospheric pressure (mmHg)/760).</td><td style="border:none;" align="left">(1) Respiratory support: oxygen inhalation,
noninvasive ventilation, invasive ventilation;
salvage therapies (lung recruitment), and
extracorporeal membrane oxygenation
(ECMO).</td></tr><tr><td style="border:none;" align="left">Patients with &#x0003e;50% lesions progression
within 24&#x02013;48 h in pulmonary imaging should
be treated as severe cases of COVID-19.</td><td style="border:none;" align="left">(2) Circulatory support: on the basis of
adequate fluid resuscitation, improved
microcirculation, and</td></tr><tr><td rowspan="6" style="border:none;" align="center" valign="middle">Critical</td><td style="border:none;" align="left">Meeting any of the following:</td><td style="border:none;" align="left">(3) Use of vasoactive drugs.</td></tr><tr><td style="border:none;" align="left">(1) Respiratory failure occurs and
mechanical ventilation is required;</td><td style="border:none;" align="left">(4) Renal replacement therapy for patients
with renal failure.</td></tr><tr><td style="border:none;" align="left">(2) Shock;</td><td style="border:none;" align="left">(5) Convalescent-phase plasma
therapy.</td></tr><tr><td style="border:none;" align="left">(3) Complicated with other organ failure
that requires monitoring and treatment in an
intensive care unit (ICU).</td><td style="border:none;" align="left">(6) Blood dialysis.</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">(7) Immunotherapy: trastuzumab for patients
with a high IL-6 level.</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">(8) Other therapies, including low dosage
of methylprednisolone (&#x02264;1&#x02013;2 mg
kg<sup>&#x02013;1</sup> day<sup>&#x02013;1</sup>)
and intestinal microecological regulators.</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>BID, twice a day; TID, three times a day.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Frequently Used TCM Prescriptions and Therapeutic
Regimens for COVID-19 Patients in China<sup><xref ref-type="bibr" rid="ref14">14</xref></sup><sup>,</sup><xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">clinical
classification</th><th style="border:none;" align="center">clinical
manifestations</th><th style="border:none;" align="center">proprietary
Chinese&#x000a0;medicine/TCM prescription</th><th style="border:none;" align="center">administration and
dosage</th></tr></thead><tbody><tr><td rowspan="2" style="border:none;" align="left">Medical&#x000a0;observation&#x000a0;period</td><td rowspan="2" style="border:none;" align="left">Fatigue with fever</td><td style="border:none;" align="left"><bold>Jinhua Qinggan granule
(JHQGG):</bold><italic>Lonicerae japonicae flos, Gypsum Fibrosum,
Herba Ephedrae, Semen Armeniacae Amarum, Radix
Scutellariae, Fructus Forsythiae, Fritillariae
Thunbergii Bulbus, Rhizoma Anemarrhenae, Fructus
Arctii, Herba Artemisiae Annuae, Herba Menthae
Haplocalycis,</italic> and <italic>Radix
Glycyrrhizae.</italic></td><td style="border:none;" align="left">6 g per packet, 1 bag each time,
BID</td></tr><tr><td style="border:none;" align="left"><bold>Lianhua Qingwen capsule
(LHQWC):</bold><italic>Fructus Forsythiae, Lonicerae japonicae
flos,</italic> roasted <italic>Herba Ephedrae,
roasted Semen Armeniacae Amarum, Gypsum Fibrosum,
Radix Isatidis,</italic> Rhizome
<italic>Dryopteridis Crassirhizomatis, Herba
Houttuyniae, Herba Pogostemonis, Radix et Rhizoma
Rhei, Radix et Rhizoma Rhodiolae
Crenulatae,</italic><sc>l</sc>-Menthol, and <italic>Radix
Glycyrrhizae</italic>.</td><td style="border:none;" align="left">0.35 g per softgel, 1 softgel each time,
TID</td></tr><tr><td colspan="4" style="border:none;" align="center">Clinical Treatment Period (Confirmed
Cases)</td></tr><tr><td colspan="2" align="left">Basic&#x000a0;prescription&#x000a0;for&#x000a0;mild,&#x000a0;moderate,&#x000a0;severe,&#x000a0;and&#x000a0;critical&#x000a0;patients</td><td style="border:none;" align="left"><bold>Lung-cleansing&#x000a0;and&#x000a0;detoxifying&#x000a0;decoction
(LCDD) (also named Qingfei Paidu Tang,
QFPDT):</bold><italic>Herba Ephedrae</italic> (9 g),
<italic>roasted Radix Glycyrrhizae</italic> (6 g),
<italic>Semen Armeniacae Amarum</italic> (9 g),
<italic>raw Gypsum Fibrosum</italic> (15&#x02013;30
g, decocted first), <italic>Ramulus
Cinnamomi</italic> (9 g), <italic>Rhizoma
Alismatis</italic> (9 g), <italic>Polyporus
Umbellatus</italic> (9 g), <italic>Rhizoma
Atractylodis Macrocephalae</italic> (9 g),
<italic>Poria</italic> (15 g), <italic>Radix
Bupleuri</italic> (16 g), <italic>Radix
Scutellariae</italic> (6 g), <italic>Rhizoma
Pinelliae Preparata</italic> (9 g),
<italic>Rhizoma Zingiberis Recens</italic> (9 g),
<italic>Radix Asteris</italic> (9 g), <italic>Flos
Farfarae</italic> (9 g), <italic>Rhizoma
Belamcandae</italic> (9 g), <italic>Herba
Asari</italic> (6 g), <italic>Rhizoma
Dioscoreae</italic> (12 g), <italic>Fructus
Aurantii Immaturus</italic> (6 g),
<italic>Pericarpium Citri Reticulatae</italic> (6
g), and <italic>Herba Pogostemonis</italic> (9
g).</td><td style="border:none;" align="left">One dose per day, BID</td></tr><tr><td style="border:none;" align="left">Moderate</td><td style="border:none;" align="left">Fever, cough with less sputum or yellow
sputum, chest tightness, and shortness of
breath</td><td style="border:none;" align="left"><bold>Prescription 3 (also named Xuanfei
Baidu Tang, XFBDT):</bold> Raw <italic>Herba
Ephedrae</italic> (6 g), <italic>Semen Armeniacae
Amarum</italic> (15 g), raw <italic>Gypsum
Fibrosum</italic> (30 g), raw <italic>Semen
Coicis</italic> (30 g), <italic>Rhizoma
Atractylodis</italic> (10 g), <italic>Herba
Pogostemonis</italic> (15 g), <italic>Herba
Artemisiae Annuae</italic> (12 g), <italic>Rhizoma
Polygoni Cuspidati</italic> (20 g), <italic>Herba
Verbenae</italic> (30 g), dry <italic>Rhizoma
Phragmitis</italic> (30 g), <italic>Semen
Lepidii</italic> (15 g), <italic>Exocarpium Citri
grandis</italic> (15 g), and <italic>Radix
Glycyrrhizae</italic> (10 g).</td><td style="border:none;" align="left">One dose per day, BID</td></tr><tr><td rowspan="2" style="border:none;" align="left">Severe</td><td style="border:none;" align="left">Fever,&#x000a0;flushing,&#x000a0;cough,&#x000a0;less&#x000a0;yellow&#x000a0;sticky
sputum with or without blood, fatigue, wheezing
and shortness of breath, and poor appetite</td><td style="border:none;" align="left"><bold>Prescription 5 (also named Huashi
Baidu Tang, HSBDT):</bold> Raw <italic>Herba
Ephedrae</italic> (6 g), <italic>Semen Armeniacae
Amarum</italic> (9 g), <italic>Gypsum
Fibrosum</italic> (15 g), <italic>Radix
Glycyrrhizae</italic> (3 g), <italic>Herba
Pogostemonis</italic> (10 g, decocted later),
<italic>Cortex Magnoliae Officinalis</italic> (10
g), <italic>Rhizoma Atractylodis</italic> (15 g),
<italic>Fructus Tsaoko</italic> (10 g),
<italic>Rhizoma Pinelliae Preparatum</italic> (9
g), <italic>Poria</italic> (15 g), raw
<italic>Radix et Rhizoma Rhei</italic> (5 g), raw
<italic>Radix Astragali seu Hedysari</italic> (10
g), <italic>Semen Lepidii</italic> (10 g), and
<italic>Radix Paeoniae Rubra</italic> (10
g).</td><td style="border:none;" align="left">One&#x000a0;dose&#x000a0;per&#x000a0;day,&#x000a0;TID,&#x000a0;administered&#x000a0;alone&#x000a0;or
in combination with Xue Bi Jing injection</td></tr><tr><td style="border:none;" align="left">Severe fever and polydipsia, anhelation,
delirium, blurred vision, hematemesis, epistaxis,
and convulsion of the limbs</td><td style="border:none;" align="left"><bold>Xue Bi Jing Injection:</bold><italic>Carthami flos, Radix Paeoniae Rubra,
Chuanxiong rhizoma, Radix Salviae
Miltiorrhizae,</italic> and <italic>Angelicae
sinensis radix</italic>.</td><td style="border:none;" align="left">100 mL each time by venoclysis after
dilution, BID</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Notes: (1) TCM should be chosen according to individual
conditions and clinical symptoms. Generally, one
course of TCM treatment lasts for 3 days; however,
the period of TCM treatment for an individual
patient highly depends on the patient&#x02019;s
conditions and recovery process. (2) TCM could be
used alone or in combination with antiviral agents.
Using two or more TCM prescription decoctions at the
same time is not recommended. However, for severe
patients, TCM injection can be used in combination
with a TCM decoction. (3) Generally, one dose of TCM
prescription is decocted with approximately
10&#x02013;12 times water (w/w) until 300&#x02013;500
mL remains; the decoction is taken in the morning,
noon, and evening before meals. BID, twice a day;
TID, three times a day.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec3"><label>3</label><title>Potential Small-Molecule Inhibitors of SARS-CoV-2</title><p>As a supplement to conventional medicine, TCM treatment has played important
roles in the campaign of managing the SARS-CoV-2 pandemic in China. However,
the effects of TCM are often influenced by multiple factors, including
esoteric TCM theory; inconsistent medicinal material quality, which could be
significantly affected by soil and climate conditions, agricultural methods,
and the process involved in their final preparation; unclear effective
ingredients and mechanism of action. Furthermore, whether TCM is effective
in the clinic often relies on the clinician&#x02019;s experience. These
variations make it very difficult to develop a standardized TCM regimen for
a particular disease.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> In addition, only a few Asian countries have the
tradition of using TCM, and most countries in the world do not practice TCM
as a complementary medicine. Therefore, potent antiviral agents against
SARS-CoV-2 and other pathogenic CoVs are urgently needed. Since the outbreak
of SARS in 2002&#x02013;2003 and MERS in 2012, some research groups have been
devoted to the development of antivirals against CoVs and documented a
number of effective compounds. As there are limited numbers of CoVs and as
these CoVs have relatively similar structures,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> it is
possible that the drugs developed for other CoVs might be useful for
managing COVID-19. In particular, SARS-CoV-2 shares 82% sequence identity
with SARS-CoV (GenBank code NC_004718.3), and there is greater than
90% sequence identity in several of the essential enzymes of SARS-CoV and
SARS-CoV-2,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> indicating that inhibitors of
SARS-CoV might be effective against SARS-CoV-2. Indeed, some commercially
available drugs, such as antiparasitic CQ/HCQ and antiviral favipiravir
(FPV), with reported activity against SARS-CoV and other CoVs, have shown
pronounced inhibition of SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> However, to date,
few reviews have focused on small molecules with reported anti-CoV activity.
In this review, we identify 72 reported small molecules with activity
against human CoVs and discuss their potential application in combating
COVID-19. On the basis of inhibitory mechanisms against CoV replication,
these compounds are categorized in <xref rid="tbl3" ref-type="other">Tables <xref rid="tbl3" ref-type="other">3</xref></xref>&#x02013;<xref rid="tbl7" ref-type="other">7</xref>. <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref> shows the <italic>in vitro</italic> and
<italic>in vivo</italic> antiviral activities of compounds
(<bold>1</bold>&#x02013;<bold>9</bold>) against CoVs, including
SARS-CoV-2. <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref> includes compounds targeting SARS-CoV
proteases: 3C-like serine protease (3CL<sup>pro</sup>) inhibitors
(<bold>10</bold>&#x02013;<bold>31</bold>) and papain-like cysteine
protease (PL<sup>pro</sup>) inhibitors
(<bold>32</bold>&#x02013;<bold>36</bold>). These compounds have been
reported to bind 3CL<sup>pro</sup> or PL<sup>pro</sup> and suppress their
enzymatic activity through competitive, noncompetitive, or mixed mechanisms
of action. <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref> contains compounds
(<bold>37</bold>&#x02013;<bold>44</bold>) targeting SARS-CoV helicase
(Hel). <xref rid="tbl6" ref-type="other">Table <xref rid="tbl6" ref-type="other">6</xref></xref> includes compounds for other targets of SARS-CoV, including
SARS-CoV-2 (<bold>45</bold>&#x02013;<bold>50</bold>). <xref rid="tbl7" ref-type="other">Table <xref rid="tbl7" ref-type="other">7</xref></xref>
includes compounds (<bold>51</bold>&#x02013;<bold>72</bold>) with undefined
inhibiting mechanisms against various CoVs. The chemical structures of the
72 inhibitors are shown in <xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref> and <xref rid="fig4" ref-type="fig">4</xref>&#x02013;<xref rid="fig7" ref-type="fig">7</xref>.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Compounds with <italic>in vitro</italic> and <italic>in
vivo</italic> antiviral activity against CoVs, including
SARS-CoV-2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0001" id="gr1" position="float"/></fig><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title><italic>In Vitro</italic> and <italic>in Vivo</italic>
Antiviral Activity of Some Potential Compounds against CoVs,
Including SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">no.</th><th style="border:none;" align="center">compd</th><th style="border:none;" align="center">reported mechanism of
action</th><th style="border:none;" align="center"><italic>in&#x000a0;vitro</italic>/<italic>in&#x000a0;vivo</italic></th><th style="border:none;" align="center">effect</th><th style="border:none;" align="center">CoV type</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td rowspan="9" style="border:none;" align="left"><bold>1</bold></td><td rowspan="9" style="border:none;" align="left">Chloroquine (CQ)</td><td rowspan="9" style="border:none;" align="left">Increases&#x000a0;endosomal&#x000a0;pH; disrupts
intracellular trafficking and viral fusion events;
and interferes with glycosylation of cellular
receptors of CoV.</td><td rowspan="6" style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">IC<sub>50</sub>:&#x000a0;1.13&#x000a0;&#x003bc;M;&#x000a0;CC<sub>50</sub>:&#x000a0;&#x0003e;100&#x000a0;&#x003bc;M;
SI: &#x0003e;88</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Wang et al.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.33 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;20 &#x003bc;M; SI:
&#x0003e;60</td><td style="border:none;" align="left">HCoV-OC43</td><td style="border:none;" align="left">Shen et al.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 4.1 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;128 &#x003bc;M; SI:
&#x0003e;31</td><td style="border:none;" align="left">SARS-CoV</td><td rowspan="2" style="border:none;" align="left">de&#x000a0;Wilde&#x000a0;et&#x000a0;al.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 3.3 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;50 &#x003bc;M; SI:
&#x0003e;15</td><td style="border:none;" align="left">HCoV-229E</td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.30 &#x003bc;M;
CC<sub>50</sub>: 419 &#x003bc;M; SI: 1369</td><td style="border:none;" align="left">HCoV-OC43</td><td style="border:none;" align="left">Keyaerts et al.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 8.8 &#x003bc;M;
CC<sub>50</sub>: 261 &#x003bc;M; SI: 30</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Keyaerts et al.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup></td></tr><tr><td rowspan="2" style="border:none;" align="left">Mouse model</td><td style="border:none;" align="left">Intranasal administration of CQ (50 mg/kg BW)
resulted in a minor reduction in viral titers in
the lung.</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Barnard et al.<sup><xref ref-type="bibr" rid="ref79">79</xref></sup></td></tr><tr><td style="border:none;" align="left">A 98.6% survival of newborn C57BL/6 mice
infected with HCoV-OC43 when mother mice were
treated daily with CQ at a dose of 15 mg/kg
BW.</td><td style="border:none;" align="left">HCoV-OC43</td><td style="border:none;" align="left">Keyaerts et al.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></td></tr><tr><td style="border:none;" align="left">Open-label&#x000a0;clinical&#x000a0;trial</td><td style="border:none;" align="left">Shorter median time to negative conversion
and the duration of fever.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Huang et al.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup></td></tr><tr><td rowspan="5" style="border:none;" align="left"><bold>2</bold></td><td rowspan="5" style="border:none;" align="left">Hydroxychloroquine (HCQ)</td><td rowspan="5" style="border:none;" align="left">The same as CQ.</td><td style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">IC<sub>50</sub>: 0.72 &#x003bc;M</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Yao et al.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup></td></tr><tr><td style="border:none;" align="left">Open-label, controlled clinical trial</td><td style="border:none;" align="left">Significantly associated with viral load
reduction/disappearance in COVID-19 patients.
Synergetic effects when used in combination with
azithromycin.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Gautret et al.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup></td></tr><tr><td style="border:none;" align="left">Randomized controlled clinical trial</td><td style="border:none;" align="left">Shorter time to clinical recovery and
promoted the absorption of pneumonia.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Chen et al.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup></td></tr><tr><td style="border:none;" align="left">Open-label, randomized controlled clinical
trial</td><td style="border:none;" align="left">No difference in negative conversion with
standard of care alone in mild and moderate
patients; higher adverse events such as
diarrhea.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Tang et al.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup></td></tr><tr><td style="border:none;" align="left">Open-label, controlled clinical trial</td><td style="border:none;" align="left">No improvement in survival for COVID-19
patients who required oxygen.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Mah&#x000e9;vas et al.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup></td></tr><tr><td rowspan="8" style="border:none;" align="left"><bold>3</bold></td><td rowspan="8" style="border:none;" align="left">Remdesivir (RDV)</td><td rowspan="8" style="border:none;" align="left">Inhibits RdRp and blocks viral
RNA synthesis; terminates the nonobligate
chain.</td><td rowspan="4" style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">IC<sub>50</sub>: 0.77 &#x003bc;M;
CC<sub>50</sub>: 100 &#x003bc;M; SI: &#x0003e;129</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Wang et al.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.15 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;10 &#x003bc;M; SI:
&#x0003e;66</td><td style="border:none;" align="left">HCoV-OC43</td><td rowspan="2" style="border:none;" align="left">Brown et al.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.024 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;10 &#x003bc;M; SI:
&#x0003e;400</td><td style="border:none;" align="left">HCoV-229E</td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.06 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;10 &#x003bc;M; SI:
&#x0003e;167</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Agostini et al.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup></td></tr><tr><td style="border:none;" align="left">Mouse model</td><td style="border:none;" align="left">Ameliorated SARS-CoV-induced weight loss;
reduced SARS-CoV-induced lung pathology and viral
load in the lungs; and improved clinical signs of
disease as well as respiratory function.</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Sheahan et al.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup></td></tr><tr><td style="border:none;" align="left">Observational, retrospective study</td><td style="border:none;" align="left">Clinical improvement was observed in 36 of 53
patients (68%) in patients receiving oxygen
support.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Grein et al.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup></td></tr><tr><td style="border:none;" align="left">Double-blind, randomized, controlled clinical
trial</td><td style="border:none;" align="left">RDV was superior to placebo in shortening the
time to recovery in patients with lower
respiratory tract infection.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Beigel et al.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup></td></tr><tr><td style="border:none;" align="left">Double-blind, randomized, controlled clinical
trial</td><td style="border:none;" align="left">No significant improvements in clinical or
antiviral effects in severe patients.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Wang et al.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup></td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>4</bold></td><td rowspan="2" style="border:none;" align="left">Favipiravir (FPV)</td><td rowspan="2" style="border:none;" align="left">Inhibits RdRp and blocks viral
RNA synthesis.</td><td style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">IC<sub>50</sub>: 61.8 &#x003bc;M;
CC<sub>50</sub>: &#x0003e;400 &#x003bc;M; SI:
&#x0003e;6.46</td><td rowspan="2" style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Wang et al.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td></tr><tr><td style="border:none;" align="left">Open-label, controlled clinical trial</td><td style="border:none;" align="left">Significant shorter time to viral clearance
and improvement in chest imaging compared with
lopinavir/ritonavir, another antiviral
drug.</td><td style="border:none;" align="left">Cai et al.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup></td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">Open-label, randomized, controlled clinical
trial</td><td style="border:none;" align="left">Did not significantly improve the clinical
recovery rate on day 7 and did not shorten the
latency to relief for pyrexia and cough.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Chen et al.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup></td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>5</bold></td><td rowspan="2" style="border:none;" align="left">Ribavirin</td><td rowspan="2" style="border:none;" align="left">Inhibits viral RNA synthesis and
mRNA capping.</td><td rowspan="2" style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">The cytopathic effect of SARS-CoV was
inhibited by ribavirin at 50 &#x003bc;g/mL</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Chu et al.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 109.5 &#x003bc;M;
CC<sub>50</sub> &#x0003e;400 &#x003bc;M; SI
&#x0003e;3.65</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Wang et al.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td></tr><tr><td rowspan="4" style="border:none;" align="left"><bold>6</bold></td><td rowspan="3" style="border:none;" align="left">Lopinavir</td><td rowspan="3" style="border:none;" align="left">Inhibits 3CL<sup>pro</sup> and
blocks the cleavage of viral peptides into
functional units.</td><td rowspan="3" style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">The cytopathic effect of the SARS-CoV was
inhibited by lopinavir at 4 &#x003bc;g/mL.</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Chu et al.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 17.1 &#x003bc;M;
CC<sub>50</sub> &#x0003e;32 &#x003bc;M; SI:
&#x0003e;2.0</td><td style="border:none;" align="left">SARS-CoV</td><td rowspan="2" style="border:none;" align="left">de Wilde et al.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 6.6 &#x003bc;M;
CC<sub>50</sub> &#x0003e;37.6 &#x003bc;M; SI: 5.7</td><td style="border:none;" align="left">HCoV-229E</td></tr><tr><td style="border:none;" align="left">Lopinavir/ritonavir</td><td style="border:none;" align="left">A fixed dose of ritonavir was used to
increase lopinavir half-life through the
inhibition of cytochrome P450.</td><td style="border:none;" align="left">Randomized, controlled, open-label clinical
trial</td><td style="border:none;" align="left">No benefits in the time to clinical
improvement and/or mortality rate at day 28 for
severe COVID-19 patients, compared with standard
care group.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Cao et al.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>7</bold></td><td style="border:none;" align="left">Matrine sodium chloride</td><td style="border:none;" align="left">Regulates immunity function and inhibits the
release of inflammatory factors.</td><td style="border:none;" align="left">Mouse model</td><td style="border:none;" align="left">Intraperitoneal injection of matrine sodium
chloride significantly improved the pathological
damage of lung tissue and reduced lung
index.</td><td style="border:none;" align="left">HCoV-229E</td><td style="border:none;" align="left">Jing et al.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup></td></tr><tr><td rowspan="4" style="border:none;" align="left"><bold>8</bold></td><td rowspan="4" style="border:none;" align="left">Lycorine</td><td rowspan="4" style="border:none;" align="left">Inhibits replication with an
undefined mechanism.</td><td rowspan="3" style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">IC<sub>50</sub>: 0.0157 &#x003bc;M; CC: 14.9
&#x003bc;M; SI: 954</td><td style="border:none;" align="left">HCoV-OC43</td><td style="border:none;" align="left">Li et al.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.15 &#x003bc;M; CC: 4.37
&#x003bc;M; SI: 29.1</td><td style="border:none;" align="left">HCoV-OC43</td><td rowspan="3" style="border:none;" align="left">Shen et al.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></td></tr><tr><td style="border:none;" align="left">IC<sub>50</sub>: 0.47 &#x003bc;M; CC: 3.81
&#x003bc;M; SI: 8.11</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td style="border:none;" align="left">Mouse model</td><td style="border:none;" align="left">Intraperitoneal injection at 15 mg/kg
provided an 83.3% protection for infected
mice.</td><td style="border:none;" align="left">HCoV-OC43</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>9</bold></td><td rowspan="2" style="border:none;" align="left">Camostat</td><td rowspan="2" style="border:none;" align="left">Inhibits transmembrane protease
serine 2.</td><td style="border:none;" align="left"><italic>In vitro</italic></td><td style="border:none;" align="left">Blocked cellular entry of the SARS-CoV-2
virus into Caco-2 cells with an EC<sub>50</sub> of
1 &#x003bc;M.</td><td style="border:none;" align="left">SARS-CoV-2</td><td style="border:none;" align="left">Hoffmann et al.<sup><xref ref-type="bibr" rid="ref78">78</xref></sup></td></tr><tr><td style="border:none;" align="left">Mouse model</td><td style="border:none;" align="left">Protected mice against SARS-CoV lethal
infection with a survival rate of 60%.</td><td style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Zhou et al.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup></td></tr></tbody></table></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>SARS-CoV inhibitors Targeting 3CL<sup>pro</sup> and
PL<sup>pro</sup>&#x0202f;<xref rid="t4fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">compd</th><th style="border:none;" align="center">source</th><th style="border:none;" align="center">IC<sub>50</sub>
(&#x003bc;M)</th><th style="border:none;" align="center"><italic>K</italic><sub><italic>i</italic></sub>
(&#x003bc;M)</th><th style="border:none;" align="center">inhibition mode</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td colspan="7" style="border:none;" align="center">Inhibitors&#x000a0;Targeting&#x000a0;3CL<sup>pro</sup></td></tr><tr><td style="border:none;" align="left"><bold>10</bold></td><td style="border:none;" align="left">Betulinic acid</td><td style="border:none;" align="left"><italic>Betula pubescens</italic></td><td style="border:none;" align="left">10</td><td style="border:none;" align="left">8.2</td><td rowspan="2" style="border:none;" align="left">Competitive</td><td rowspan="2" style="border:none;" align="left">Wen et al.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>11</bold></td><td style="border:none;" align="left">Savinin</td><td style="border:none;" align="left"><italic>Chamaecyparis obtusa</italic></td><td style="border:none;" align="left">25</td><td style="border:none;" align="left">9.1</td></tr><tr><td style="border:none;" align="left"><bold>12</bold></td><td style="border:none;" align="left">Celastrol</td><td rowspan="4" style="border:none;" align="left"><italic>Tripterygium regelii</italic></td><td style="border:none;" align="left">10</td><td style="border:none;" align="left">4.2</td><td rowspan="4" style="border:none;" align="left">Competitive</td><td rowspan="4" style="border:none;" align="left">Ryu et al.<sup><xref ref-type="bibr" rid="ref92">92</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>13</bold></td><td style="border:none;" align="left">Pristimerin</td><td style="border:none;" align="left">5.5</td><td style="border:none;" align="left">3.1</td></tr><tr><td style="border:none;" align="left"><bold>14</bold></td><td style="border:none;" align="left">Tingenone</td><td style="border:none;" align="left">9.9</td><td style="border:none;" align="left">4.0</td></tr><tr><td style="border:none;" align="left"><bold>15</bold></td><td style="border:none;" align="left">Iguesterin</td><td style="border:none;" align="left">2.6</td><td style="border:none;" align="left">0.8</td></tr><tr><td style="border:none;" align="left"><bold>16</bold></td><td style="border:none;" align="left">Hesperetin</td><td style="border:none;" align="left"><italic>Isatis indigotica</italic></td><td style="border:none;" align="left">8.3</td><td style="border:none;" align="left">NT</td><td style="border:none;" align="left">-</td><td style="border:none;" align="left">Lin et al.<sup><xref ref-type="bibr" rid="ref93">93</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>17</bold></td><td style="border:none;" align="left">Dieckol</td><td style="border:none;" align="left"><italic>Ecklonia cava</italic></td><td style="border:none;" align="left">2.7</td><td style="border:none;" align="left">2.4</td><td style="border:none;" align="left">Competitive</td><td style="border:none;" align="left">Park et al.<sup><xref ref-type="bibr" rid="ref94">94</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>18</bold></td><td style="border:none;" align="left">Amentoflavone</td><td rowspan="3" style="border:none;" align="left"><italic>Torreya nucifera</italic></td><td style="border:none;" align="left">8.3</td><td style="border:none;" align="left">13.8</td><td style="border:none;" align="left">Noncompetitive</td><td rowspan="3" style="border:none;" align="left">Ryu et al.<sup><xref ref-type="bibr" rid="ref96">96</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>19</bold></td><td style="border:none;" align="left">Luteolin</td><td style="border:none;" align="left">20.2</td><td rowspan="2" style="border:none;" align="left">NT</td><td rowspan="2" style="border:none;" align="left">-</td></tr><tr><td style="border:none;" align="left"><bold>20</bold></td><td style="border:none;" align="left">Quercetin</td><td style="border:none;" align="left">23.8</td></tr><tr><td style="border:none;" align="left"><bold>20</bold></td><td style="border:none;" align="left">Quercetin</td><td rowspan="3" style="border:none;" align="left">NM</td><td style="border:none;" align="left">73</td><td rowspan="2" style="border:none;" align="left">NT</td><td rowspan="2" style="border:none;" align="left">-</td><td rowspan="3" style="border:none;" align="left">Nguyen et al.<sup><xref ref-type="bibr" rid="ref97">97</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>21</bold></td><td style="border:none;" align="left">Epigallocatechin&#x000a0;gallate</td><td style="border:none;" align="left">73</td></tr><tr><td style="border:none;" align="left"><bold>22</bold></td><td style="border:none;" align="left">Gallocatechin gallate</td><td style="border:none;" align="left">47</td><td style="border:none;" align="left">25</td><td style="border:none;" align="left">Competitive</td></tr><tr><td style="border:none;" align="left"><bold>23</bold></td><td style="border:none;" align="left">Rhoifolin</td><td rowspan="3" style="border:none;" align="left">NM</td><td style="border:none;" align="left">27.4</td><td rowspan="3" style="border:none;" align="left">NT</td><td rowspan="3" style="border:none;" align="left">-</td><td rowspan="3" style="border:none;" align="left">Jo et al.<sup><xref ref-type="bibr" rid="ref98">98</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>24</bold></td><td style="border:none;" align="left">Herbacetin</td><td style="border:none;" align="left">33.1</td></tr><tr><td style="border:none;" align="left"><bold>25</bold></td><td style="border:none;" align="left">Pectolinarin</td><td style="border:none;" align="left">37.7</td></tr><tr><td style="border:none;" align="left"><bold>26</bold></td><td style="border:none;" align="left">Xanthoangelol E</td><td style="border:none;" align="left"><italic>Angelica keiskei</italic></td><td style="border:none;" align="left">7.1</td><td style="border:none;" align="left">16.1</td><td style="border:none;" align="left">Competitive</td><td style="border:none;" align="left">Park&#x000a0;et&#x000a0;al.<sup><xref ref-type="bibr" rid="ref99">99</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>27</bold></td><td style="border:none;" align="left">5-Sulfonyl isatin a</td><td rowspan="2" style="border:none;" align="left">Derivative</td><td style="border:none;" align="left">1.04</td><td rowspan="2" style="border:none;" align="left">NT</td><td rowspan="2" style="border:none;" align="left">-</td><td rowspan="2" style="border:none;" align="left">Liu et al.<sup><xref ref-type="bibr" rid="ref100">100</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>28</bold></td><td style="border:none;" align="left">5-Sulfonyl isatin b</td><td style="border:none;" align="left">1.18</td></tr><tr><td style="border:none;" align="left"><bold>29</bold></td><td style="border:none;" align="left">GC376</td><td style="border:none;" align="left">Synthesized</td><td style="border:none;" align="left">4.35</td><td style="border:none;" align="left">NT</td><td style="border:none;" align="left">-</td><td style="border:none;" align="left">Kim et al.<sup><xref ref-type="bibr" rid="ref101">101</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>30</bold></td><td style="border:none;" align="left">Peptide anilide</td><td style="border:none;" align="left">Synthesized</td><td style="border:none;" align="left">0.06</td><td style="border:none;" align="left">0.03</td><td style="border:none;" align="left">Competitive</td><td style="border:none;" align="left">Shie et al.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>31</bold></td><td style="border:none;" align="left">Peptidomimetic</td><td style="border:none;" align="left">Derivative</td><td style="border:none;" align="left">0.20</td><td style="border:none;" align="left">NT</td><td style="border:none;" align="left">-</td><td style="border:none;" align="left">Kumar et al.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup></td></tr><tr><td colspan="7" style="border:none;" align="center">Inhibitors&#x000a0;Targeting&#x000a0;Papain-like&#x000a0;Protease&#x000a0;(PL<sup>pro</sup>)</td></tr><tr><td style="border:none;" align="left"><bold>32</bold></td><td style="border:none;" align="left">Hirsutenone</td><td style="border:none;" align="left"><italic>Alnus japonica</italic></td><td style="border:none;" align="left">4.1</td><td style="border:none;" align="left">10</td><td style="border:none;" align="left">Noncompetitive</td><td style="border:none;" align="left">Park et al.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>26</bold></td><td style="border:none;" align="left">Xanthoangelol E</td><td style="border:none;" align="left"><italic>Angelica keiskei</italic></td><td style="border:none;" align="left">1.2</td><td style="border:none;" align="left">1.2</td><td rowspan="2" style="border:none;" align="left">Noncompetitive</td><td style="border:none;" align="left">Park et al.<sup><xref ref-type="bibr" rid="ref99">99</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>33</bold></td><td style="border:none;" align="left">Papyriflavonol A</td><td style="border:none;" align="left"><italic>Broussonetia&#x000a0;papyrifera</italic></td><td style="border:none;" align="left">3.7</td><td style="border:none;" align="left">5.9</td><td style="border:none;" align="left">Park et al.<sup><xref ref-type="bibr" rid="ref107">107</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>34</bold></td><td style="border:none;" align="left">Isobavachalcone</td><td rowspan="2" style="border:none;" align="left"><italic>Psoralea corylifolia</italic></td><td style="border:none;" align="left">7.3</td><td style="border:none;" align="left">4.9</td><td rowspan="2" style="border:none;" align="left">Mixed</td><td rowspan="2" style="border:none;" align="left">Kim et al.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>35</bold></td><td style="border:none;" align="left">Psoralidin</td><td style="border:none;" align="left">4.2</td><td style="border:none;" align="left">1.7</td></tr><tr><td style="border:none;" align="left"><bold>36</bold></td><td style="border:none;" align="left">Terrestrimine</td><td style="border:none;" align="left"><italic>Tribulus terrestris</italic></td><td style="border:none;" align="left">15.8</td><td style="border:none;" align="left">10</td><td style="border:none;" align="left">Mixed</td><td style="border:none;" align="left">Song et al.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="t4fn1"><label>a</label><p>NM, not mentioned; NT, not tested. Competitive inhibition, an
inhibitor molecule competes with a substrate by binding at
the active site to the protease. Noncompetitive
inhibition, an inhibitor binds at an allosteric site to
the protease&#x02019;s active site but has an equal or
higher affinity than that of the substrate to the
protease. Mixed inhibition, an inhibitor molecule binds at
an allosteric site to the protease but has a different
affinity to substrate-bound protease or free protease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title>SARS-CoV Inhibitors Targeting Hel</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">compd</th><th style="border:none;" align="center">source</th><th style="border:none;" align="center">ATPase (&#x003bc;M)</th><th style="border:none;" align="center">helicase (&#x003bc;M)</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>37</bold></td><td style="border:none;" align="left">Bananin</td><td rowspan="4" style="border:none;" align="left">Derivative</td><td style="border:none;" align="left">2.3</td><td style="border:none;" align="left">3.0</td><td rowspan="4" style="border:none;" align="left">Tanner&#x000a0;et&#x000a0;al.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>38</bold></td><td style="border:none;" align="left">Vanillinbananin</td><td style="border:none;" align="left">0.68</td><td style="border:none;" align="left">2.7</td></tr><tr><td style="border:none;" align="left"><bold>39</bold></td><td style="border:none;" align="left">Iodobananin</td><td style="border:none;" align="left">0.54</td><td style="border:none;" align="left">7.0</td></tr><tr><td style="border:none;" align="left"><bold>40</bold></td><td style="border:none;" align="left">Eubananin</td><td style="border:none;" align="left">2.8</td><td style="border:none;" align="left">5.4</td></tr><tr><td style="border:none;" align="left"><bold>41</bold></td><td style="border:none;" align="left">EMMDPD</td><td style="border:none;" align="left">Synthesized</td><td style="border:none;" align="left">8.66</td><td style="border:none;" align="left">41.6</td><td style="border:none;" align="left">Cho et al.<sup><xref ref-type="bibr" rid="ref110">110</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>42</bold></td><td style="border:none;" align="left">FSPA</td><td style="border:none;" align="left">Synthesized</td><td style="border:none;" align="left">2.09</td><td style="border:none;" align="left">13.2</td><td style="border:none;" align="left">Lee et al.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>43</bold></td><td style="border:none;" align="left">Myricetin</td><td style="border:none;" align="left">ChromaDex</td><td style="border:none;" align="left">2.71</td><td style="border:none;" align="left">&#x000a0;</td><td rowspan="2" style="border:none;" align="left">Yu et al.<sup><xref ref-type="bibr" rid="ref114">114</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>44</bold></td><td style="border:none;" align="left">Scutellarein</td><td style="border:none;" align="left"><italic>Scutellaria baicalensis</italic></td><td style="border:none;" align="left">0.86</td><td style="border:none;" align="left">&#x000a0;</td></tr></tbody></table></table-wrap><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><title>Inhibitors with Other Targets against SARS-CoV<xref rid="t6fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">compd</th><th style="border:none;" align="center">reported mechanism of
action</th><th style="border:none;" align="center">IC<sub>50</sub>
(&#x003bc;M)</th><th style="border:none;" align="center">CC (&#x003bc;M)</th><th style="border:none;" align="center">SI</th><th style="border:none;" align="center">CoV type</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>45</bold></td><td style="border:none;" align="left">K11777</td><td rowspan="3" style="border:none;" align="left">Targets&#x000a0;cathepsin-mediated
cell entry and the endosomal proteolysis.</td><td style="border:none;" align="left">3.2&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;4</sup></td><td rowspan="3" style="border:none;" align="left">NT</td><td rowspan="3" style="border:none;" align="left">NT</td><td rowspan="3" style="border:none;" align="left">SARS-CoV</td><td rowspan="3" style="border:none;" align="left">Zhou et al.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>46</bold></td><td style="border:none;" align="left">SMDC256159</td><td style="border:none;" align="left">7.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;5</sup></td></tr><tr><td style="border:none;" align="left"><bold>47</bold></td><td style="border:none;" align="left">SMDC256160</td><td style="border:none;" align="left">8.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;5</sup></td></tr><tr><td style="border:none;" align="left"><bold>48</bold></td><td style="border:none;" align="left">Nitazoxanide</td><td style="border:none;" align="left">Induces the host innate immune response to
produce IFNs.</td><td style="border:none;" align="left">2.12</td><td style="border:none;" align="left">&#x0003e;35.5</td><td style="border:none;" align="left">&#x0003e;16.7</td><td rowspan="3" style="border:none;" align="left">SARS-CoV-2</td><td rowspan="3" style="border:none;" align="left">Wang&#x000a0;et&#x000a0;al.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>49</bold></td><td style="border:none;" align="left">Nafamostat</td><td style="border:none;" align="left">Inhibits S protein-mediated membrane
fusion.</td><td style="border:none;" align="left">22.5</td><td style="border:none;" align="left">&#x0003e;100</td><td style="border:none;" align="left">&#x0003e;4.4</td></tr><tr><td style="border:none;" align="left"><bold>50</bold></td><td style="border:none;" align="left">Penciclovir</td><td style="border:none;" align="left">Inhibits RdRp.</td><td style="border:none;" align="left">95.9</td><td style="border:none;" align="left">&#x0003e;400</td><td style="border:none;" align="left">&#x0003e;4.2</td></tr></tbody></table><table-wrap-foot><fn id="t6fn1"><label>a</label><p>NT, not tested.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl7" position="float"><label>Table 7</label><caption><title>Replication Inhibitors with an Undefined Mechanism against
CoVs<xref rid="t7fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">compd</th><th style="border:none;" align="center">source</th><th style="border:none;" align="center">IC<sub>50</sub>
(&#x003bc;M)</th><th style="border:none;" align="center">CC (&#x003bc;M)</th><th style="border:none;" align="center">SI</th><th style="border:none;" align="center">CoV type</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>51</bold></td><td style="border:none;" align="left">Glycyrrhizin (GL)</td><td rowspan="3" style="border:none;" align="left"><italic>Glycyrrhiza glabra</italic></td><td style="border:none;" align="left">365</td><td style="border:none;" align="left">24,000</td><td style="border:none;" align="left">66</td><td rowspan="4" style="border:none;" align="left">SARS-CoV</td><td style="border:none;" align="left">Cinatl et al.<sup><xref ref-type="bibr" rid="ref118">118</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>52</bold></td><td style="border:none;" align="left">GL derivatives a</td><td style="border:none;" align="left">40</td><td style="border:none;" align="left">3,000</td><td style="border:none;" align="left">75</td><td rowspan="2" style="border:none;" align="left">Hoever&#x000a0;et&#x000a0;al.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>53</bold></td><td style="border:none;" align="left">GL derivatives b</td><td style="border:none;" align="left">35</td><td style="border:none;" align="left">1,462</td><td style="border:none;" align="left">41</td></tr><tr><td style="border:none;" align="left"><bold>54</bold></td><td style="border:none;" align="left">&#x003b1;-Hederin</td><td style="border:none;" align="left">Aescin&#x000a0;derivative</td><td style="border:none;" align="left">10</td><td style="border:none;" align="left">NT</td><td style="border:none;" align="left">NT</td><td style="border:none;" align="left">Wu et al.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>55</bold></td><td style="border:none;" align="left">Saikosaponin&#x000a0;B2&#x000a0;(SSB<sub>2</sub>)</td><td style="border:none;" align="left"><italic>Bupleurum falcatum</italic></td><td style="border:none;" align="left">1.7</td><td style="border:none;" align="left">383</td><td style="border:none;" align="left">222</td><td style="border:none;" align="left">HCoV-229E</td><td style="border:none;" align="left">Cheng et al.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>56</bold></td><td style="border:none;" align="left">Betulonic acid</td><td style="border:none;" align="left"><italic>Juniperus formosana</italic></td><td style="border:none;" align="left">0.63</td><td style="border:none;" align="left">&#x0003e;100</td><td style="border:none;" align="left">&#x0003e;180</td><td rowspan="5" style="border:none;" align="left">SARS-CoV</td><td rowspan="5" style="border:none;" align="left">Wen et al.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>57</bold></td><td style="border:none;" align="left">Ferruginol</td><td rowspan="2" style="border:none;" align="left"><italic>Chamaecyparis obtusa</italic></td><td style="border:none;" align="left">1.39</td><td style="border:none;" align="left">80.4</td><td style="border:none;" align="left">58</td></tr><tr><td style="border:none;" align="left"><bold>58</bold></td><td style="border:none;" align="left">8&#x003b2;-Hydroxyabieta-9(11),13-dien-12-one</td><td style="border:none;" align="left">1.47</td><td style="border:none;" align="left">&#x0003e;750</td><td style="border:none;" align="left">&#x0003e;510</td></tr><tr><td style="border:none;" align="left"><bold>59</bold></td><td style="border:none;" align="left">7&#x003b2;-Hydroxydeoxycryptojaponol</td><td style="border:none;" align="left"><italic>Cryptomeria japonica</italic></td><td style="border:none;" align="left">1.15</td><td style="border:none;" align="left">127</td><td style="border:none;" align="left">111</td></tr><tr><td style="border:none;" align="left"><bold>60</bold></td><td style="border:none;" align="left">3&#x003b2;,12-Diacetoxyabieta-6,8,11,13-tetraene</td><td style="border:none;" align="left"><italic>Juniperus formosana</italic></td><td style="border:none;" align="left">1.57</td><td style="border:none;" align="left">303</td><td style="border:none;" align="left">193</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>61</bold></td><td rowspan="2" style="border:none;" align="left">Mycophenolic acid</td><td rowspan="2" style="border:none;" align="left"><italic>Penicillium</italic>
metabolite</td><td style="border:none;" align="left">1.95</td><td style="border:none;" align="left">3.55</td><td style="border:none;" align="left">1.8</td><td style="border:none;" align="left">HCoV-OC43</td><td rowspan="12" style="border:none;" align="left">Shen et al.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></td></tr><tr><td style="border:none;" align="left">0.18</td><td style="border:none;" align="left">3.44</td><td style="border:none;" align="left">19</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>62</bold></td><td rowspan="2" style="border:none;" align="left">Emetine</td><td rowspan="2" style="border:none;" align="left"><italic>Uragoga ipecacuanha</italic></td><td style="border:none;" align="left">0.30</td><td style="border:none;" align="left">2.69</td><td style="border:none;" align="left">9.0</td><td style="border:none;" align="left">HCoV-OC43</td></tr><tr><td style="border:none;" align="left">1.43</td><td style="border:none;" align="left">3.63</td><td style="border:none;" align="left">2.5</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>63</bold></td><td rowspan="2" style="border:none;" align="left">Mycophenolate mofetil</td><td rowspan="2" style="border:none;" align="left">Derivative</td><td style="border:none;" align="left">1.58</td><td style="border:none;" align="left">3.43</td><td style="border:none;" align="left">2.2</td><td style="border:none;" align="left">HCoV-OC43</td></tr><tr><td style="border:none;" align="left">0.23</td><td style="border:none;" align="left">3.01</td><td style="border:none;" align="left">13</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>64</bold></td><td rowspan="2" style="border:none;" align="left">Phenazopyridine</td><td rowspan="2" style="border:none;" align="left">Synthesized</td><td style="border:none;" align="left">1.9</td><td style="border:none;" align="left">&#x0003e;20</td><td style="border:none;" align="left">&#x0003e;10</td><td style="border:none;" align="left">HCoV-OC43</td></tr><tr><td style="border:none;" align="left">2.02</td><td style="border:none;" align="left">&#x0003e;20</td><td style="border:none;" align="left">&#x0003e;9.9</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>65</bold></td><td rowspan="2" style="border:none;" align="left">Monensin sodium</td><td rowspan="2" style="border:none;" align="left">Derivative</td><td style="border:none;" align="left">3.81</td><td style="border:none;" align="left">&#x0003e;20</td><td style="border:none;" align="left">&#x0003e;5.3</td><td style="border:none;" align="left">HCoV-OC43</td></tr><tr><td style="border:none;" align="left">1.54</td><td style="border:none;" align="left">&#x0003e;20</td><td style="border:none;" align="left">&#x0003e;13</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td rowspan="2" style="border:none;" align="left"><bold>66</bold></td><td rowspan="2" style="border:none;" align="left">Pyrvinium pamoate</td><td rowspan="2" style="border:none;" align="left">Synthesized</td><td style="border:none;" align="left">3.21</td><td style="border:none;" align="left">&#x0003e;20</td><td style="border:none;" align="left">&#x0003e;6.2</td><td style="border:none;" align="left">HCoV-OC43</td></tr><tr><td style="border:none;" align="left">3.35</td><td style="border:none;" align="left">&#x0003e;20</td><td style="border:none;" align="left">&#x0003e;6.0</td><td style="border:none;" align="left">HCoV-NL63</td></tr><tr><td style="border:none;" align="left"><bold>67</bold></td><td style="border:none;" align="left">Tetrandrine</td><td rowspan="3" style="border:none;" align="left"><italic>Stephania tetrandra</italic></td><td style="border:none;" align="left">0.29</td><td style="border:none;" align="left">14.5</td><td style="border:none;" align="left">50</td><td rowspan="3" style="border:none;" align="left">HCoV-OC43</td><td rowspan="3" style="border:none;" align="left">Kim et al.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>68</bold></td><td style="border:none;" align="left">Fangchinoline</td><td style="border:none;" align="left">0.91</td><td style="border:none;" align="left">12.4</td><td style="border:none;" align="left">11</td></tr><tr><td style="border:none;" align="left"><bold>69</bold></td><td style="border:none;" align="left">Cepharanthine</td><td style="border:none;" align="left">0.72</td><td style="border:none;" align="left">10.5</td><td style="border:none;" align="left">13</td></tr><tr><td style="border:none;" align="left"><bold>70</bold></td><td style="border:none;" align="left">Reserpine</td><td style="border:none;" align="left"><italic>Rauwolfia serpentina</italic></td><td style="border:none;" align="left">3.4</td><td style="border:none;" align="left">25</td><td style="border:none;" align="left">7.3</td><td rowspan="3" style="border:none;" align="left">SARS-CoV</td><td rowspan="3" style="border:none;" align="left">Wu et al.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup></td></tr><tr><td style="border:none;" align="left"><bold>71</bold></td><td style="border:none;" align="left">Aescin</td><td style="border:none;" align="left">NM</td><td style="border:none;" align="left">6.0</td><td style="border:none;" align="left">25</td><td style="border:none;" align="left">2.5</td></tr><tr><td style="border:none;" align="left"><bold>72</bold></td><td style="border:none;" align="left">Valinomycin</td><td style="border:none;" align="left">NM</td><td style="border:none;" align="left">0.85</td><td style="border:none;" align="left">68</td><td style="border:none;" align="left">80</td></tr></tbody></table><table-wrap-foot><fn id="t7fn1"><label>a</label><p>NM, not mentioned; NT, not tested.</p></fn></table-wrap-foot></table-wrap><sec id="sec3.1"><label>3.1</label><title>Antivirals with <italic>in Vitro</italic> and <italic>in Vivo</italic>
Activity against CoVs</title><p>Recently, Li et al. summarized a list of approved antiviral drugs with
anti-CoV potential, including preclinical compounds under
consideration for further study or as starting points for further
development of newer agents.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> The efficacy of the
commercially available drugs ribavirin, nitazoxanide, penciclovir,
nafamostat, CQ/HCQ, remdesivir (RDV, GS-5734), and favipiravir (FPV,
T-705) was evaluated for activity against SARS-CoV-2 <italic>in
vitro.</italic> Among all seven tested drugs, CQ/HCQ and RDV
potently blocked viral infection at low micromolar concentrations in
cell cultures and showed a high selective index (SI) against
SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> The findings of this study,
along with other previous important studies on CQ/HCQ, RDV and FPV
against CoVs, are discussed in the following section.</p><sec id="sec3.1.1"><label>3.1.1</label><title>CQ, HCQ, RDV, and FPV: Four Potential Drugs against
SARS-CoV-2</title><sec id="sec3.1.1.1"><label>a</label><title>CQ and HCQ</title><p>CQ (<bold>1</bold>), a widely used antimalarial and
autoimmune inhibitory drug, was reported to be a potential
broad-spectrum antiviral drug.<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup>
Recently, Wang et al. evaluated the antiviral effect of CQ
against a clinical isolate of SARS-CoV-2 <italic>in
vitro</italic> in Vero E6 cells. CQ was able to
block viral replication at a low concentration [effective
concentration for 50% inhibition (IC<sub>50</sub>) of 1.13
&#x003bc;M] with acceptable cytotoxicity (50% cytotoxic
concentration (CC<sub>50</sub>) of &#x0003e;100
&#x003bc;M).<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Previously, Shen et
al.,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> de Wilde et al.,<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> and Keyaerts et al.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> showed that CQ inhibited the replication of three human
CoVs, HCoV-OC43, SARS-CoV, and HCoV-229E, respectively,
<italic>in vitro</italic> at submicromolar
concentrations. Keyaerts et al. developed an <italic>in
vivo</italic> model to test CQ against HCoV-OC43 in
newborn C57BL/6 mice. The highest survival rate (98.6%)
was found when the mother mice were treated daily with CQ
at a dose of 15 mg/kg body weight (BW).<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> These results suggested that CQ might be an effective
drug to manage human CoV infections. Since the outbreak of
the COVID-19 pandemic in February 2020, CQ and its analog
HCQ have drawn intense attention, and a series of clinical
trials evaluating the therapeutic effects of CQ and HCQ on
SARS-CoV-2 have been conducted in several countries. Huang
and collaborators performed a multicenter prospective
observational study to evaluate the clinical effects of CQ
on SARS-CoV-2, in which a total of 197 patients from 12
hospitals in Guangdong and Hubei Provinces in China were
treated with CQ, and 176 patients were included as
historical controls. The median time for viral RNA to be
undetectable and the duration of fever were shorter in the
CQ-treated group than in the control group. The authors
suggested that CQ could be a cost-effective therapy
without serious adverse events for combating the COVID-19
pandemic.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup></p><p>HCQ sulfate, a derivative of CQ, was first synthesized in
1946 by introducing a hydroxyl group into CQ, and it
showed significantly reduced (&#x0223c;40%) toxicity
compared to CQ.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Gautret et al.
conducted the first open-label, nonrandomized controlled
clinical trial for a therapeutic evaluation of HCQ in 36
COVID-19 patients in France and suggested that 600 mg/day
HCQ significantly reduced viral loads in these patients.
They also showed that when HCQ was used in combination
with azithromycin, it was more efficacious.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> However, this report was questionable
because six HCQ-treated patients who withdrew from the
study were excluded from their data analysis. The
beneficial outcomes of HCQ treatment on COVID-19 patients
were also confirmed by Chen et al., a medical team in
Wuhan, China. They conducted a randomized controlled
clinical trial that included 62 patients to test the
efficacy of HCQ and showed that HCQ treatment
significantly shortened the disease course.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> However, the effectiveness of HCQ for
treating COVID-19 has been the subject of debate.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Recently, Tang and other groups
reported various contradictory effects of HCQ in COVID-19
patients, which disapproved the use of
HCQ.<sup><xref ref-type="bibr" rid="ref44">44</xref>&#x02212;<xref ref-type="bibr" rid="ref47">47</xref></sup> Tang and colleagues conducted an
open-label, randomized controlled trial to evaluate the
efficacy of HCQ in 150 COVID-19 patients within the mild
to moderate clinical classifications. The results showed
that HCQ did not lead to a significantly higher
probability of negative conversion compared to standard
care alone in hospitalized patients with persistent mild
to moderate COVID-19 symptoms. Adverse events, mainly
diarrhea, were significantly higher in patients who
received HCQ.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> Another recent study of
HCQ in 181 COVID-19 patients who required oxygen also did
not support the use of HCQ in patients admitted to the
hospital who required oxygen.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> In
addition, Mehra and colleagues recently conducted a
multinational registry analysis of the use of HCQ or CQ
with or without a macrolide for the treatment of COVID-19,
in which 96&#x0202f;032 patients from 671 hospitals on six
continents were included. The results showed that HCQ or
CQ, used with or without a macrolide, was associated with
decreased in-hospital survival, and increased frequency of
ventricular arrhythmias.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> Therefore,
the FDA withdrew the emergency approval for HCQ as
treatment of COVID-19 based on its ineffectiveness and
serious side effects.</p></sec><sec id="sec3.1.1.2"><label>b</label><title>RDV</title><p>RDV (GS-5734, <bold>2</bold>) is a broad-spectrum antiviral
nucleotide prodrug with potency against a wide array of
RNA viruses, including SARS-CoV and MERS-CoV, in cultured
cells and mouse models.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> It is an
adenosine analog that is incorporated into nascent viral
RNA chains, leading to premature termination.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> A recent study conducted by Wang et
al. showed that the effective concentration for 90%
inhibition (EC<sub>90</sub>) and effective concentration
for 50% inhibition (EC<sub>50</sub>) values of RDV against
SARS-CoV-2 in Vero E6 cells were 1.76 &#x003bc;M and 0.77
&#x003bc;M, respectively. The time-of-addition assay
confirmed that RDV affects viral replication postviral
entry, supporting its mode of action as a nucleotide
analog.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Another <italic>in
vitro</italic> study reported potent antiviral
activity of RDV against HCoV-OC43 and HCoV-229E in Huh7
cells with submicromolar EC<sub>50</sub> values of 0.15
and 0.024 &#x003bc;M, respectively.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup>
Additionally, it potently inhibited SARS-CoV in human
airway epithelial (HAE) cells with an IC<sub>50</sub> of
0.06 &#x003bc;M and SI &#x0003e; 10.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Sheahan
et al. reported that prophylactic or early therapeutic
administration of RDV significantly reduced lung viral
loads and improved clinical outcomes in a murine infection
model.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Holshue and colleagues
reported the first patient diagnosed with COVID-19 in
Washington, USA, who was compassionately treated with
intravenous RDV for the progression of pneumonia on day 7
of hospitalization (illness day 11). Encouragingly, the
patient&#x02019;s clinical condition improved since the
next day after RDV administration, and no adverse effects
were observed.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> Grein and
collaborators reported that in a cohort of hospitalized
severe COVID-19 patients who were treated with
compassionate use of RDV, clinical improvement was
observed in 36 of 53 patients (68%).<sup><xref ref-type="bibr" rid="ref55">55</xref></sup>
In another study, a total of 1063 hospitalized COVID-19
patients were included in a double-blind, randomized,
placebo-controlled trial to test the efficacy of
intravenous RDV against SARS-CoV-2. Preliminary results
revealed that RDV therapy resulted in a median recovery
time of 11 days compared with 15 days in those who
received placebo. This study demonstrated that RDV
treatment could shorten the recovery time in hospitalized
COVID-19 adult patients with lower respiratory tract
infection.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> However, Wang and
collaborators recently reported another study on
hospitalized severe COVID-19 adult patients, in which RDV
did not yield significant clinical benefits. In this
study, 237 patients with severe COVID-19 in 10 hospitals
in Wuhan, China, were enrolled and randomly assigned to
two groups (158 in the RDV group and 79 in the placebo
group) for a treatment course of 10 days. RDV did not
significantly shorten time to clinical improvement.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Although RDV has been expected to be
one of the &#x0201c;powerful weapons&#x0201d; for fighting
the current COVID-19 pandemic, its clinical effectiveness
remains to be further confirmed.</p></sec><sec id="sec3.1.1.3"><label>c</label><title>FPV</title><p>FPV (T-705, <bold>3</bold>), a guanine analog approved for
influenza treatment in Japan in 2014, can effectively
inhibit the RNA-dependent RNA polymerase (RdRp) of RNA
viruses such as influenza, Ebola, yellow fever,
chikungunya, norovirus and
enterovirus.<sup><xref ref-type="bibr" rid="ref58">58</xref>,<xref ref-type="bibr" rid="ref59">59</xref></sup> FPV is
converted into an active phosphoribosylated form (FPV-RTP)
in cells that is recognized as a substrate by the viral
RNA polymerase, thus inhibiting RNA polymerase
activity.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> A recent study
conducted by Wang et al. showed that the EC<sub>50</sub>
of FPV against SARS-CoV-2 in Vero E6 cells was 61.88
&#x003bc;M; the CC<sub>50</sub> value was &#x0003e;400 &#x003bc;M;
and the SI was &#x0003e;6.46.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> FPV was 100%
protective against Ebola virus challenge in mice, although
the EC<sub>50</sub> in Vero E6 cells was as high as 67
&#x003bc;M.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> Since late February
2020, two randomized clinical trials were commenced to
evaluate the efficacy of FPV in treating COVID-19 patients
in China. Cai et al. conducted an open-label controlled
study to evaluate FPV&#x02019;s clinical efficacy for
COVID-19. In this study, 35 patients received oral FPV
plus IFN-&#x003b1; as an inhaled aerosol, and 45 patients
received lopinavir/ritonavir plus IFN-&#x003b1; as an
inhaled aerosol. A significantly shorter viral clearance
time was observed in the FPV group than in the
lopinavir/ritonavir group by day 7. The FPV group also
showed significant improvement in chest imaging compared
with the lopinavir/ritonavir group, with an improvement
rate of 91.4% versus 62.2% at day 4 after treatment. The
rate of adverse reactions in the FPV group (11.4%) was
significantly smaller compared to the lopinavir/ritonavir
group (55.6%).<sup><xref ref-type="bibr" rid="ref62">62</xref></sup></p><p>Chen et al. conducted a prospective, randomized, controlled,
open-label multicenter trial involving adult patients with
COVID-19. A total of 240 enrolled COVID-19 patients were
randomly assigned to receive conventional therapy plus FPV
or Arbidol (120 patients in each group), a broad-spectrum
antiviral compound that blocks viral fusion,<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> for 10 days. The results showed that
FPV led to significantly shorter latencies to relief of
pyrexia by 1.70 days and cough by 1.75 days. However, no
differences were observed in the rate of auxiliary oxygen
therapy or noninvasive mechanical ventilation. The most
frequently observed FPV-associated adverse event was
elevation of serum uric acid.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup></p><p>FPV currently appears to be relatively safe and effective
against COVID-19. Since the two studies reviewed above
used other antiviral drugs (lopinavir/ritonavir and
Arbidol) as their controls, the exact effectiveness of FPV
for COVID-19 remains to be further evaluated with
randomized and controlled clinical studies.</p></sec></sec><sec id="sec3.1.2"><label>3.1.2</label><title>Other Effective CoV Inhibitors</title><p>Another guanine derivative, ribavirin (<bold>4</bold>), approved
for treating hepatitis C virus (HCV) and respiratory syncytial
virus (RSV) infections clinically, has been evaluated in SARS
and MERS patients, but side effects such as anemia can be severe
at high doses,<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> and whether it offers
sufficient potency against SARS-CoV-2 is uncertain. A fixed dose
of the anti-HIV combination therapy, lopinavir/ritonavir, has
been proposed for combating COVID-19 as it was effective in
treating SARS in various studies.<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref66">66</xref></sup> Lopinavir
(<bold>5</bold>) is an HIV-1 protease inhibitor reported
to block the SARS-CoV 3CL<sup>pro67</sup> and is usually
combined with ritonavir (<bold>6</bold>) to increase the
half-life of lopinavir by inhibiting cytochrome P450.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> On January 18, 2020, a randomized,
controlled, open-label trial involving 199 hospitalized severe
COVID-19 patients was initiated to evaluate the efficacy of
lopinavir/ritonavir treatment in hospitals in Wuhan, China.
Disappointingly, no differences were observed between
lopinavir/ritonavir treatment and standard care in clinical
improvement or mortality within 28 days.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup></p><p>Alkaloids represent a class of phytocompounds with broad
bioactivities, including antiviral activity.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> Matrine (<bold>7</bold>), an alkaloid extracted from
<italic>Sophora flavescens,</italic> shows a wide range of
pharmacological effects, including antioxidant, anticancer, and
anti-inflammatory effects.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> Various studies
showed that matrine exhibited antiviral activities against
coxsackievirus B3 (CVB3) in Vero cells and influenza H3N2 virus
in MDCK cells.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> Recently, Jing et al.
evaluated the therapeutic effect of matrine sodium chloride in a
mouse pneumonia model infected with HCoV-229E. The results
showed that intraperitoneal injection of matrine sodium chloride
significantly decreased the pathological damage to the lung
tissue and reduced the lung index. The percentage of
CD4<sup>+</sup> and CD8<sup>+</sup> T cells, the number of
B cells in peripheral blood, the production of IL-6, IL-10,
TNF-&#x003b1;, IFN-&#x003b3;, and the viral load in the lung were
significantly inhibited compared to those in the controls.
Therefore, matrine sodium chloride showed a therapeutic effect
on HCoV-229E-infected mice via a mechanism related to the
regulation of immune function.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup></p><p>Another alkaloid, lycorine (<bold>8</bold>), isolated from
<italic>Amaryllidaceae</italic> plants, has been reported
to inhibit poliomyelitis virus, Bunyamwera virus, herpes simplex
virus, dengue virus, West Nile virus, and SARS-CoV <italic>in
vitro.</italic>(<xref ref-type="bibr" rid="ref74">74</xref>,<xref ref-type="bibr" rid="ref75">75</xref>) Lycorine exhibited
significant inhibition of SARS-CoV in Vero cell-based cytopathic
effect (CPE) inhibition assays, with an EC<sub>50</sub> of
0.0157 &#x003bc;M, CC<sub>50</sub> of 14.98 &#x003bc;M, and an SI of
954.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> The anti-CoV activity of
lycorine was recently confirmed by Shen and colleagues.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Furthermore, they found that lycorine
protected BALB/c mice against lethal HCoV-OC43 infection by
suppressing viral replication in the central nervous system.
Twenty days after HCoV-OC43 infection, intraperitoneal injection
of lycorine at 15 mg/kg provided 83.3% protection in infected
mice, similar to the survival rate of the CQ-treated
group.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> These results suggest that
lycorine could be a broad-spectrum antiviral agent against CoV
infection and might offer promising therapeutic possibilities
for combating SARS-CoV-2 infection.</p><p>Camostat (<bold>9</bold>) is a serine protease inhibitor used to
treat chronic pancreatitis. Zhou et al. reported that camostat
was effective in protecting mice from a lethal infection by
SARS-CoV, with a survival rate of 60%.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup>
Recently, Hoffman et al. indicated that SARS-CoV-2 utilizes the
SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) and the
cellular protease transmembrane protease serine 2 (TMPRSS2) to
enter lung cells. Camostat was able to inhibit TMPRSS2,
effectively inhibiting SARS-CoV-2 entry into mouse lung
cells.<sup><xref ref-type="bibr" rid="ref78">78</xref></sup> These findings suggest that
camostat may be a valuable therapeutic against COVID-19.</p></sec></sec><sec id="sec3.2"><label>3.2</label><title>Potential Plant-Derived Compounds against SARS-CoV-2</title><p>Natural products and TCMs are rich sources of antiviral compounds,
including terpenoids, alkaloids, flavonoids, and
polyphenols.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref81">81</xref>,<xref ref-type="bibr" rid="ref82">82</xref></sup> In the
past two decades, due to ongoing efforts to develop antivirals against
SARS-CoV and MERS-CoV infections, multiple small molecules derived
from TCMs and natural plants were identified to have significant
anti-CoV activity.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref83">83</xref></sup> In the next sections, we
summarize the natural inhibitors reported to suppress CoV replication.
These inhibitors might be developed into effective antiviral
treatments against SARS-CoV-2 and emerging novel CoVs.</p><p>SARS-CoV has a single-stranded RNA genome approximately 30 kb long
containing 5&#x02032;-methylated caps and 3&#x02032;-polyadenylated
tails. The partially overlapping 5&#x02032;-terminal open reading frame
1a/b (ORF1a/ORF1b) within the 5&#x02032; two-thirds of the genome
encodes the large replicase polyproteins 1a (pp1a) and pp1ab. The
polyproteins are cleaved by two virus-encoded proteinases:
PL<sup>pro</sup> and 3CL<sup>pro</sup> to produce 16
nonstructural proteins (NSPs), as shown in <xref rid="fig2" ref-type="fig">Figure
<xref rid="fig2" ref-type="fig">2</xref></xref>. Among the 16 NSPs, RdRp and Hel
are involved in the transcription and replication of the virus genome.
The 3&#x02032; one-third of the CoV genome encodes structural proteins
essential for virus binding to cell-surface receptors and virion
assembly.<sup><xref ref-type="bibr" rid="ref65">65</xref>,<xref ref-type="bibr" rid="ref84">84</xref>,<xref ref-type="bibr" rid="ref85">85</xref></sup>
3CL<sup>pro</sup>, PL<sup>pro</sup>, RdRp, and Hel/RNA
nucleoside triphosphatase (NTPase) play pivotal roles in SARS-CoV
replication and are therefore ideal drug targets.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup>
Some small molecules from the terpenoid, lignoid, polyphenol, and
flavonoid classes were identified as effective SARS-CoV inhibitors by
targeting viral proteinases.<sup><xref ref-type="bibr" rid="ref87">87</xref>,<xref ref-type="bibr" rid="ref88">88</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Genome structures of SARS-CoV- 2 and SARS-CoV. A typical CoV
has a single-stranded positive-sense genome (top panel).
Next to the 5&#x02032; UTR, two-thirds of the genome
consists of partially overlapping ORFs (ORF1a and ORF1b)
encoding large NSPs (nsp1 to nsp16). During translation,
the ORF1b protein is produced by a 1 bp ribosomal
frameshift in the reading frame of ORF1a. The remaining
one-third of the genome at the 3&#x02032; end encodes
structural proteins such as the spike (S), membrane (M),
envelope (E), and nucleocapsid (N) proteins. Other
proteins, such as SARS-CoV-2 ORF3 (NC-045512) and SARS-CoV
3a (NC-004178.3), are shown. The key enzymes, namely,
papain-like protease (PL<sup>pro</sup>), 3C-like serine
protease (3CL<sup>pro</sup>), RNA-dependent RNA polymerase
(RdRp), and helicase (Hel), are shown. The clinical
applications of the key pathogenic nonstructural genes or
gene products are shown in boxes. (Bottom panel) A
schematic representation of the morphology of the
SARS-CoV-2 virus. The virus is a large pleomorphic
spherical particle with a lipid bilayer composed of the S,
M, and E proteins surrounding the helical
nucleocapsid-wrapped single-stranded RNA ribonucleoprotein
genome.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0002" id="gr2" position="float"/></fig><p>In a recent study, it was demonstrated that SARS-CoV-2 and SARS-CoV share
a remarkable 96% sequence identity in their 3CL<sup>pro</sup> and RdRp
and 83% sequence identity in their
PL<sup>pro</sup>.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> Therefore,
existing SARS-CoV inhibitors may be effective against
SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref89">89</xref>,<xref ref-type="bibr" rid="ref90">90</xref></sup><xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>represents the candidate antiviral agents for
SARS-CoV-2.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Candidate antiviral agents for SARS-CoV-2 in relation to the
viral replication cycle. SARS-CoV-2 enters host cells
either through an endosomal pathway or by
virus&#x02013;cell fusion mediated by spike (S)
glycoprotein binding to the host cell receptor
angiotensin-converting enzyme 2 (ACE2). Viral genomic RNA
is unveiled in the cytoplasm, and the single-stranded
positive-sense genome is transcribed to produce the viral
proteases papain-like protease (PL<sup>pro</sup>) and
3C-like serine protease (3CL<sup>pro</sup>), which cleave
the two large polyproteins (pp1a and pp1ab) into 16 mature
nonstructural proteins (NSPs), including two replicase
polyproteins (RNA-dependent RNA polymerase (RdRp) and
helicase (Hel)). Mature NSPs and the RdRp and Hel proteins
are gathered into replication&#x02013;transcription
complexes (RTCs) for viral replication and transcription.
RTCs synthesize negative-strand guide RNA (gRNA) and a set
of subgenomic RNAs for viral replication and
transcription. The newly produced subgenomic RNAs are
translated into viral structural proteins such as the S,
membrane (M), and envelope (E) proteins. These proteins
are inserted into the membrane of the rough endoplasmic
reticulum (ER) and then transported to the ER-Golgi
intermediate compartment (ERGIC) to assemble with the N
protein-encapsidated RNA to form viral particles. Virions
are then released from the cell through exocytosis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0003" id="gr3" position="float"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>SARS-CoV inhibitors targeting 3CL protease
(3CL<sup>pro</sup>) and papain-like protease
(PL<sup>pro</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0004" id="gr4" position="float"/></fig><fig id="fig5" position="float"><label>Figure 5</label><caption><p>SARS-CoV inhibitors targeting Hel.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0005" id="gr5" position="float"/></fig><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Inhibitors with other targets against SARS-CoV.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0006" id="gr6" position="float"/></fig><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Replication inhibitors with an undefined mechanism against
various CoVs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_0007" id="gr7" position="float"/></fig><sec id="sec3.2.1"><label>3.2.1</label><title>SARS-CoV 3CL<sup>pro</sup> Inhibitors</title><p>SARS-CoV encodes a chymotrypsin-like protease (3CL<sup>pro</sup>),
which is also called the main protease because it plays a
pivotal role in processing viral polyproteins and controlling
replicase complex activity.<sup><xref ref-type="bibr" rid="ref91">91</xref></sup> Research on
drugging SARS-CoV has focused on developing small molecules such
as 3CL<sup>pro</sup> inhibitors. Here, we discuss various
3CL<sup>pro</sup> inhibitors from different classes, such
as terpenoids, lignoids, phlorotannins, and flavonoids.</p><p>Twenty-two compounds were evaluated for activity against SARS-CoV
3CL<sup>pro</sup>. The terpenoid betulinic acid
(<bold>10</bold>) and the lignanoid savinin
(<bold>11</bold>) inhibited 3CL<sup>pro</sup> activity
with IC<sub>50</sub> values of 10 and 25 &#x003bc;M,
respectively.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup> Quinone-methide
triterpenes (<bold>12</bold>&#x02013;<bold>15</bold>) isolated
from <italic>Tripterygium regelii</italic> exhibited potent
inhibitory activities of 3CL<sup>pro</sup> with IC<sub>50</sub>
values ranging from 2.6 to 10 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref92">92</xref></sup>
Seven flavonoids from <italic>Isatis indigotica</italic> roots
were evaluated for their anti-SARS-CoV 3CL<sup>pro</sup>
activities. Among them, the flavonoid hesperetin
(<bold>16</bold>, IC<sub>50</sub> = 8.3 &#x003bc;M) showed
the highest inhibitory activity of 3CL<sup>pro</sup> in a
dose-dependent manner.<sup><xref ref-type="bibr" rid="ref93">93</xref></sup></p><p>Marine algae are rich sources of structurally diverse bioactive
compounds that have great potential as pharmaceutical and
biomedical agents. Park et al. reported that nine phlorotannins
isolated from the edible brown algae <italic>Ecklonia
cava</italic> possessed SARS-CoV 3CL<sup>pro</sup>
inhibitory activities in a dose-dependent and competitive
manner. Among the nine compounds, dieckol (<bold>17</bold>),
with a structure of two eckol groups linked to diphenyl ether,
exhibited the most potent SARS-CoV 3CL<sup>pro</sup> inhibitory
activity with an IC<sub>50</sub> value of 2.7 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref94">94</xref></sup></p><p>Flavonoids are one class of the most abundant natural products with
extensive physiological activities, including antioxidation,
anti-inflammation, and antiviral effects.<sup><xref ref-type="bibr" rid="ref95">95</xref></sup>
Ryu et al. found that biflavone amentoflavone (<bold>18</bold>)
isolated from <italic>Torreya nucifera</italic> possessed
stronger SARS-CoV 3CL<sup>pro</sup> inhibitory activity
(IC<sub>50</sub> = 8.3 &#x003bc;M) than two authentic
flavonoids, luteolin (<bold>19</bold>) and quercetin
(<bold>20</bold>, IC<sub>50</sub> = 20.2 and 23.8
&#x003bc;M, respectively). Structure&#x02013;activity relationship
analysis suggested that flavonoids against 3CL<sup>pro</sup>
appeared to be associated with an apigenin moiety at the
C-3&#x02032; position.<sup><xref ref-type="bibr" rid="ref96">96</xref></sup> In another study,
quercetin (<bold>20</bold>), epigallocatechin gallate
(<bold>21</bold>), and gallocatechin gallate
(<bold>22</bold>) displayed significant inhibition of
3CL<sup>pro</sup> with IC<sub>50</sub> values of 73, 73,
and 47 &#x003bc;M, respectively. Gallocatechin gallate was found
to be a competitive inhibitor of 3CL<sup>pro</sup>.<sup><xref ref-type="bibr" rid="ref97">97</xref></sup> Recently, by use of a flavonoid library,
several flavonoids with a wide range of inhibitory activities
against 3CL<sup>pro</sup> were detected. Rhoifolin
(<bold>23</bold>), herbacetin (<bold>24</bold>), and
pectolinarin (<bold>25</bold>) showed the highest inhibitory
activity against SARS-CoV 3CL<sup>pro</sup>. The enzyme kinetics
assay and docking simulation results suggested that the active
flavonoids have a wide range of binding affinities to SARS-CoV
3CL<sup>pro</sup> due to their hydrophobic aromatic rings
and hydrophilic hydroxyl groups. The presence of carbohydrate
groups appeared to be important for the binding affinity of the
chromen-4-one moiety.<sup><xref ref-type="bibr" rid="ref98">98</xref></sup> Therefore, direct
inhibition of the 3CL<sup>pro</sup> protein may be the mechanism
of action of flavonoids.</p><p>Park et al. reported that nine alkylated chalcones isolated from
<italic>Angelica keiskei</italic> exhibited different
inhibitory activities against SARS-CoV 3CL<sup>pro</sup> and
PL<sup>pro</sup> based on a cell-free assay. Of the nine
chalcones, xanthoangelol E (<bold>26</bold>), containing a
perhydroxyl group, showed the most potent 3CL<sup>pro</sup> and
PL<sup>pro</sup> inhibitory activity (IC<sub>50</sub> =
7.1 and 1.2 &#x003bc;M, respectively). Protein inhibitor analysis
showed that chalcones exhibited competitive inhibition of
SARS-CoV 3CL<sup>pro</sup>, while noncompetitive inhibition was
evident with SARS-CoV PL<sup>pro</sup>.<sup><xref ref-type="bibr" rid="ref99">99</xref></sup></p><p>A series of isatin derivatives were designed as possible SARS-CoV
3CL<sup>pro</sup> inhibitors and evaluated by protease
assay. Compounds <bold>27</bold> and <bold>28</bold> displayed
significant inhibition of 3CL<sup>pro</sup> with IC<sub>50</sub>
values of 1.04 and 1.18 &#x003bc;M, respectively.<sup><xref ref-type="bibr" rid="ref100">100</xref></sup> Additionally, the peptidyl bisulfite adduct
GC376 (<bold>29</bold>) was found to be a potent inhibitor with
an IC<sub>50</sub> of 4.35 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref101">101</xref></sup></p><p>For developing anti-SARS agents, Shie et al. prepared a diversified
library of peptide anilides and evaluated their inhibition
activities against SARS-CoV 3CL<sup>pro</sup>. Among the 32
tested compounds, the peptide anilide JMF1507 (<bold>30</bold>)
showed the most potent inhibition, with an IC<sub>50</sub> value
of 0.06 &#x003bc;M and a
<italic>K</italic><sub><italic>i</italic></sub> value of
0.03 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> Another highly potent
compound that is a peptidomimetic inhibitor (<bold>31</bold>)
was reported to have a SARS-CoV 3CL<sup>pro</sup> inhibitory
activity of 0.20 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup></p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>SARS-CoV PL<sup>pro</sup> Inhibitors</title><p>Recent studies directed at PL<sup>pro</sup> suggested potential
roles beyond viral peptide cleavage, including deISGylation,
deubiquitination, and involvement in evasion of the innate
immune response.<sup><xref ref-type="bibr" rid="ref104">104</xref>,<xref ref-type="bibr" rid="ref105">105</xref></sup> Compared to the
existing SARS-CoV 3CL<sup>pro</sup> inhibitors, fewer natural
compounds have been reported for PL<sup>pro</sup> inhibition.
Since 2012, Park et al. have made ongoing efforts to develop CoV
PL<sup>pro</sup> inhibitors. They isolated nine
diarylheptanoids from <italic>Alnus japonica</italic> and found
that hirsutenone (<bold>32</bold>) exhibited an IC<sub>50</sub>
value of 4.1 &#x003bc;M with noncompetitive inhibition. Further
structure&#x02013;activity relationship analysis suggested that
the &#x003b1;,&#x003b2;-unsaturated carbonyl groups linked to a
catechol moiety in the structure of hirsutenone were the key
requirement for PL<sup>pro</sup> inhibition.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> In a later study, they found a polyphenol, papyriflavonol A
(<bold>33</bold>), derived from <italic>Broussonetia
papyrifera</italic>, with a promising inhibitory effect on
PL<sup>pro</sup> (IC<sub>50</sub>, 3.7 &#x003bc;M).<sup><xref ref-type="bibr" rid="ref107">107</xref></sup> Kim et al. found that the ethanol extract
of <italic>Psoralea corylifolia</italic> seeds showed strong
activity against SARS-CoV PL<sup>pro</sup> (IC<sub>50</sub> = 15
&#x003bc;g/mL). Furthermore, they demonstrated that six flavonoids
isolated from the ethanol extract displayed PL<sup>pro</sup>
inhibition in a dose-dependent manner with IC<sub>50</sub>
values ranging from 4.2 to 38.4 &#x003bc;M, in which the compounds
isobavachalcone (<bold>34</bold>) and psoralidin
(<bold>35</bold>) were the most promising, inhibiting
PL<sup>pro</sup> with IC<sub>50</sub> values of 7.3 and
4.2 &#x003bc;M, respectively. Interestingly, the inhibition
kinetics analysis by Lineweaver&#x02013;Burk plots showed that
isobavachalcone and psoralidin are mixed-type inhibitors, as the
two compounds exhibited affinities for both the substrate-bound
and free enzymes.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> Similarly, the cinnamic
amide terrestrimine (<bold>36</bold>), isolated from
<italic>Tribulus terrestris</italic> fruits, was also
found to be a mixed-type inhibitor with an IC<sub>50</sub> value
of 15.8 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup></p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>SARS-CoV Hel Inhibitors</title><p>The SARS-CoV NTPase/Hel, another NSP (nsp13), is also an attractive
target, as it is indispensable for viral replication.<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> Hel has been reported to possess the
ability to translocate along with nucleic acids by hydrolyzing
ATP.<sup><xref ref-type="bibr" rid="ref111">111</xref></sup> Important progress has been
made in the identification of novel CoV Hel inhibitors in
natural compounds and their derivatives. Tanner et al. reported
that four adamantane-derived bananins, including bananin
(<bold>37</bold>), vanillinbananin (<bold>38</bold>),
iodobananin (<bold>39</bold>), and eubananin (<bold>40</bold>),
exhibited potent inhibition against both ATPase and Hel activity
with IC<sub>50</sub> values in the ranges of 0.54&#x02013;2.8
&#x003bc;M and 2.7&#x02013;7.0 &#x003bc;M, respectively. In a cell
culture system of SARS-CoV, bananin (<bold>37</bold>) showed
significant antiviral activity with an EC<sub>50</sub> of less
than 10 &#x003bc;M and a CC<sub>50</sub> of 390 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup> Another compound,
7-ethyl-8-mercapto-3-methyl-3,7-dihydro-1<italic>H</italic>-purine-2,6-dione
(EMMDPD, <bold>41</bold>), was identified as a SARS-CoV Hel
inhibitor and was able to suppress ATP hydrolysis.<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> Similarly,
(<italic>E</italic>)-3-(furan-2-yl)-<italic>N</italic>-(4-sulfamoylphenyl)acrylamide
(FSPA, <bold>42</bold>) was also found to inhibit ATP hydrolysis
and Hel activities and did not show significant cytotoxicity at
40 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> Two natural compounds,
myricetin (<bold>43</bold>) and scutellarein <bold>(44</bold>),
were reported as strong inhibitors of the ATPase activity of
SARS-CoV Hel (IC<sub>50</sub> = 2.71 and 0.86 &#x003bc;M,
respectively).<sup><xref ref-type="bibr" rid="ref114">114</xref></sup></p></sec><sec id="sec3.2.4"><label>3.2.4</label><title>Inhibitors of Other Targets against SARS-CoV</title><p>Zhou et al. synthesized a series of vinyl sulfone analogs and
evaluated their antiviral activity against SARS-CoV. Among all
tested analogs, K11777 (<bold>45</bold>), SMDC256159
(<bold>46</bold>), and SMDC256160 (<bold>47</bold>) showed
the most potent antiviral activities in 293T-ACE2 cells, with
IC<sub>50</sub> values of 3.2 &#x000d7;
10<sup>&#x02013;4</sup>, 7.0 &#x000d7; 10<sup>&#x02013;5</sup>,
and 8.0 &#x000d7; 10<sup>&#x02013;5</sup> &#x003bc;M, respectively.
Structurally, the potent antiviral activity of vinyl sulfones is
associated with the presence of a basic piperazine ring at the
P3 position, which is consistent with accumulation in endosomal
(acidic) compartments where the target cysteine proteases
required for viral entry are located.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup> Thus,
vinyl sulfones are promising antiviral lead compounds for
further optimization as potential CoV inhibitors.</p><p>Nitazoxanide (<bold>48</bold>) is a commercially available
antiprotozoal agent with potential antiviral activity against a
number of viruses, including animal and human CoVs. Wang et al.
recently reported that nitazoxanide inhibited SARS-CoV-2 with an
EC<sub>50</sub> of 2.12 &#x003bc;M. Nafamostat
(<bold>49</bold>), a highly efficacious inhibitor of
MERS-CoV as it prevents membrane fusion, inhibited SARS-CoV-2
with an EC<sub>50</sub> of 22.5 &#x003bc;M. However, the
nucleoside analog penciclovir (<bold>50</bold>) was required for
viral inhibition, yielding an EC<sub>50</sub> of 95.96 &#x003bc;M.
Further <italic>in vivo</italic> studies of the two drugs
against SARS-CoV-2 infection are recommended.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></p></sec><sec id="sec3.2.5"><label>3.2.5</label><title>Inhibitors with Undefined Replication Inhibiting Mechanisms
against CoVs</title><p>Terpenoids display a wide range of biological activities against
various diseases, such as influenza, malaria, cancer, and
inflammation.<sup><xref ref-type="bibr" rid="ref115">115</xref></sup> One of the important
bioactive compounds from licorice root (<italic>Glycyrrhiza
radix</italic>) is the triterpene glycoside GL
<bold>51</bold>.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup> It has been
reported to have broad-spectrum antiviral activity<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> and is currently used to treat patients
infected with HCV and upper respiratory tract infections.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> Cinatl et al. examined the antiviral
effects of GL on clinical isolates of SARS-CoV (strains FFM-1
and FFM-2) in Vero cells. GL was effective when given both
during and after the virus adsorption period with an
EC<sub>50</sub> value of 365 &#x003bc;M and little
cytotoxicity (CC<sub>50</sub> = 24&#x0202f;000 &#x003bc;M).<sup><xref ref-type="bibr" rid="ref118">118</xref></sup></p><p>The antiviral activities of 15 GL derivatives against SARS-CoV
replication in Vero cells were evaluated by Hoever and
colleagues. Among the 15 derivatives tested, seven inhibited
SARS-CoV replication at concentrations lower than GL. Addition
of <italic>N</italic>-acetylglucosamine into the GL glycoside
chain increased anti-SARS-CoV activity approximately 9 times
compared to GL. Compound <bold>52</bold> inhibited SARS-CoV
replication (EC<sub>50</sub> = 40 &#x003bc;M with a
CC<sub>50</sub> of &#x0003e;3000 &#x003bc;M), resulting in an SI
of &#x0003e;75. It is proposed that addition of the
<italic>N</italic>-acetylglucosamine residue into the
carbohydrate part of the GL molecule increases its hydrophilic
properties, which might be important for the interaction of GL
with viral proteins, especially the highly glycosylated S
protein on the virus envelope. The S protein is important for
viral entry into the cell by binding to cellular
receptors.<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> It is speculated that
viral entry was inhibited by
<italic>N</italic>-acetylglucosamine binding to the
carbohydrates of the S proteins.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> In
addition, the anti-SARS-CoV activity of several GL glycopeptides
has been studied. For example, the glycopeptide containing
<sc>l</sc>-Cys (SBn, <bold>53</bold>) exhibited the
strongest activity with an EC<sub>50</sub> of 35 &#x003bc;M and a
CC<sub>50</sub> of 1462 &#x003bc;M, which was 10-fold
increased antiviral activity compared to GL (EC<sub>50</sub>,
365 &#x003bc;M).<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> One derivative of aescin,
&#x003b1;-hederin (<bold>54</bold>), showed strong anti-SARS-CoV
activity at concentrations of <italic>&#x0003c;</italic>100
&#x003bc;M.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> In addition, previous
studies demonstrated that modification of GL may lead to novel
anti-SARS-CoV drugs with increased activity.</p><p>SSs, including SSa, SSb, SSc, and SSd, are active triterpenoids
isolated from <italic>Bupleurum</italic> species.<sup><xref ref-type="bibr" rid="ref120">120</xref></sup> These compounds are effective against
viruses such as HIV, influenza virus, and herpes simplex
virus.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> Cheng et al. evaluated the
antiviral activity of four types of SSs against HCoV-229E in
Vero cells and found that saikosaponin B<sub>2</sub>
(SSB<sub>2</sub>, <bold>55</bold>) exhibited the strongest
anti-HCoV-229E activity with an IC<sub>50</sub> value of 1.7
&#x003bc;M. Time-of-addition studies showed that SSb
(<bold>55</bold>) interferes with viral replication early
during the viral replication cycle, likely due to absorption and
penetration of the virus.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> In addition,
triterpenoid betulonic acid (<bold>56</bold>) was found to be a
potent inhibitor for SARS-CoV replication with an
EC<sub>50</sub> value of 0.63 &#x003bc;M and CC<sub>50</sub>
of &#x0003e;100 &#x003bc;M in an <italic>in vitro</italic> study
reported by Wen and colleagues. Meanwhile, they found that
diterpenoids (<bold>57</bold>&#x02013;<bold>60</bold>) were also
potent SARS-CoV inhibitors with EC<sub>50</sub> values ranging
from 1.15 to 1.57 &#x003bc;M. These findings provide a new
direction for the development of anti-SARS-CoV agents.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup></p><p>Shen et al. screened a 2000-compound library of approved drugs and
pharmacologically active compounds and identified seven
compounds (lycorine (<bold>8</bold>), mycophenolic acid
(<bold>61</bold>), emetine (<bold>62</bold>),
mycophenolate mofetil (<bold>63</bold>), phenazopyridine
(<bold>64</bold>), monensin sodium (<bold>65</bold>), and
pyrvinium pamoate (<bold>66</bold>)) as broad-spectrum
inhibitors for four CoVs (HCoV-OC43, HCoV-NL63, MERS-CoV, and
MHV-A59) with EC<sub>50</sub> values ranging from 0.12 to 4.12
&#x003bc;M <italic>in vitro.</italic>(<xref ref-type="bibr" rid="ref1">1</xref>) In
addition, three bisbenzylisoquinoline alkaloids, including
tetrandrine (<bold>67</bold>), fangchinoline (<bold>68</bold>),
and cepharanthine (<bold>69</bold>) isolated from
<italic>Stephania tetrandra,</italic> have shown
anti-HCoV-OC43 activity in MRC-5 human lung cell cultures. The
IC<sub>50</sub> values of tetrandrine, fangchinoline, and
cepharanthine were 0.29, 0.91, and 0.72 &#x003bc;M, respectively,
indicating that compound <bold>67</bold> was more effective
against HCoV-OC43 than the other two alkaloids. Tetrandrine
appeared to inhibit viral replication during the early infection
stage, likely related to interaction with the viral S and N
proteins.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup></p><p>A SARS-CoV and Vero E6 cell-based assay was developed to screen
existing drugs to identify effective anti-SARS agents. The
potent inhibitors found were reserpine (<bold>70</bold>), a
well-known antihypertensive drug derived from several members of
the genus <italic>Rauwolfia</italic>, andaescin
(<bold>71</bold>), a cerebrovascular drug widely used in Europe,
and valinomycin (<bold>72</bold>), a peptide insecticide
targeting potassium ion transporter. The IC<sub>50</sub>, based
on ELISA, and SI for reserpine, aescin, and valinomycin were 3.4
&#x003bc;M (SI = 7.3), 6.0 &#x003bc;M (SI = 2.5), and 0.85 &#x003bc;M
(SI = 80), respectively, against SARS-CoV.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup></p><p>In <xref rid="tbl7" ref-type="other">Table <xref rid="tbl7" ref-type="other">7</xref></xref>, compounds
<bold>54</bold>&#x02013;<bold>72</bold> showed significant
antiviral activity against CoV replication <italic>in
vitro</italic> with IC<sub>50</sub> &#x02264; 10 &#x003bc;M.
Although GL and its derivatives
(<bold>51</bold>&#x02013;<bold>53</bold>) exhibited less
inhibitory activity with IC<sub>50</sub> values ranging from 35
to 365 &#x003bc;M, their cytotoxicity was much lower with
CC<sub>50</sub> values ranging from 1462 to 24&#x0202f;000
&#x003bc;M. The detailed mechanism(s) of action of these compounds
needs to be investigated further to better target
SARS-CoV-2.</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Outlook and Future Perspectives</title><p>The present pandemic caused by SARS-CoV-2 is spreading globally and has posed
major challenges to public health due to a lack of a specific vaccine and
antiviral drugs. Complementary and alternative treatments are urgently
needed for the management of COVID-19 patients. In China, TCM has been used
for thousands of years in the treatment of pandemic and endemic diseases.
Since the outbreak of COVID-19 in early January 2020, integrated treatments
of TCMs with conventional medicines have been extensively used to treat
COVID-19 patients in China and have achieved positive effects. However, the
major challenges in the use of TCM are inconsistencies in the origins of the
herbs used and incomplete understandings of the active compounds in these
preparations and their mechanisms of action.</p><p>While randomized, double-blind and placebo-controlled studies are the most
effective methods to assess therapeutic efficacy; most studies evaluating
the efficacy of TCMs in the treatment of SARS-CoV infections were found to
be poorly designed. Hopefully, current and future clinical studies to
evaluate the efficacy of TCMs in the treatment of COVID-19 will be conducted
using stricter protocols and allocation concealment. Furthermore,
standardized manufacturing, quality control and monitoring should be
established to ensure consistency. Although the identification of all
components in a TCM formula is almost impossible, the identification of
harmful components and the main active components is indispensable for
understanding the underlying mechanism of TCMs and avoiding potentially
harmful TCMs in the treatment of COVID-19. Some TCM herbs are reported to
contain mutagens and nephrotoxins,<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> while the
toxicology of most TCM herbs remains to be fully understood.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup> In addition, some components in TCMs might interact
with Western medicines and lead to additive, synergistic, or antagonistic
effects.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> Thus, the safety of TCMs used against
COVID-19 should be carefully evaluated.</p><p>Since the COVID-19 outbreak in early January 2020, global ongoing efforts to
identify effective drugs against COVID-19 have been undertaken, including
clinical trials to evaluate the effectiveness of some commercially available
drugs. CQ and its analog HCQ have received the highest attention; however,
the FDA has withdrawn the emergency approval for HCQ as a treatment of
COVID-19 based on its ineffectiveness and serious side effects. RDV and FPV
might be relatively effective drugs for COVID-19 at present, but the exact
effectiveness of the two drugs remains to be further evaluated with
randomized and controlled clinical studies. Therefore, effective
therapeutics against COVID-19 are still urgently needed. Various stages of
the SARS-CoV-2 viral life cycle could be targeted by small molecule
antiviral inhibitors. Four viral NSPs, including protease 3CL<sup>pro</sup>,
PL<sup>pro</sup>, RdRp, and Hel play pivotal roles in SARS-CoV
replication and are therefore ideal targets. The drug-repurposing effort
summarized in this report focuses primarily on small-molecule inhibitors
known to be effective against CoVs, including SARS-CoV and MERS-CoV, with a
wide variety of chemical structure categories. However, among the 72
identified small-molecule inhibitors summarized in <xref rid="tbl3" ref-type="other">Tables
<xref rid="tbl3" ref-type="other">3</xref></xref>&#x02013;<xref rid="tbl7" ref-type="other">7</xref>, only a few
potential inhibitors have progressed beyond the identification of having an
effect <italic>in vivo</italic>, and most of the agents with <italic>in
vitro</italic> anti-CoV activity remain to be evaluated for their
<italic>in vivo</italic> antiviral activity.</p><p>Suitable animal models are critical for testing anti-CoV drugs. Some non-human
primates were found permissive to SARS-CoV, but none consistently reproduced
severe human disease.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Small animals, including mice
strains such as BALB/c, knockout mice with immune deficiencies, ferrets, and
golden Syrian hamsters can be productively infected with SARS-CoV, but few
develop clinical symptoms.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Recently, Sun et al.
successfully developed a mouse model expressing human ACE2 via inoculation
with a replication-deficient adenovirus (Ad5-hACE2). These mice showed
weight loss, severe pulmonary pathology, and high viral load in the lungs
post-SARS-CoV-2 infection but no mortality.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> Therefore,
the limited availability of animal models remains an obstacle<sup><xref ref-type="bibr" rid="ref65">65</xref></sup></p><p>Due to the acute nature of COVID-19 and the importance of immunopathology,
combination therapies aimed at the virus and host are likely to yield the
best clinical outcomes. Fatal SARS-CoV-2 cases are closely related to
cytokine storms in patient lungs, similar to SARS-CoV and highly pathogenic
IAV infections.<sup><xref ref-type="bibr" rid="ref128">128</xref>,<xref ref-type="bibr" rid="ref129">129</xref></sup> Thus, the application of anti-inflammatory drugs for
COVID-19 patients, especially for severe cases, is almost equally as
important as antivirals. In fact, glucocorticoids such as methylprednisolone
have been approved to treat some severe COVID-19 patients in combination
with antiviral agents in China. Recently, researchers at the University of
Oxford found that a low-to-moderate dose (6 mg/day for 10 days) of
dexamethasone reduced deaths in hospitalized COVID-19 patients who were on
ventilators by one-third or receiving oxygen support by one-fifth, but the
steroid did not benefit hospitalized COVID-19 patients who did not require
respiratory support.<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> However, the use of
glucocorticoids might cause side effects for patients, including
immunosuppression, delayed virus clearance time, and osteoporosis.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> In this regard, nonsteroidal anti-inflammatory drugs
(NSAIDs) that are not associated with these side effects might be a
preferred option for treating COVID-19 patients in combination with
antiviral agents. Further studies are urgently needed to identify potent
anti-inflammatory drugs for COVID-19 patients from a large number of NSAIDs.
In addition, treatment (especially antiviral therapy) should be started as
early as possible to prevent extensive lung damage.</p><p>The COVID-19 pandemic represents the greatest challenge to global public health
in the past century. However, the speed and number of basic and clinical
studies aimed at identifying and developing potential vaccines and drugs
bring hope that effective countermeasures against SARS-CoV-2 will be made
available in the coming months.</p></sec></body><back><notes id="NOTES-d7e4662-autogenerated" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00626?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00626</ext-link>.<list id="silist" list-type="simple"><list-item><p>Tables of TCM
prescriptions and therapeutic regimens and Latin names of
herbs for treatment (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c00626/suppl_file/jm0c00626_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c00626_si_001.pdf"><caption><p>jm0c00626_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes1"><title>Author Contributions</title><p><sup>#</sup> N.C. and X.Z. contributed equally to this work.</p></notes><notes notes-type="COI-statement" id="NOTES-d7e4675-autogenerated"><p>The authors declare no competing financial interest.</p></notes><bio id="BIO-d7e4891-autogenerated" rid="ath1"><p><bold>Namrta Choudhry</bold> obtained her Ph.D. in Botany (major Pharmacognosy)
from the Aligarh Muslim University, Aligarh, and in collaboration with the
Council of Scientific and Industrial Research- NBRI, Lucknow India in 2015,
later she joined a project entitled &#x02018;World Herbal
Encyclopedia&#x02019; at Patanjali Research Institute, Haridwar India. Her
main research interests focus on the standardizing of medicinal herbs and
focus on bioactive plantderived compounds for therapeutic uses. Since 2018,
she has been working as a postdoctoral fellow to study the effect of
terpenoids on the IAV and CoVs at the College of Veterinary Medicine, South
China Agricultural University in Guangzhou, China.</p></bio><bio id="BIO-d7e4896-autogenerated" rid="ath2"><p><bold>Xin Zhao</bold> received his Ph.D. in Medicinal Chemistry from the
Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of
Sciences, in 2012, subsequently becoming a research assistant at the GIBH.
In 2016, he worked at the University of Arizona, U.S., as a visiting
scholar. He started his independent research in 2018 and is currently a
Associate Professor in Guangdong Institute of Analysis (China National
Analytical Center, Guangzhou). His research interests are focused on
detections and small-molecule targeted interventions for respiratory
diseases.</p></bio><bio id="BIO-d7e4901-autogenerated" rid="ath3"><p><bold>Dan Xu</bold> received her Ph.D. in Cell Biology from Northwest
Agriculture and Forest University, China, in 2017. She has been working at
the College of Veterinary Medicine, South China Agriculture University, in
Guangzhou, China. Her main research interests encompass understanding the
interactions between the host and animal viruses.</p></bio><bio id="BIO-d7e4906-autogenerated" rid="ath4"><p><bold>Mark Zanin</bold> is a professor at the State Key Laboratory of
Respiratory Diseases, Guangzhou, and the School of Public Health, The
University of Hong Kong. He earned a Ph.D. from Monash University,
Australia, in Microbiology and completed a postdoctoral fellowship with Dr.
Richard Webby and Dr. Robert Webster at St. Jude Children&#x02019;s Research
Hospital in Memphis, Tennessee. His main research interests encompass
understanding the host, viral, and environmental factors behind the
transmission of influenza viruses.</p></bio><bio id="BIO-d7e4911-autogenerated" rid="ath5"><p><bold>Weisan Chen</bold> is a professor at the Department of Biochemistry and
Genetics, La Trobe University in Melbourne, Australia. He earned a Ph.D. in
Immunology at Flinders University in Adelaide in 1994. During
1996&#x02013;2000, he took a postdoctoral position at the National Institutes
of Health (NIH), Bethesda, Maryland, U.S. During this time, he discovered
the 11th IAV gene product PB1-F2. He returned to Australia in 2001 and
established his independent T Cell Laboratory at the Ludwig Institute in
Melbourne. He joined La Trobe University in 2012.</p></bio><bio id="BIO-d7e4916-autogenerated" rid="ath6"><p><bold>Zifeng Yang</bold> is a professor at State Key Laboratory of Respiratory
Diseases, the First Affiliated Hospital of Guangzhou Medical University in
Guangzhou, China. He is a clinician scientist with particular interest in
emerging viral diseases at the animal&#x02013;human interface, including
avian H7N9 and H5N6 influenza virus and MERS-CoV, as well as the associated
viral immunology. His research interests also involve the use of
pharmaceutical animal models, including mice, ferrets, and tree shrews, to
understand the protective effects, optimized regimens, and underlying
mechanisms of approved drugs, novel compounds, and TCMs against respiratory
viruses.</p></bio><bio id="BIO-d7e4921-autogenerated" rid="ath7"><p><bold>Jianxin Chen</bold> is a professor at College of Veterinary Medicine,
South China Agricultural University in Guangzhou, China. He earned a B.S. in
Analytical Chemistry from Wuhan University in 1989, an M.S. in Analytical
Chemistry from Changchun Institute of Applied Chemistry, Chinese Academy of
Sciences in 1998, and a Ph.D. in Medicinal Chemistry from Jinan University
in 2010. His main research interests encompass the development of novel
antiviral compounds from TCMs and natural products against influenza viruses
and porcine reproductive and respiratory syndrome viruses (PRRSV).</p></bio><ack><title>Acknowledgments</title><p>We thank Prof. Jincun Zhao from Guangzhou Medical University for his
constructive suggestions on the manuscript. We also acknowledge Prof. Jing
Zhao from the University of Macau and Prof. Geng Li from Guangzhou
University of Chinese Medicine for comments on the manuscript. This work was
funded by the National Key Research and Development Program of China (Grant
2017YFD0501404), Guangdong Special Support Program Innovation Team (Grant
2019BT02N054), Special Technologies R&#x00026;D Program for COVID-19 of
Guangdong Province (Grant 2020A111128014), and Special Technologies R&#x00026;D
Program for COVID-19 by Education Commission of Guangdong Province (Grant
2020KZDZX1039). X.Z. thanks the support from the Pearl River S&#x00026;T Nova
Program of Guangzhou (Grant 201806010115).</p></ack><glossary id="dl1"><def-list><title>Abbreviations Used</title><def-item><term>3CL<sup>pro</sup></term><def><p>3C-like serine protease</p></def></def-item><def-item><term>ACE2</term><def><p>angiotensin-converting enzyme 2</p></def></def-item><def-item><term>BALB/c</term><def><p>albino, laboratory-bred strain of the house mouse</p></def></def-item><def-item><term>CC<sub>50</sub></term><def><p>50% cytotoxic concentration</p></def></def-item><def-item><term>CoV</term><def><p>coronavirus</p></def></def-item><def-item><term>COVID-19</term><def><p>coronavirus disease 2019</p></def></def-item><def-item><term>CPE</term><def><p>cytopathogenic effect</p></def></def-item><def-item><term>CVB3</term><def><p>coxsackievirus B3</p></def></def-item><def-item><term>GL</term><def><p>glycyrrhizic acid (glycyrrhizin)</p></def></def-item><def-item><term>HAE</term><def><p>human airway epithelial</p></def></def-item><def-item><term>HCoV-229E</term><def><p>human coronavirus 229E</p></def></def-item><def-item><term>GFP</term><def><p>green fluorescent protein</p></def></def-item><def-item><term>HCoV-HKU1</term><def><p>human coronavirus HKU1</p></def></def-item><def-item><term>HCoV-NL63</term><def><p>human coronavirus NL63</p></def></def-item><def-item><term>HCoV-OC43</term><def><p>human coronavirus OC43</p></def></def-item><def-item><term>HSBDT</term><def><p>Huashi Baidu Tang</p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p>the half maximal inhibitory concentration</p></def></def-item><def-item><term>IFN-&#x003b2;</term><def><p>interferon &#x003b2;</p></def></def-item><def-item><term>JHQGG</term><def><p>Jinhua Qinggan granule</p></def></def-item><def-item><term>LHQWC</term><def><p>Lianhua Qingwen capsule</p></def></def-item><def-item><term>MERS-CoV</term><def><p>Middle East respiratory syndrome coronavirus</p></def></def-item><def-item><term>NHC</term><def><p>National Health Commission</p></def></def-item><def-item><term>NSP</term><def><p>nonstructural protein</p></def></def-item><def-item><term>NTPase/Hel</term><def><p>RNA nucleoside triphosphatasehelicase</p></def></def-item><def-item><term>PL<sup>pro</sup></term><def><p>papain-like cysteine protease</p></def></def-item><def-item><term>QFPDT</term><def><p>Qingfei Paidu Tang</p></def></def-item><def-item><term>RdRp</term><def><p>RNA-dependent RNA polymerase</p></def></def-item><def-item><term>NTPase</term><def><p>RNA nucleoside triphosphatase</p></def></def-item><def-item><term>SARS-CoV</term><def><p>severe acute respiratory syndrome coronavirus</p></def></def-item><def-item><term>SI</term><def><p>selective index</p></def></def-item><def-item><term>TCM</term><def><p>traditional Chinese medicine</p></def></def-item><def-item><term>TMPRSS2</term><def><p>transmembrane protease, serine 2</p></def></def-item><def-item><term>XFBDT</term><def><p>Xuanfei Baidu Tang.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Shen</surname><given-names>L.</given-names></name>; <name><surname>Niu</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Zhu</surname><given-names>N.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Ye</surname><given-names>F.</given-names></name>; <name><surname>Cen</surname><given-names>S.</given-names></name>; <name><surname>Tan</surname><given-names>W.</given-names></name>
<article-title>High-throughput screening and identification of potent
broad-spectrum inhibitors of coronaviruses</article-title>. <source>J. Virol.</source>
<year>2019</year>, <volume>93</volume>, <fpage>e00023-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.00023-19</pub-id>.<pub-id pub-id-type="pmid">30918074</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Cui</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>F.</given-names></name>; <name><surname>Shi</surname><given-names>Z. L.</given-names></name>
<article-title>Origin and evolution of pathogenic
coronaviruses</article-title>. <source>Nat. Rev. Microbiol.</source>
<year>2019</year>, <volume>17</volume>, <fpage>181</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id>.<pub-id pub-id-type="pmid">30531947</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Zhong</surname><given-names>N. S.</given-names></name>; <name><surname>Zheng</surname><given-names>B. J.</given-names></name>; <name><surname>Li</surname><given-names>Y. M.</given-names></name>; <name><surname>Poon</surname></name>; <name><surname>Xie</surname><given-names>Z. H.</given-names></name>; <name><surname>Chan</surname><given-names>K. H.</given-names></name>; <name><surname>Li</surname><given-names>P. H.</given-names></name>; <name><surname>Tan</surname><given-names>S. Y.</given-names></name>; <name><surname>Chang</surname><given-names>Q.</given-names></name>; <name><surname>Xie</surname><given-names>J. P.</given-names></name>; <name><surname>Liu</surname><given-names>X. Q.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>D. X.</given-names></name>; <name><surname>Yuen</surname><given-names>K. Y.</given-names></name>; <name><surname>Peiris</surname></name>; <name><surname>Guan</surname><given-names>Y.</given-names></name>
<article-title>Epidemiology and cause of severe acute respiratory
syndrome (SARS) in Guangdong, People&#x02019;s Republic of China,
in February, 2003</article-title>. <source>Lancet</source>
<year>2003</year>, <volume>362</volume>, <fpage>1353</fpage>&#x02013;<lpage>1358</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)14630-2</pub-id>.<pub-id pub-id-type="pmid">14585636</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Ksiazek</surname><given-names>T. G.</given-names></name>; <name><surname>Erdman</surname><given-names>D.</given-names></name>; <name><surname>Goldsmith</surname><given-names>C. S.</given-names></name>; <name><surname>Zaki</surname><given-names>S. R.</given-names></name>; <name><surname>Peret</surname><given-names>T.</given-names></name>; <name><surname>Emery</surname><given-names>S.</given-names></name>; <name><surname>Tong</surname><given-names>S.</given-names></name>; <name><surname>Urbani</surname><given-names>C.</given-names></name>; <name><surname>Comer</surname><given-names>J. A.</given-names></name>; <name><surname>Lim</surname><given-names>W.</given-names></name>; <name><surname>Rollin</surname><given-names>P. E.</given-names></name>; <name><surname>Dowell</surname><given-names>S. F.</given-names></name>; <name><surname>Ling</surname><given-names>A. E.</given-names></name>; <name><surname>Humphrey</surname><given-names>C. D.</given-names></name>; <name><surname>Shieh</surname><given-names>W. J.</given-names></name>; <name><surname>Guarner</surname><given-names>J.</given-names></name>; <name><surname>Paddock</surname><given-names>C. D.</given-names></name>; <name><surname>Rota</surname><given-names>P.</given-names></name>; <name><surname>Fields</surname><given-names>B.</given-names></name>; <name><surname>DeRisi</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>J. Y.</given-names></name>; <name><surname>Cox</surname><given-names>N.</given-names></name>; <name><surname>Hughes</surname><given-names>J. M.</given-names></name>; <name><surname>LeDuc</surname><given-names>J. W.</given-names></name>; <name><surname>Bellini</surname><given-names>W. J.</given-names></name>; <name><surname>Anderson</surname><given-names>L. J.</given-names></name>
<article-title>A novel coronavirus associated with severe acute
respiratory syndrome</article-title>. <source>N. Engl. J. Med.</source>
<year>2003</year>, <volume>348</volume>, <fpage>1953</fpage>&#x02013;<lpage>1966</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa030781</pub-id>.<pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Drosten</surname><given-names>C.</given-names></name>; <name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name>; <name><surname>Preiser</surname><given-names>W.</given-names></name>; <name><surname>Van der Werf</surname><given-names>S.</given-names></name>; <name><surname>Brodt</surname><given-names>H. R.</given-names></name>; <name><surname>Becker</surname><given-names>S.</given-names></name>; <name><surname>Rabenau</surname><given-names>H.</given-names></name>; <name><surname>Panning</surname><given-names>M.</given-names></name>; <name><surname>Kolesnikova</surname><given-names>L.</given-names></name>; <name><surname>Fouchier</surname><given-names>R. A. M.</given-names></name>; <name><surname>Berger</surname><given-names>A.</given-names></name>; <name><surname>Burgui&#x000e8;re</surname><given-names>A. M.</given-names></name>; <name><surname>Cinatl</surname><given-names>J.</given-names></name>; <name><surname>Eickmann</surname><given-names>M.</given-names></name>; <name><surname>Escriou</surname><given-names>N.</given-names></name>; <name><surname>Grywna</surname><given-names>K.</given-names></name>; <name><surname>Kramme</surname><given-names>S.</given-names></name>; <name><surname>Manuguerra</surname><given-names>J. C.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>S.</given-names></name>; <name><surname>Rickerts</surname><given-names>V.</given-names></name>; <name><surname>St&#x000fc;rmer</surname><given-names>M.</given-names></name>; <name><surname>Vieth</surname><given-names>S.</given-names></name>; <name><surname>Klenk</surname><given-names>H. D.</given-names></name>; <name><surname>Osterhaus</surname><given-names>A. D. M. E.</given-names></name>; <name><surname>Schmitz</surname><given-names>H.</given-names></name>; <name><surname>Doerr</surname><given-names>H. W.</given-names></name>
<article-title>Identification of a novel coronavirus in patients with
severe acute respiratory syndrome</article-title>. <source>N. Engl. J. Med.</source>
<year>2003</year>, <volume>348</volume>, <fpage>1967</fpage>&#x02013;<lpage>1976</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa030747</pub-id>.<pub-id pub-id-type="pmid">12690091</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="weblink" id="cit6">Revised U.S. Surveillance Case
Definition for Severe Acute Respiratory Syndrome (SARS) and Update on
SARS Cases&#x02014;United States and Worldwide, December 12, 2003. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5249a2.htm">https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5249a2.htm</uri>
(accessed Jun 29, <year>2020</year>).</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="weblink" id="cit7">World Health Organization.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 11 March
2019. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)">https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)</uri>
(accessed Jun 29, <year>2020</year>).</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Zhou</surname><given-names>P.</given-names></name>; <name><surname>Yang</surname><given-names>X. L.</given-names></name>; <name><surname>Wang</surname><given-names>X. G.</given-names></name>; <name><surname>Hu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Si</surname><given-names>H.-R.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>B.</given-names></name>; <name><surname>Huang</surname><given-names>C. L.</given-names></name>; <name><surname>Chen</surname><given-names>H. D.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Luo</surname><given-names>Y.</given-names></name>; <name><surname>Guo</surname><given-names>H.</given-names></name>; <name><surname>Jiang</surname><given-names>R.-D.</given-names></name>; <name><surname>Liu</surname><given-names>M. Q.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Shen</surname><given-names>X. R.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zheng</surname><given-names>X.-S.</given-names></name>; <name><surname>Zhao</surname><given-names>K.</given-names></name>; <name><surname>Chen</surname><given-names>Q. J.</given-names></name>; <name><surname>Deng</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>L. L.</given-names></name>; <name><surname>Yan</surname><given-names>B.</given-names></name>; <name><surname>Zhan</surname><given-names>F.-X.</given-names></name>; <name><surname>Wang</surname><given-names>Y. Y.</given-names></name>; <name><surname>Xiao</surname><given-names>G. F.</given-names></name>; <name><surname>Shi</surname><given-names>Z. L.</given-names></name>
<article-title>A pneumonia outbreak associated with a new coronavirus
of probable bat origin</article-title>. <source>Nature</source>
<year>2020</year>, <volume>579</volume>, <fpage>270</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>.<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>van Dorp</surname><given-names>L.</given-names></name>; <name><surname>Acman</surname><given-names>M.</given-names></name>; <name><surname>Richard</surname><given-names>D.</given-names></name>; <name><surname>Shaw</surname><given-names>L. P.</given-names></name>; <name><surname>Ford</surname><given-names>C. E.</given-names></name>; <name><surname>Ormond</surname><given-names>L.</given-names></name>; <name><surname>Owen</surname><given-names>C. J.</given-names></name>; <name><surname>Pang</surname><given-names>J.</given-names></name>; <name><surname>Tan</surname><given-names>C. C. S.</given-names></name>; <name><surname>Boshier</surname><given-names>F. A. T.</given-names></name>; <name><surname>Ortiz</surname><given-names>A. T.</given-names></name>; <name><surname>Balloux</surname><given-names>F.</given-names></name>
<article-title>Emergence of genomic diversity and recurrent mutations
in SARS-CoV-2</article-title>. <source>Infect., Genet. Evol.</source>
<year>2020</year>, <volume>83</volume>, <fpage>104351</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104351</pub-id>.<pub-id pub-id-type="pmid">32387564</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="weblink" id="cit10">World Health Organization.
Coronavirus Disease (COVID-19) Pandemic. Augest 14, 2020, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</uri>
(accessed Aug 14, <year>2020</year>).</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Li</surname><given-names>G.</given-names></name>; <name><surname>De Clercq</surname><given-names>E.</given-names></name>
<article-title>Therapeutic options for the 2019 novel coronavirus
(2019-nCoV)</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2020</year>, <volume>19</volume>, <fpage>149</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id>.<pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Morse</surname><given-names>J. S.</given-names></name>; <name><surname>Lalonde</surname><given-names>T.</given-names></name>; <name><surname>Xu</surname><given-names>S.</given-names></name>; <name><surname>Liu</surname><given-names>W. R.</given-names></name>
<article-title>Learning from the past: possible urgent prevention and
treatment options for severe acute respiratory infections caused
by 2019-nCoV</article-title>. <source>ChemBioChem</source>
<year>2020</year>, <volume>21</volume>, <fpage>730</fpage>&#x02013;<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.202000047</pub-id>.<pub-id pub-id-type="pmid">32022370</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Jia</surname><given-names>W.</given-names></name>; <name><surname>Gao</surname><given-names>W.</given-names></name>
<article-title>Is Traditional Chinese medicine useful in the treatment
of SARS?</article-title>. <source>Phytother. Res.</source>
<year>2003</year>, <volume>17</volume>, <fpage>840</fpage>&#x02013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.1397</pub-id>.<pub-id pub-id-type="pmid">12916093</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="book" id="cit14"><person-group person-group-type="allauthors"><collab>National Health
Commission (NHC) of the PRC, National Administration of
Traditional Chinese Medicine of the
PRC</collab></person-group>. <source>Guidance for Corona Virus
Disease 2019: Prevention, Control, Diagnosis and
Management</source>; <publisher-name>People&#x02019;s Medical
Publishing House</publisher-name>:
<publisher-loc>Beijing</publisher-loc>, <fpage>2020</fpage>;
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pmph.com/">http://www.pmph.com/</uri>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Chan</surname><given-names>J. F. W.</given-names></name>; <name><surname>Yao</surname><given-names>Y.</given-names></name>; <name><surname>Yeung</surname><given-names>M. L.</given-names></name>; <name><surname>Deng</surname><given-names>W.</given-names></name>; <name><surname>Bao</surname><given-names>L.</given-names></name>; <name><surname>Jia</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>F.</given-names></name>; <name><surname>Xiao</surname><given-names>C.</given-names></name>; <name><surname>Gao</surname><given-names>H.</given-names></name>; <name><surname>Yu</surname><given-names>P.</given-names></name>; <name><surname>Cai</surname><given-names>J.-P.</given-names></name>; <name><surname>Chu</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Qin</surname><given-names>C.</given-names></name>; <name><surname>Yuen</surname><given-names>K. Y.</given-names></name>
<article-title>Treatment with Lopinavir/Ritonavir or interferon-
&#x003b2;1b improves outcome of MERS-CoV infection in a nonhuman
primate model of common marmoset</article-title>. <source>J. Infect. Dis.</source>
<year>2015</year>, <volume>212</volume>, <fpage>1904</fpage>&#x02013;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv392</pub-id>.<pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Cao</surname><given-names>R.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>M.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Hu</surname><given-names>Z.</given-names></name>; <name><surname>Zhong</surname><given-names>W.</given-names></name>; <name><surname>Xiao</surname><given-names>G.</given-names></name>
<article-title>Remdesivir and chloroquine effectively inhibit the
recently emerged novel coronavirus (2019-nCoV) in
vitro</article-title>. <source>Cell Res.</source>
<year>2020</year>, <volume>30</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Gao</surname><given-names>J.</given-names></name>; <name><surname>Tian</surname><given-names>Z.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>
<article-title>Breakthrough: Chloroquine phosphate has shown apparent
efficacy in treatment of COVID-19 associated pneumonia in
clinical studies</article-title>. <source>BioSci. Trends</source>
<year>2020</year>, <volume>14</volume>, <fpage>72</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2020.01047</pub-id>.<pub-id pub-id-type="pmid">32074550</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Lai</surname><given-names>S. T.</given-names></name>
<article-title>Treatment of severe acute respiratory
syndrome</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source>
<year>2005</year>, <volume>24</volume>, <fpage>583</fpage>&#x02013;<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-005-0004-z</pub-id>.<pub-id pub-id-type="pmid">16172857</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Coomes</surname><given-names>E. A.</given-names></name>; <name><surname>Haghbayan</surname><given-names>H.</given-names></name>
<article-title>Interleukin-6 in COVID-19: a systematic review and
meta-analysis</article-title>. <source>medRxiv</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1101/2020.03.30.20048058</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Xie</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Xiao</surname><given-names>Y.</given-names></name>; <name><surname>Tian</surname><given-names>Q.</given-names></name>; <name><surname>Fan</surname><given-names>B.</given-names></name>; <name><surname>Zhao</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>
<article-title>Follow-up study on pulmonary function and lung
radiographic changes in rehabilitating severe acute respiratory
syndrome patients after discharge</article-title>. <source>Chest</source>
<year>2005</year>, <volume>127</volume>, <fpage>2119</fpage>&#x02013;<lpage>2124</lpage>. <pub-id pub-id-type="doi">10.1378/chest.127.6.2119</pub-id>.<pub-id pub-id-type="pmid">15947329</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Tong</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Duan</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Hua</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>D.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Shi</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>P.</given-names></name>; <name><surname>Tian</surname><given-names>X.</given-names></name>; <name><surname>Lin</surname><given-names>F.</given-names></name>; <name><surname>Cao</surname><given-names>Y.</given-names></name>; <name><surname>Jin</surname><given-names>L.</given-names></name>; <name><surname>Chang</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>
<article-title>TCM treatment of infectious atypical pneumonia--a
report of 16 cases</article-title>. <source>J. Tradit. Chin. Med.</source>
<year>2004</year>, <volume>24</volume>, <fpage>266</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">15688692</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>He</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>Y. P.</given-names></name>; <name><surname>Kang</surname><given-names>Y. K.</given-names></name>
<article-title>Chinese herbs combined with western medicine for severe
acute respiratory syndrome (SARS)</article-title>. <source>Cochrane Database Syst. Rev.</source>
<year>2006</year>, <pub-id pub-id-type="doi">10.1002/14651858.CD004882.pub2</pub-id>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Zhang</surname><given-names>M. M.</given-names></name>; <name><surname>Liu</surname><given-names>X. M.</given-names></name>; <name><surname>He</surname><given-names>L.</given-names></name>
<article-title>Effect of Integrated traditional Chinese and western
medicine on SARS: a review of clinical evidence</article-title>. <source>World J. Gastroenterol.</source>
<year>2004</year>, <volume>10</volume>, <fpage>3500</fpage>&#x02013;<lpage>3505</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v10.i23.3500</pub-id>.<pub-id pub-id-type="pmid">15526373</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="weblink" id="cit24">CHICTR. Chinease Clinical Trail
Registry. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.chictr.org.cn/searchproj.aspx">http://www.chictr.org.cn/searchproj.aspx</uri> (accessed Jun
29, <year>2020</year>).</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Yang</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Bai</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Guo</surname><given-names>R.</given-names></name>; <name><surname>Wu</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Leung</surname><given-names>E.</given-names></name>; <name><surname>Chang</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>P.</given-names></name>; <name><surname>Liu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>
<article-title>Chemical composition and pharmacological mechanism of
Qingfei Paidu decoction and Ma Xing Shi Gan decoction against
coronavirus disease 2019 (COVID-19): In Silico and Experimental
Study</article-title>. <source>Pharmacol. Res.</source>
<year>2020</year>, <volume>157</volume>, <fpage>104820</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104820</pub-id>.<pub-id pub-id-type="pmid">32360484</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Gou</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Luo</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Jin</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Zeng</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>
<article-title>Effect of Jinhua Qinggan granules on novel coronavirus
pneumonia in patients</article-title>. <source>J. Tradit. Chin. Med.</source>
<year>2020</year>, <volume>40</volume>, <fpage>467</fpage>&#x02013;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.19852/j.cnki.jtcm.2020.03.016</pub-id>.<pub-id pub-id-type="pmid">32506862</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Hu</surname><given-names>K.</given-names></name>; <name><surname>Guan</surname><given-names>W.</given-names></name>; <name><surname>Bi</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Song</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Duan</surname><given-names>Z.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Yang</surname><given-names>Z.</given-names></name>; <name><surname>Liang</surname><given-names>J.</given-names></name>; <name><surname>Han</surname><given-names>M.</given-names></name>; <name><surname>Ruan</surname><given-names>L.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Jia</surname><given-names>Z.</given-names></name>; <name><surname>Zhong</surname><given-names>N.</given-names></name>
<article-title>Efficacy and safety of Lianhuaqingwen capsules, a
repurposed Chinese herb, in patients with coronavirus disease
2019: a multicenter, prospective, randomized controlled
trial</article-title>. <source>Phytomedicine</source>
<year>2020</year>, <fpage>153242</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153242</pub-id>.<pub-id pub-id-type="pmid">32425361</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="weblink" id="cit28">Vital function and effective
formulas of Chinese Medicines in the prevention and treating of
COVID-19 in China, March 23, <year>2020</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/42768/index.htm">http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/42768/index.htm</uri>
(accessed Jun 29, <year>2020</year>).</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Ren</surname><given-names>J.-l.</given-names></name>; <name><surname>Zhang</surname><given-names>A.-H.</given-names></name>; <name><surname>Wang</surname><given-names>X.-J.</given-names></name>
<article-title>Corrigendum to &#x0201c;Traditional Chinese medicine for
COVID-19 treatment&#x0201d; [Pharmacol. Res. 155 (2020)
104743]</article-title>. <source>Pharmacol. Res.</source>
<year>2020</year>, <volume>155</volume>, <fpage>104768</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104768</pub-id>.<pub-id pub-id-type="pmid">32222346</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Islam</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>
<article-title>Traditional Chinese medicine in the treatment of
patients infected with 2019-new coronavirus (SARS-CoV-2): a
review and perspective</article-title>. <source>Int. J. Biol. Sci.</source>
<year>2020</year>, <volume>16</volume>, <fpage>1708</fpage>&#x02013;<lpage>1717</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.45538</pub-id>.<pub-id pub-id-type="pmid">32226288</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Peng</surname><given-names>T.</given-names></name>
<article-title>Traditional Chinese herbal medicine as a source of
molecules with antiviral activity</article-title>. <source>Antiviral Res.</source>
<year>2013</year>, <volume>97</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2012.10.006</pub-id>.<pub-id pub-id-type="pmid">23153834</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Li</surname><given-names>W. F.</given-names></name>; <name><surname>Jiang</surname><given-names>J. G.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>
<article-title>Chinese medicine and its modernization
demands</article-title>. <source>Arch. Med. Res.</source>
<year>2008</year>, <volume>39</volume>, <fpage>246</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.arcmed.2007.09.011</pub-id>.<pub-id pub-id-type="pmid">18164973</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Xu</surname><given-names>Z.</given-names></name>
<article-title>Modernization: one step at a time</article-title>. <source>Nature</source>
<year>2011</year>, <volume>480</volume>, <fpage>S90</fpage>&#x02013;<lpage>S92</lpage>. <pub-id pub-id-type="doi">10.1038/480S90a</pub-id>.<pub-id pub-id-type="pmid">22190089</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Savarino</surname><given-names>A.</given-names></name>; <name><surname>Di Trani</surname><given-names>L.</given-names></name>; <name><surname>Donatelli</surname><given-names>I.</given-names></name>; <name><surname>Cauda</surname><given-names>R.</given-names></name>; <name><surname>Cassone</surname><given-names>A.</given-names></name>
<article-title>New insights into the antiviral effects of
chloroquine</article-title>. <source>Lancet Infect. Dis.</source>
<year>2006</year>, <volume>6</volume>, <fpage>67</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(06)70361-9</pub-id>.<pub-id pub-id-type="pmid">16439323</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Yan</surname><given-names>Y.</given-names></name>; <name><surname>Zou</surname><given-names>Z.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>K. F.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Jin</surname><given-names>N.</given-names></name>; <name><surname>Jiang</surname><given-names>C.</given-names></name>
<article-title>Anti-malaria drug chloroquine is highly effective in
treating avian influenza A H5N1 virus infection in an animal
model</article-title>. <source>Cell Res.</source>
<year>2013</year>, <volume>23</volume>, <fpage>300</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2012.165</pub-id>.<pub-id pub-id-type="pmid">23208422</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>De Wilde</surname><given-names>A. H.</given-names></name>; <name><surname>Jochmans</surname><given-names>D.</given-names></name>; <name><surname>Posthuma</surname><given-names>C. C.</given-names></name>; <name><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name>; <name><surname>Van Nieuwkoop</surname><given-names>S.</given-names></name>; <name><surname>Bestebroer</surname><given-names>T. M.</given-names></name>; <name><surname>Van Den Hoogen</surname><given-names>B. G.</given-names></name>; <name><surname>Neyts</surname><given-names>J.</given-names></name>; <name><surname>Snijder</surname><given-names>E. J.</given-names></name>
<article-title>Screening of an FDA-approved compound library
identifies four small-molecule inhibitors of middle east
respiratory syndrome coronavirus replication in cell
culture</article-title>. <source>Antimicrob. Agents Chemother.</source>
<year>2014</year>, <volume>58</volume>, <fpage>4875</fpage>&#x02013;<lpage>4884</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id>.<pub-id pub-id-type="pmid">24841269</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Keyaerts</surname><given-names>E.</given-names></name>; <name><surname>Vijgen</surname><given-names>L.</given-names></name>; <name><surname>Maes</surname><given-names>P.</given-names></name>; <name><surname>Neyts</surname><given-names>J.</given-names></name>; <name><surname>Van Ranst</surname><given-names>M.</given-names></name>
<article-title>In vitro inhibition of severe acute respiratory
syndrome coronavirus by chloroquine</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<year>2004</year>, <volume>323</volume>, <fpage>264</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.085</pub-id>.<pub-id pub-id-type="pmid">15351731</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Keyaerts</surname><given-names>E.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Vijgen</surname><given-names>L.</given-names></name>; <name><surname>Rysman</surname><given-names>E.</given-names></name>; <name><surname>Verbeeck</surname><given-names>J.</given-names></name>; <name><surname>Van Ranst</surname><given-names>M.</given-names></name>; <name><surname>Maes</surname><given-names>P.</given-names></name>
<article-title>Antiviral activity of chloroquine against human
coronavirus OC43 infection in newborn mice</article-title>. <source>Antimicrob. Agents Chemother.</source>
<year>2009</year>, <volume>53</volume>, <fpage>3416</fpage>&#x02013;<lpage>3421</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01509-08</pub-id>.<pub-id pub-id-type="pmid">19506054</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Huang</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Xiao</surname><given-names>F.</given-names></name>; <name><surname>Liang</surname><given-names>J.</given-names></name>; <name><surname>Pang</surname><given-names>P.</given-names></name>; <name><surname>Tang</surname><given-names>T.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>B.</given-names></name>; <name><surname>Shu</surname><given-names>J.</given-names></name>; <name><surname>You</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Tang</surname><given-names>M.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Jiang</surname><given-names>G.</given-names></name>; <name><surname>Xiang</surname><given-names>J.</given-names></name>; <name><surname>Hong</surname><given-names>W.</given-names></name>; <name><surname>He</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Feng</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>C.</given-names></name>; <name><surname>Ye</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Zhong</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>R.</given-names></name>; <name><surname>Hong</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Pei</surname><given-names>D.</given-names></name>; <name><surname>Tian</surname><given-names>L.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Jiang</surname><given-names>S.</given-names></name>; <name><surname>Zhong</surname><given-names>N.</given-names></name>; <name><surname>Shan</surname><given-names>H.</given-names></name>
<article-title>Preliminary evidence from a multicenter prospective
observational study of the safety and efficacy of chloroquine
for the treatment of COVID-19</article-title>. <source>medRxiv</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1101/2020.04.26.20081059</pub-id>.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>McChesney</surname><given-names>E. W.</given-names></name>
<article-title>Animal toxicity and pharmacokinetics of
hydroxychloroquine sulfate</article-title>. <source>Am. J. Med.</source>
<year>1983</year>, <volume>75</volume>, <fpage>11</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9343(83)91265-2</pub-id>.<pub-id pub-id-type="pmid">6408923</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Gautret</surname><given-names>P.</given-names></name>; <name><surname>Lagier</surname><given-names>J.-C.</given-names></name>; <name><surname>Parola</surname><given-names>P.</given-names></name>; <name><surname>Hoang</surname><given-names>V. T.</given-names></name>; <name><surname>Meddeb</surname><given-names>L.</given-names></name>; <name><surname>Mailhe</surname><given-names>M.</given-names></name>; <name><surname>Doudier</surname><given-names>B.</given-names></name>; <name><surname>Courjon</surname><given-names>J.</given-names></name>; <name><surname>Giordanengo</surname><given-names>V.</given-names></name>; <name><surname>Vieira</surname><given-names>V. E.</given-names></name>; <name><surname>Dupont</surname><given-names>H. T.</given-names></name>; <name><surname>Honor&#x000e9;</surname><given-names>S.</given-names></name>; <name><surname>Colson</surname><given-names>P.</given-names></name>; <name><surname>Chabri&#x000e8;re</surname><given-names>E.</given-names></name>; <name><surname>La Scola</surname><given-names>B.</given-names></name>; <name><surname>Rolain</surname><given-names>J.-M.</given-names></name>; <name><surname>Brouqui</surname><given-names>P.</given-names></name>; <name><surname>Raoult</surname><given-names>D.</given-names></name>
<article-title>Hydroxychloroquine and azithromycin as a treatment of
COVID-19: results of an open-label non-randomized clinical
trial</article-title>. <source>Int. J. Antimicrob. Agents</source>
<year>2020</year>, <volume>56</volume>, <fpage>105949</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id>.<pub-id pub-id-type="pmid">32205204</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Hu</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Jiang</surname><given-names>S.</given-names></name>; <name><surname>Han</surname><given-names>S.</given-names></name>; <name><surname>Yan</surname><given-names>D.</given-names></name>; <name><surname>Zhuang</surname><given-names>R.</given-names></name>; <name><surname>Hu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>
<article-title>Efficacy of hydroxychloroquine in patients with
COVID-19: results of a randomized clinical trial</article-title>. <source>medRxiv</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1101/2020.03.22.20040758</pub-id>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Kim</surname><given-names>A. H. J.</given-names></name>; <name><surname>Sparks</surname><given-names>J. A.</given-names></name>; <name><surname>Liew</surname><given-names>J. W.</given-names></name>; <name><surname>Putman</surname><given-names>M. S.</given-names></name>; <name><surname>Berenbaum</surname><given-names>F.</given-names></name>; <name><surname>Duarte-Garc&#x000ed;a</surname><given-names>A.</given-names></name>; <name><surname>Graef</surname><given-names>E. R.</given-names></name>; <name><surname>Korsten</surname><given-names>P.</given-names></name>; <name><surname>Sattui</surname><given-names>S. E.</given-names></name>; <name><surname>Sirotich</surname><given-names>E.</given-names></name>; <name><surname>Ugarte-Gil</surname><given-names>M. F.</given-names></name>; <name><surname>Webb</surname><given-names>K.</given-names></name>; <name><surname>Grainger</surname><given-names>R.</given-names></name>
<article-title>A rush to judgment? rapid reporting and dissemination
of results and its consequences regarding the use of
hydroxychloroquine for COVID-19</article-title>. <source>Ann. Intern. Med.</source>
<year>2020</year>, <volume>172</volume>, <fpage>819</fpage>&#x02013;<lpage>821</lpage>. <pub-id pub-id-type="doi">10.7326/M20-1223</pub-id>.<pub-id pub-id-type="pmid">32227189</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Tang</surname><given-names>W.</given-names></name>; <name><surname>Cao</surname><given-names>Z.</given-names></name>; <name><surname>Han</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Sun</surname><given-names>W.</given-names></name>; <name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Xiao</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>E.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Zhao</surname><given-names>Q.</given-names></name>; <name><surname>Yan</surname><given-names>Y.</given-names></name>; <name><surname>Xie</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>D.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>Qu</surname><given-names>J.</given-names></name>; <name><surname>Ning</surname><given-names>G.</given-names></name>; <name><surname>Shi</surname><given-names>G.</given-names></name>; <name><surname>Xie</surname><given-names>Q.</given-names></name>
<article-title>Hydroxychloroquine in patients with mainly mild to
moderate coronavirus disease 2019: open label, randomised
controlled trial</article-title>. <source>BMJ.</source>
<year>2020</year>, <volume>369</volume>, <fpage>m1849</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1849</pub-id>.<pub-id pub-id-type="pmid">32409561</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Mah&#x000e9;vas</surname><given-names>M.</given-names></name>; <name><surname>Tran</surname><given-names>V.-T.</given-names></name>; <name><surname>Roumier</surname><given-names>M.</given-names></name>; <name><surname>Chabrol</surname><given-names>A.</given-names></name>; <name><surname>Paule</surname><given-names>R.</given-names></name>; <name><surname>Guillaud</surname><given-names>C.</given-names></name>; <name><surname>Fois</surname><given-names>E.</given-names></name>; <name><surname>Lepeule</surname><given-names>R.</given-names></name>; <name><surname>Szwebel</surname><given-names>T.-A.</given-names></name>; <name><surname>Lescure</surname><given-names>F.-X.</given-names></name>; <name><surname>Schlemmer</surname><given-names>F.</given-names></name>; <name><surname>Matignon</surname><given-names>M.</given-names></name>; <name><surname>Khellaf</surname><given-names>M.</given-names></name>; <name><surname>Crickx</surname><given-names>E.</given-names></name>; <name><surname>Terrier</surname><given-names>B.</given-names></name>; <name><surname>Morbieu</surname><given-names>C.</given-names></name>; <name><surname>Legendre</surname><given-names>P.</given-names></name>; <name><surname>Dang</surname><given-names>J.</given-names></name>; <name><surname>Schoindre</surname><given-names>Y.</given-names></name>; <name><surname>Pawlotsky</surname><given-names>J.-M.</given-names></name>; <name><surname>Michel</surname><given-names>M.</given-names></name>; <name><surname>Perrodeau</surname><given-names>E.</given-names></name>; <name><surname>Carlier</surname><given-names>N.</given-names></name>; <name><surname>Roche</surname><given-names>N.</given-names></name>; <name><surname>de Lastours</surname><given-names>V.</given-names></name>; <name><surname>Ourghanlian</surname><given-names>C.</given-names></name>; <name><surname>Kerneis</surname><given-names>S.</given-names></name>; <name><surname>M&#x000e9;nager</surname><given-names>P.</given-names></name>; <name><surname>Mouthon</surname><given-names>L.</given-names></name>; <name><surname>Audureau</surname><given-names>E.</given-names></name>; <name><surname>Ravaud</surname><given-names>P.</given-names></name>; <name><surname>Godeau</surname><given-names>B.</given-names></name>; <name><surname>Gallien</surname><given-names>S.</given-names></name>; <name><surname>Costedoat-Chalumeau</surname><given-names>N.</given-names></name>
<article-title>Clinical efficacy of hydroxychloroquine in patients
with Covid-19 pneumonia who require oxygen: observational
comparative study using routine care data</article-title>. <source>BMJ.</source>
<year>2020</year>, <volume>369</volume>, <fpage>m1844</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1844</pub-id>.<pub-id pub-id-type="pmid">32409486</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Boulware</surname><given-names>D. R.</given-names></name>; <name><surname>Pullen</surname><given-names>M. F.</given-names></name>; <name><surname>Bangdiwala</surname><given-names>A. S.</given-names></name>; <name><surname>Pastick</surname><given-names>K. A.</given-names></name>; <name><surname>Lofgren</surname><given-names>S. M.</given-names></name>; <name><surname>Okafor</surname><given-names>E. C.</given-names></name>; <name><surname>Skipper</surname><given-names>C. P.</given-names></name>; <name><surname>Nascene</surname><given-names>A. A.</given-names></name>; <name><surname>Nicol</surname><given-names>M. R.</given-names></name>; <name><surname>Abassi</surname><given-names>M.</given-names></name>; <name><surname>Engen</surname><given-names>N. W.</given-names></name>; <name><surname>Cheng</surname><given-names>M. P.</given-names></name>; <name><surname>LaBar</surname><given-names>D.</given-names></name>; <name><surname>Lother</surname><given-names>S. A.</given-names></name>; <name><surname>MacKenzie</surname><given-names>L. J.</given-names></name>; <name><surname>Drobot</surname><given-names>G.</given-names></name>; <name><surname>Marten</surname><given-names>N.</given-names></name>; <name><surname>Zarychanski</surname><given-names>R.</given-names></name>; <name><surname>Kelly</surname><given-names>L. E.</given-names></name>; <name><surname>Schwartz</surname><given-names>I. S.</given-names></name>; <name><surname>McDonald</surname><given-names>E. G.</given-names></name>; <name><surname>Rajasingham</surname><given-names>R.</given-names></name>; <name><surname>Lee</surname><given-names>T. C.</given-names></name>; <name><surname>Hullsiek</surname><given-names>K. H.</given-names></name>
<article-title>A randomized trial of hydroxychloroquine as
postexposure prophylaxis for Covid-19</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>383</volume>, <fpage>517</fpage><pub-id pub-id-type="doi">10.1056/NEJMoa2016638</pub-id>.<pub-id pub-id-type="pmid">32492293</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Molina</surname><given-names>J. M.</given-names></name>; <name><surname>Delaugerre</surname><given-names>C.</given-names></name>; <name><surname>Le Goff</surname><given-names>J.</given-names></name>; <name><surname>Mela-Lima</surname><given-names>B.</given-names></name>; <name><surname>Ponscarme</surname><given-names>D.</given-names></name>; <name><surname>Goldwirt</surname><given-names>L.</given-names></name>; <name><surname>de Castro</surname><given-names>N.</given-names></name>
<article-title>No evidence of rapid antiviral clearance or clinical
benefit with the combination of hydroxychloroquine and
azithromycin in patients with severe COVID-19
infection</article-title>. <source>Med. Mal. Infect.</source>
<year>2020</year>, <volume>50</volume>, <fpage>384</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/j.medmal.2020.03.006</pub-id>.<pub-id pub-id-type="pmid">32240719</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Mehra</surname><given-names>M. R.</given-names></name>; <name><surname>Desai</surname><given-names>S. S.</given-names></name>; <name><surname>Ruschitzka</surname><given-names>F.</given-names></name>; <name><surname>Patel</surname><given-names>A. N.</given-names></name>
<article-title>RETRACTED: Hydroxychloroquine or chloroquine with or
without a macrolide for treatment of COVID-19: a multinational
registry analysis</article-title>. <source>Lancet</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31180-6</pub-id>.</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name>; <name><surname>Sims</surname><given-names>A. C.</given-names></name>; <name><surname>Leist</surname><given-names>S. R.</given-names></name>; <name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name>; <name><surname>Won</surname><given-names>J.</given-names></name>; <name><surname>Brown</surname><given-names>A. J.</given-names></name>; <name><surname>Montgomery</surname><given-names>S. A.</given-names></name>; <name><surname>Hogg</surname><given-names>A.</given-names></name>; <name><surname>Babusis</surname><given-names>D.</given-names></name>; <name><surname>Clarke</surname><given-names>M. O.</given-names></name>; <name><surname>Spahn</surname><given-names>J. E.</given-names></name>; <name><surname>Bauer</surname><given-names>L.</given-names></name>; <name><surname>Sellers</surname><given-names>S.</given-names></name>; <name><surname>Porter</surname><given-names>D.</given-names></name>; <name><surname>Feng</surname><given-names>J. Y.</given-names></name>; <name><surname>Cihlar</surname><given-names>T.</given-names></name>; <name><surname>Jordan</surname><given-names>R.</given-names></name>; <name><surname>Denison</surname><given-names>M. R.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name>
<article-title>Comparative therapeutic efficacy of remdesivir and
combination lopinavir, ritonavir, and interferon beta against
MERS-CoV</article-title>. <source>Nat. Commun.</source>
<year>2020</year>, <volume>11</volume>, <fpage>222</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id>.<pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Warren</surname><given-names>T. K.</given-names></name>; <name><surname>Jordan</surname><given-names>R.</given-names></name>; <name><surname>Lo</surname><given-names>M. K.</given-names></name>; <name><surname>Ray</surname><given-names>A. S.</given-names></name>; <name><surname>Mackman</surname><given-names>R. L.</given-names></name>; <name><surname>Soloveva</surname><given-names>V.</given-names></name>; <name><surname>Siegel</surname><given-names>D.</given-names></name>; <name><surname>Perron</surname><given-names>M.</given-names></name>; <name><surname>Bannister</surname><given-names>R.</given-names></name>; <name><surname>Hui</surname><given-names>H. C.</given-names></name>; <name><surname>Larson</surname><given-names>N.</given-names></name>; <name><surname>Strickley</surname><given-names>R.</given-names></name>; <name><surname>Wells</surname><given-names>J.</given-names></name>; <name><surname>Stuthman</surname><given-names>K. S.</given-names></name>; <name><surname>Van Tongeren</surname><given-names>S. A.</given-names></name>; <name><surname>Garza</surname><given-names>N. L.</given-names></name>; <name><surname>Donnelly</surname><given-names>G.</given-names></name>; <name><surname>Shurtleff</surname><given-names>A. C.</given-names></name>; <name><surname>Retterer</surname><given-names>C. J.</given-names></name>; <name><surname>Gharaibeh</surname><given-names>D.</given-names></name>; <name><surname>Zamani</surname><given-names>R.</given-names></name>; <name><surname>Kenny</surname><given-names>T.</given-names></name>; <name><surname>Eaton</surname><given-names>B. P.</given-names></name>; <name><surname>Grimes</surname><given-names>E.</given-names></name>; <name><surname>Welch</surname><given-names>L. S.</given-names></name>; <name><surname>Gomba</surname><given-names>L.</given-names></name>; <name><surname>Wilhelmsen</surname><given-names>C. L.</given-names></name>; <name><surname>Nichols</surname><given-names>D. K.</given-names></name>; <name><surname>Nuss</surname><given-names>J. E.</given-names></name>; <name><surname>Nagle</surname><given-names>E. R.</given-names></name>; <name><surname>Kugelman</surname><given-names>J. R.</given-names></name>; <name><surname>Palacios</surname><given-names>G.</given-names></name>; <name><surname>Doerffler</surname><given-names>E.</given-names></name>; <name><surname>Neville</surname><given-names>S.</given-names></name>; <name><surname>Carra</surname><given-names>E.</given-names></name>; <name><surname>Clarke</surname><given-names>M. O.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Lew</surname><given-names>W.</given-names></name>; <name><surname>Ross</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Chun</surname><given-names>K.</given-names></name>; <name><surname>Wolfe</surname><given-names>L.</given-names></name>; <name><surname>Babusis</surname><given-names>D.</given-names></name>; <name><surname>Park</surname><given-names>Y.</given-names></name>; <name><surname>Stray</surname><given-names>K. M.</given-names></name>; <name><surname>Trancheva</surname><given-names>I.</given-names></name>; <name><surname>Feng</surname><given-names>J. Y.</given-names></name>; <name><surname>Barauskas</surname><given-names>O.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Wong</surname><given-names>P.</given-names></name>; <name><surname>Braun</surname><given-names>M. R.</given-names></name>; <name><surname>Flint</surname><given-names>M.</given-names></name>; <name><surname>McMullan</surname><given-names>L. K.</given-names></name>; <name><surname>Chen</surname><given-names>S. S.</given-names></name>; <name><surname>Fearns</surname><given-names>R.</given-names></name>; <name><surname>Swaminathan</surname><given-names>S.</given-names></name>; <name><surname>Mayers</surname><given-names>D. L.</given-names></name>; <name><surname>Spiropoulou</surname><given-names>C. F.</given-names></name>; <name><surname>Lee</surname><given-names>W. A.</given-names></name>; <name><surname>Nichol</surname><given-names>S. T.</given-names></name>; <name><surname>Cihlar</surname><given-names>T.</given-names></name>; <name><surname>Bavari</surname><given-names>S.</given-names></name>
<article-title>Therapeutic efficacy of the small molecule GS-5734
against ebola virus in rhesus monkeys</article-title>. <source>Nature</source>
<year>2016</year>, <volume>531</volume>, <fpage>381</fpage>&#x02013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1038/nature17180</pub-id>.<pub-id pub-id-type="pmid">26934220</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Brown</surname><given-names>A. J.</given-names></name>; <name><surname>Won</surname><given-names>J. J.</given-names></name>; <name><surname>Graham</surname><given-names>R. L.</given-names></name>; <name><surname>Dinnon</surname><given-names>K. H.</given-names></name>; <name><surname>Sims</surname><given-names>A. C.</given-names></name>; <name><surname>Feng</surname><given-names>J. Y.</given-names></name>; <name><surname>Cihlar</surname><given-names>T.</given-names></name>; <name><surname>Denison</surname><given-names>M. R.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name>; <name><surname>Sheahan</surname><given-names>T. P.</given-names></name>
<article-title>Broad spectrum antiviral remdesivir inhibits human
endemic and zoonotic deltacoronaviruses with a highly divergent
RNA dependent RNA polymerase</article-title>. <source>Antiviral Res.</source>
<year>2019</year>, <volume>169</volume>, <fpage>104541</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104541</pub-id>.<pub-id pub-id-type="pmid">31233808</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Agostini</surname><given-names>M. L.</given-names></name>; <name><surname>Andres</surname><given-names>E. L.</given-names></name>; <name><surname>Sims</surname><given-names>A. C.</given-names></name>; <name><surname>Graham</surname><given-names>R. L.</given-names></name>; <name><surname>Sheahan</surname><given-names>T. P.</given-names></name>; <name><surname>Lu</surname><given-names>X.</given-names></name>; <name><surname>Smith</surname><given-names>E. C.</given-names></name>; <name><surname>Case</surname><given-names>J. B.</given-names></name>; <name><surname>Feng</surname><given-names>J. Y.</given-names></name>; <name><surname>Jordan</surname><given-names>R.</given-names></name>; <name><surname>Ray</surname><given-names>A. S.</given-names></name>; <name><surname>Cihlar</surname><given-names>T.</given-names></name>; <name><surname>Siegel</surname><given-names>D.</given-names></name>; <name><surname>Mackman</surname><given-names>R. L.</given-names></name>; <name><surname>Clarke</surname><given-names>M. O.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name>; <name><surname>Denison</surname><given-names>M. R.</given-names></name>
<article-title>Coronavirus susceptibility to the antiviral remdesivir
(GS-5734) is mediated by the viral polymerase and the
proofreading exoribonuclease</article-title>. <source>mBio</source>
<year>2018</year>, <volume>9</volume>, <fpage>e00221-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.00221-18</pub-id>.<pub-id pub-id-type="pmid">29511076</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name>; <name><surname>Sims</surname><given-names>A. C.</given-names></name>; <name><surname>Graham</surname><given-names>R. L.</given-names></name>; <name><surname>Menachery</surname><given-names>V. D.</given-names></name>; <name><surname>Gralinski</surname><given-names>L. E.</given-names></name>; <name><surname>Case</surname><given-names>J. B.</given-names></name>; <name><surname>Leist</surname><given-names>S. R.</given-names></name>; <name><surname>Pyrc</surname><given-names>K.</given-names></name>; <name><surname>Feng</surname><given-names>J. Y.</given-names></name>; <name><surname>Trantcheva</surname><given-names>I.</given-names></name>; <name><surname>Bannister</surname><given-names>R.</given-names></name>; <name><surname>Park</surname><given-names>Y.</given-names></name>; <name><surname>Babusis</surname><given-names>D.</given-names></name>; <name><surname>Clarke</surname><given-names>M. O.</given-names></name>; <name><surname>MacKman</surname><given-names>R. L.</given-names></name>; <name><surname>Spahn</surname><given-names>J. E.</given-names></name>; <name><surname>Palmiotti</surname><given-names>C. A.</given-names></name>; <name><surname>Siegel</surname><given-names>D.</given-names></name>; <name><surname>Ray</surname><given-names>A. S.</given-names></name>; <name><surname>Cihlar</surname><given-names>T.</given-names></name>; <name><surname>Jordan</surname><given-names>R.</given-names></name>; <name><surname>Denison</surname><given-names>M. R.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name>
<article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic
and zoonotic coronaviruses</article-title>. <source>Sci. Transl. Med.</source>
<year>2017</year>, <volume>9</volume>, <fpage>eaal3653</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id>.<pub-id pub-id-type="pmid">28659436</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Holshue</surname><given-names>M. L.</given-names></name>; <name><surname>DeBolt</surname><given-names>C.</given-names></name>; <name><surname>Lindquist</surname><given-names>S.</given-names></name>; <name><surname>Lofy</surname><given-names>K. H.</given-names></name>; <name><surname>Wiesman</surname><given-names>J.</given-names></name>; <name><surname>Bruce</surname><given-names>H.</given-names></name>; <name><surname>Spitters</surname><given-names>C.</given-names></name>; <name><surname>Ericson</surname><given-names>K.</given-names></name>; <name><surname>Wilkerson</surname><given-names>S.</given-names></name>; <name><surname>Tural</surname><given-names>A.</given-names></name>; <name><surname>Diaz</surname><given-names>G.</given-names></name>; <name><surname>Cohn</surname><given-names>A.</given-names></name>; <name><surname>Fox</surname><given-names>L.</given-names></name>; <name><surname>Patel</surname><given-names>A.</given-names></name>; <name><surname>Pharm</surname><given-names>D.</given-names></name>; <name><surname>Gerber</surname><given-names>S. I.</given-names></name>; <name><surname>Kim</surname><given-names>L.</given-names></name>; <name><surname>Tong</surname><given-names>S.</given-names></name>; <name><surname>Ph</surname><given-names>D.</given-names></name>; <name><surname>Lu</surname><given-names>X.</given-names></name>; <name><surname>Lindstrom</surname><given-names>S.</given-names></name>; <name><surname>Ph</surname><given-names>D.</given-names></name>; <name><surname>Pallansch</surname><given-names>M. A.</given-names></name>; <name><surname>Ph</surname><given-names>D.</given-names></name>; <name><surname>Weldon</surname><given-names>W. C.</given-names></name>; <name><surname>Ph</surname><given-names>D.</given-names></name>; <name><surname>Biggs</surname><given-names>H. M.</given-names></name>; <name><surname>Uyeki</surname><given-names>T. M.</given-names></name>; <name><surname>Pillai</surname><given-names>S. K.</given-names></name>
<article-title>First case of 2019 novel coronavirus in the United
States</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>929</fpage>&#x02013;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id>.<pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Grein</surname><given-names>J.</given-names></name>; <name><surname>Ohmagari</surname><given-names>N.</given-names></name>; <name><surname>Shin</surname><given-names>D.</given-names></name>; <name><surname>Diaz</surname><given-names>G.</given-names></name>; <name><surname>Asperges</surname><given-names>E.</given-names></name>; <name><surname>Castagna</surname><given-names>A.</given-names></name>; <name><surname>Feldt</surname><given-names>T.</given-names></name>; <name><surname>Green</surname><given-names>G.</given-names></name>; <name><surname>Green</surname><given-names>M. L.</given-names></name>; <name><surname>Lescure</surname><given-names>F.-X.</given-names></name>; <name><surname>Nicastri</surname><given-names>E.</given-names></name>; <name><surname>Oda</surname><given-names>R.</given-names></name>; <name><surname>Yo</surname><given-names>K.</given-names></name>; <name><surname>Quiros-Roldan</surname><given-names>E.</given-names></name>; <name><surname>Studemeister</surname><given-names>A.</given-names></name>; <name><surname>Redinski</surname><given-names>J.</given-names></name>; <name><surname>Ahmed</surname><given-names>S.</given-names></name>; <name><surname>Bernett</surname><given-names>J.</given-names></name>; <name><surname>Chelliah</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>D.</given-names></name>; <name><surname>Chihara</surname><given-names>S.</given-names></name>; <name><surname>Cohen</surname><given-names>S. H.</given-names></name>; <name><surname>Cunningham</surname><given-names>J.</given-names></name>; <name><surname>D&#x02019;Arminio Monforte</surname><given-names>A.</given-names></name>; <name><surname>Ismail</surname><given-names>S.</given-names></name>; <name><surname>Kato</surname><given-names>H.</given-names></name>; <name><surname>Lapadula</surname><given-names>G.</given-names></name>; <name><surname>L&#x02019;Her</surname><given-names>E.</given-names></name>; <name><surname>Maeno</surname><given-names>T.</given-names></name>; <name><surname>Majumder</surname><given-names>S.</given-names></name>; <name><surname>Massari</surname><given-names>M.</given-names></name>; <name><surname>Mora-Rillo</surname><given-names>M.</given-names></name>; <name><surname>Mutoh</surname><given-names>Y.</given-names></name>; <name><surname>Nguyen</surname><given-names>D.</given-names></name>; <name><surname>Verweij</surname><given-names>E.</given-names></name>; <name><surname>Zoufaly</surname><given-names>A.</given-names></name>; <name><surname>Osinusi</surname><given-names>A. O.</given-names></name>; <name><surname>DeZure</surname><given-names>A.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Zhong</surname><given-names>L.</given-names></name>; <name><surname>Chokkalingam</surname><given-names>A.</given-names></name>; <name><surname>Elboudwarej</surname><given-names>E.</given-names></name>; <name><surname>Telep</surname><given-names>L.</given-names></name>; <name><surname>Timbs</surname><given-names>L.</given-names></name>; <name><surname>Henne</surname><given-names>I.</given-names></name>; <name><surname>Sellers</surname><given-names>S.</given-names></name>; <name><surname>Cao</surname><given-names>H.</given-names></name>; <name><surname>Tan</surname><given-names>S. K.</given-names></name>; <name><surname>Winterbourne</surname><given-names>L.</given-names></name>; <name><surname>Desai</surname><given-names>P.</given-names></name>; <name><surname>Mera</surname><given-names>R.</given-names></name>; <name><surname>Gaggar</surname><given-names>A.</given-names></name>; <name><surname>Myers</surname><given-names>R. P.</given-names></name>; <name><surname>Brainard</surname><given-names>D. M.</given-names></name>; <name><surname>Childs</surname><given-names>R.</given-names></name>; <name><surname>Flanigan</surname><given-names>T.</given-names></name>
<article-title>Compassionate use of remdesivir for patients with
severe Covid-19</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>2327</fpage>&#x02013;<lpage>2336</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2007016</pub-id>.<pub-id pub-id-type="pmid">32275812</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Beigel</surname><given-names>J. H.</given-names></name>; <name><surname>Tomashek</surname><given-names>K. M.</given-names></name>; <name><surname>Dodd</surname><given-names>L. E.</given-names></name>; <name><surname>Mehta</surname><given-names>A. K.</given-names></name>; <name><surname>Zingman</surname><given-names>B. S.</given-names></name>; <name><surname>Kalil</surname><given-names>A. C.</given-names></name>; <name><surname>Hohmann</surname><given-names>E.</given-names></name>; <name><surname>Chu</surname><given-names>H. Y.</given-names></name>; <name><surname>Luetkemeyer</surname><given-names>A.</given-names></name>; <name><surname>Kline</surname><given-names>S.</given-names></name>; <name><surname>de Castilla</surname><given-names>D. L.</given-names></name>; <name><surname>Finberg</surname><given-names>R. W.</given-names></name>; <name><surname>Dierberg</surname><given-names>K.</given-names></name>; <name><surname>Tapson</surname><given-names>V.</given-names></name>; <name><surname>Hsieh</surname><given-names>L.</given-names></name>; <name><surname>Patterson</surname><given-names>T. F.</given-names></name>; <name><surname>Paredes</surname><given-names>R.</given-names></name>; <name><surname>Sweeney</surname><given-names>D. A.</given-names></name>; <name><surname>Short</surname><given-names>W. R.</given-names></name>; <name><surname>Touloumi</surname><given-names>G.</given-names></name>; <name><surname>Lye</surname><given-names>D. C.</given-names></name>; <name><surname>Ohmagari</surname><given-names>N.</given-names></name>; <name><surname>Oh</surname><given-names>M. D.</given-names></name>; <name><surname>Ruiz-Palacios</surname><given-names>G. M.</given-names></name>; <name><surname>Benfield</surname><given-names>T.</given-names></name>; <name><surname>F&#x000e4;tkenheuer</surname><given-names>G.</given-names></name>; <name><surname>Kortepeter</surname><given-names>M. G.</given-names></name>; <name><surname>Atmar</surname><given-names>R. L.</given-names></name>; <name><surname>Creech</surname><given-names>C. B.</given-names></name>; <name><surname>Lundgren</surname><given-names>J.</given-names></name>; <name><surname>Babiker</surname><given-names>A. G.</given-names></name>; <name><surname>Pett</surname><given-names>S.</given-names></name>; <name><surname>Neaton</surname><given-names>J. D.</given-names></name>; <name><surname>Burgess</surname><given-names>T. H.</given-names></name>; <name><surname>Bonnett</surname><given-names>T.</given-names></name>; <name><surname>Green</surname><given-names>M.</given-names></name>; <name><surname>Makowski</surname><given-names>M.</given-names></name>; <name><surname>Osinusi</surname><given-names>A.</given-names></name>; <name><surname>Nayak</surname><given-names>S.</given-names></name>; <name><surname>Lane</surname><given-names>H. C.</given-names></name>
<article-title>Remdesivir for the treatment of Covid-19- preliminary
report</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id>.</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Du</surname><given-names>G.</given-names></name>; <name><surname>Du</surname><given-names>R.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Jin</surname><given-names>Y.</given-names></name>; <name><surname>Fu</surname><given-names>S.</given-names></name>; <name><surname>Gao</surname><given-names>L.</given-names></name>; <name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Lu</surname><given-names>Q.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Luo</surname><given-names>G.</given-names></name>; <name><surname>Wang</surname><given-names>K.</given-names></name>; <name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Ruan</surname><given-names>S.</given-names></name>; <name><surname>Yang</surname><given-names>C.</given-names></name>; <name><surname>Mei</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Ding</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>F.</given-names></name>; <name><surname>Tang</surname><given-names>X.</given-names></name>; <name><surname>Ye</surname><given-names>X.</given-names></name>; <name><surname>Ye</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Yin</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>A.</given-names></name>; <name><surname>Fan</surname><given-names>G.</given-names></name>; <name><surname>Zhou</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Shang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Cao</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>T.</given-names></name>; <name><surname>Wan</surname><given-names>Y.</given-names></name>; <name><surname>Qin</surname><given-names>H.</given-names></name>; <name><surname>Jiang</surname><given-names>Y.</given-names></name>; <name><surname>Jaki</surname><given-names>T.</given-names></name>; <name><surname>Hayden</surname><given-names>F. G.</given-names></name>; <name><surname>Horby</surname><given-names>P. W.</given-names></name>; <name><surname>Cao</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>
<article-title>Remdesivir in adults with severe COVID-19: A
randomised, double-blind, placebo-controlled, multicentre
trial</article-title>. <source>Lancet</source>
<year>2020</year>, <volume>395</volume>, <fpage>1569</fpage>&#x02013;<lpage>1578</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id>.<pub-id pub-id-type="pmid">32423584</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>De Clercq</surname><given-names>E.</given-names></name>
<article-title>New nucleoside Analogues for the treatment of
hemorrhagic fever virus infections</article-title>. <source>Chem. - Asian J.</source>
<year>2019</year>, <volume>14</volume>, <fpage>3962</fpage>&#x02013;<lpage>3968</lpage>. <pub-id pub-id-type="doi">10.1002/asia.201900841</pub-id>.<pub-id pub-id-type="pmid">31389664</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Dong</surname><given-names>L.</given-names></name>; <name><surname>Hu</surname><given-names>S.</given-names></name>; <name><surname>Gao</surname><given-names>J.</given-names></name>
<article-title>Discovering drugs to treat coronavirus disease 2019
(COVID-19)</article-title>. <source>Drug Discoveries Ther.</source>
<year>2020</year>, <volume>14</volume>, <fpage>58</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.5582/ddt.2020.01012</pub-id>.</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Furuta</surname><given-names>Y.</given-names></name>; <name><surname>Gowen</surname><given-names>B. B.</given-names></name>; <name><surname>Takahashi</surname><given-names>K.</given-names></name>; <name><surname>Shiraki</surname><given-names>K.</given-names></name>; <name><surname>Smee</surname><given-names>D. F.</given-names></name>; <name><surname>Barnard</surname><given-names>D. L.</given-names></name>
<article-title>Favipiravir (T-705), a novel viral RNA polymerase
inhibitor</article-title>. <source>Antiviral Res.</source>
<year>2013</year>, <volume>100</volume>, <fpage>446</fpage>&#x02013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.09.015</pub-id>.<pub-id pub-id-type="pmid">24084488</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Oestereich</surname><given-names>L.</given-names></name>; <name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name>; <name><surname>Wurr</surname><given-names>S.</given-names></name>; <name><surname>Rieger</surname><given-names>T.</given-names></name>; <name><surname>Mu&#x000f1;oz-Fontela</surname><given-names>C.</given-names></name>; <name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name>
<article-title>Successful treatment of advanced ebola virus infection
with T-705 (Favipiravir) in a small animal model</article-title>. <source>Antiviral Res.</source>
<year>2014</year>, <volume>105</volume>, <fpage>17</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2014.02.014</pub-id>.<pub-id pub-id-type="pmid">24583123</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Cai</surname><given-names>Q.</given-names></name>; <name><surname>Yang</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Shu</surname><given-names>D.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Liao</surname><given-names>X.</given-names></name>; <name><surname>Gu</surname><given-names>Y.</given-names></name>; <name><surname>Cai</surname><given-names>Q.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Shen</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Peng</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>D.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Cao</surname><given-names>R.</given-names></name>; <name><surname>Zhong</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>
<article-title>Experimental treatment with favipiravir for COVID-19:
an open-label control study</article-title>. <source>Engineering (Beijing)</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1016/j.eng.2020.03.007</pub-id>.</mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Boriskin</surname><given-names>Y.</given-names></name>; <name><surname>Leneva</surname><given-names>I.</given-names></name>; <name><surname>Pecheur</surname><given-names>E.-I.</given-names></name>; <name><surname>Polyak</surname><given-names>S.</given-names></name>
<article-title>Arbidol: a broad-spectrum antiviral compound that
blocks viral fusion</article-title>. <source>Curr. Med. Chem.</source>
<year>2008</year>, <volume>15</volume>, <fpage>997</fpage>&#x02013;<lpage>1005</lpage>. <pub-id pub-id-type="doi">10.2174/092986708784049658</pub-id>.<pub-id pub-id-type="pmid">18393857</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Yin</surname><given-names>P.</given-names></name>; <name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>B.</given-names></name>; <name><surname>Lu</surname><given-names>M.</given-names></name>; <name><surname>Luo</surname><given-names>Y.</given-names></name>; <name><surname>Ju</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>
<article-title>Favipiravir versus Arbidol for COVID-19: a randomized
clinical trial</article-title>. <source>medRxiv</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1101/2020.03.17.20037432</pub-id>.</mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Zumla</surname><given-names>A.</given-names></name>; <name><surname>Chan</surname><given-names>J. F. W.</given-names></name>; <name><surname>Azhar</surname><given-names>E. I.</given-names></name>; <name><surname>Hui</surname><given-names>D. S. C.</given-names></name>; <name><surname>Yuen</surname><given-names>K. Y.</given-names></name>
<article-title>Coronaviruses-drug discovery and therapeutic
options</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2016</year>, <volume>15</volume>, <fpage>327</fpage>&#x02013;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id>.<pub-id pub-id-type="pmid">26868298</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Chu</surname><given-names>C. M.</given-names></name>; <name><surname>Cheng</surname><given-names>V. C. C.</given-names></name>; <name><surname>Hung</surname><given-names>I. F. N.</given-names></name>; <name><surname>Wong</surname><given-names>M. M. L.</given-names></name>; <name><surname>Chan</surname><given-names>K. H.</given-names></name>; <name><surname>Chan</surname><given-names>K. S.</given-names></name>; <name><surname>Kao</surname><given-names>R. Y. T.</given-names></name>; <name><surname>Poon</surname><given-names>L. L. M.</given-names></name>; <name><surname>Wong</surname><given-names>C. L. P.</given-names></name>; <name><surname>Guan</surname><given-names>Y.</given-names></name>; <name><surname>Peiris</surname><given-names>J. S. M.</given-names></name>; <name><surname>Yuen</surname><given-names>K. Y.</given-names></name>
<article-title>Role of lopinavir/ritonavir in the treatment of SARS:
initial virological and clinical findings</article-title>. <source>Thorax</source>
<year>2004</year>, <volume>59</volume>, <fpage>252</fpage>&#x02013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id>.<pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Wu</surname><given-names>C. Y.</given-names></name>; <name><surname>Jan</surname><given-names>J. T.</given-names></name>; <name><surname>Ma</surname><given-names>S. H.</given-names></name>; <name><surname>Kuo</surname><given-names>C. J.</given-names></name>; <name><surname>Juan</surname><given-names>H. F.</given-names></name>; <name><surname>Cheng</surname><given-names>Y. S. E.</given-names></name>; <name><surname>Hsu</surname><given-names>H. H.</given-names></name>; <name><surname>Huang</surname><given-names>H. C.</given-names></name>; <name><surname>Wu</surname><given-names>D.</given-names></name>; <name><surname>Brik</surname><given-names>A.</given-names></name>; <name><surname>Liang</surname><given-names>F.-S.</given-names></name>; <name><surname>Liu</surname><given-names>R. S.</given-names></name>; <name><surname>Fang</surname><given-names>J. M.</given-names></name>; <name><surname>Chen</surname><given-names>S. T.</given-names></name>; <name><surname>Liang</surname><given-names>P. H.</given-names></name>; <name><surname>Wong</surname><given-names>C. H.</given-names></name>
<article-title>Small molecules targeting severe acute respiratory
syndrome human coronavirus</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2004</year>, <volume>101</volume>, <fpage>10012</fpage>&#x02013;<lpage>10017</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403596101</pub-id>.<pub-id pub-id-type="pmid">15226499</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Chandwani</surname><given-names>A.</given-names></name>; <name><surname>Shuter</surname><given-names>J.</given-names></name>
<article-title>Lopinavir/ritonavir in the treatment of HIV-1
infection: a review</article-title>. <source>Ther. Clin. Risk Manage.</source>
<year>2008</year>, <volume>4</volume>, <fpage>1023</fpage>&#x02013;<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S3285</pub-id>.</mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Cao</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wen</surname><given-names>D.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Fan</surname><given-names>G.</given-names></name>; <name><surname>Ruan</surname><given-names>L.</given-names></name>; <name><surname>Song</surname><given-names>B.</given-names></name>; <name><surname>Cai</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>N.</given-names></name>; <name><surname>Xiang</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Bai</surname><given-names>T.</given-names></name>; <name><surname>Xie</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Yuan</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Huang</surname><given-names>H.</given-names></name>; <name><surname>Tu</surname><given-names>S.</given-names></name>; <name><surname>Gong</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Dong</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>F.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Shang</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>K.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Dong</surname><given-names>X.</given-names></name>; <name><surname>Qu</surname><given-names>Z.</given-names></name>; <name><surname>Lu</surname><given-names>S.</given-names></name>; <name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Ruan</surname><given-names>S.</given-names></name>; <name><surname>Luo</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Peng</surname><given-names>L.</given-names></name>; <name><surname>Cheng</surname><given-names>F.</given-names></name>; <name><surname>Pan</surname><given-names>L.</given-names></name>; <name><surname>Zou</surname><given-names>J.</given-names></name>; <name><surname>Jia</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Ge</surname><given-names>Q.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Zhan</surname><given-names>H.</given-names></name>; <name><surname>Qiu</surname><given-names>F.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Jaki</surname><given-names>T.</given-names></name>; <name><surname>Hayden</surname><given-names>F. G.</given-names></name>; <name><surname>Horby</surname><given-names>P. W.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>
<article-title>A trial of lopinavir-ritonavir in adults hospitalized
with severe Covid-19</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>1787</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>.<pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Moradi</surname><given-names>M. T.</given-names></name>; <name><surname>Karimi</surname><given-names>A.</given-names></name>; <name><surname>Lorigooini</surname><given-names>Z.</given-names></name>
<article-title>Alkaloids as the natural anti-influenza virus agents: a
systematic review</article-title>. <source>Toxin Rev.</source>
<year>2018</year>, <volume>37</volume>, <fpage>11</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1080/15569543.2017.1323338</pub-id>.</mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Sun</surname><given-names>N.</given-names></name>; <name><surname>Sun</surname><given-names>P.</given-names></name>; <name><surname>Lv</surname><given-names>H.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Guo</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Luo</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>
<article-title>Matrine displayed antiviral activity in porcine
alveolar macrophages co-infected by porcine reproductive and
respiratory syndrome virus and porcine circovirus type
2</article-title>. <source>Sci. Rep.</source>
<year>2016</year>, <volume>6</volume>, <fpage>24401</fpage><pub-id pub-id-type="doi">10.1038/srep24401</pub-id>.<pub-id pub-id-type="pmid">27080155</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Pan</surname><given-names>Q. M.</given-names></name>; <name><surname>Li</surname><given-names>Y. H.</given-names></name>; <name><surname>Hua</surname><given-names>J.</given-names></name>; <name><surname>Huang</surname><given-names>F. P.</given-names></name>; <name><surname>Wang</surname><given-names>H. S.</given-names></name>; <name><surname>Liang</surname><given-names>D.</given-names></name>
<article-title>Antiviral matrine-type alkaloids from the Rhizomes of
Sophora Tonkinensis</article-title>. <source>J. Nat. Prod.</source>
<year>2015</year>, <volume>78</volume>, <fpage>1683</fpage>&#x02013;<lpage>1688</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00325</pub-id>.<pub-id pub-id-type="pmid">26132528</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Jing</surname><given-names>S.</given-names></name>; <name><surname>Rong-hua</surname><given-names>Z.</given-names></name>; <name><surname>Shan-shan</surname><given-names>G.</given-names></name>; <name><surname>Yu-jing</surname><given-names>S.</given-names></name>; <name><surname>Lei</surname><given-names>B.</given-names></name>; <name><surname>Zi-han</surname><given-names>G.</given-names></name>; <name><surname>Ying-jie</surname><given-names>G.</given-names></name>; <name><surname>Jian</surname><given-names>L.</given-names></name>; <name><surname>Qiong</surname><given-names>L.</given-names></name>; <name><surname>Xiao-lan</surname><given-names>S.</given-names></name>
<article-title>Effect of matrine sodium chloride injection on a mouse
model combining disease with syndrome of human coronavirus
pneumonia with cold-dampness pestilence attacking the
lung</article-title>. <source>Acta Pharm. Sin.</source>
<year>2020</year>, <volume>55</volume>, <fpage>366</fpage>&#x02013;<lpage>373</lpage>.</mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Hwang</surname><given-names>Y. C.</given-names></name>; <name><surname>Chu</surname><given-names>J. J. H.</given-names></name>; <name><surname>Yang</surname><given-names>P. L.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Yates</surname><given-names>M. V.</given-names></name>
<article-title>Rapid identification of inhibitors that interfere with
poliovirus replication using a cell-based assay</article-title>. <source>Antiviral Res.</source>
<year>2008</year>, <volume>77</volume>, <fpage>232</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2007.12.009</pub-id>.<pub-id pub-id-type="pmid">18243348</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Gabrielsen</surname><given-names>B.</given-names></name>; <name><surname>Monath</surname><given-names>T. P.</given-names></name>; <name><surname>Huggins</surname><given-names>J. W.</given-names></name>; <name><surname>Kefauver</surname><given-names>D. F.</given-names></name>; <name><surname>Pettit</surname><given-names>G. R.</given-names></name>; <name><surname>Groszek</surname><given-names>G.</given-names></name>; <name><surname>Hollingshead</surname><given-names>M.</given-names></name>; <name><surname>Kirsi</surname><given-names>J. J.</given-names></name>; <name><surname>Shannon</surname><given-names>W. M.</given-names></name>; <name><surname>Schubert</surname><given-names>E. M.</given-names></name>; <name><surname>Dare</surname><given-names>J.</given-names></name>; <name><surname>Ugarkar</surname><given-names>B.</given-names></name>; <name><surname>Ussery</surname><given-names>M. A.</given-names></name>; <name><surname>Phelan</surname><given-names>M. J.</given-names></name>
<article-title>Antiviral (RNA) activity of selected amaryllidaceae
isoquinoline constituents and synthesis of related
substances</article-title>. <source>J. Nat. Prod.</source>
<year>1992</year>, <volume>55</volume>, <fpage>1569</fpage>&#x02013;<lpage>1581</lpage>. <pub-id pub-id-type="doi">10.1021/np50089a003</pub-id>.<pub-id pub-id-type="pmid">1336040</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Guo</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Hua</surname><given-names>S.</given-names></name>; <name><surname>Yu</surname><given-names>J.</given-names></name>; <name><surname>Xiao</surname><given-names>P.</given-names></name>; <name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Tan</surname><given-names>X.</given-names></name>
<article-title>Identification of natural compounds with antiviral
activities against SARS-associated coronavirus</article-title>. <source>Antiviral Res.</source>
<year>2005</year>, <volume>67</volume>, <fpage>18</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.02.007</pub-id>.<pub-id pub-id-type="pmid">15885816</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Vedantham</surname><given-names>P.</given-names></name>; <name><surname>Lu</surname><given-names>K.</given-names></name>; <name><surname>Agudelo</surname><given-names>J.</given-names></name>; <name><surname>Carrion</surname><given-names>R.</given-names></name>; <name><surname>Nunneley</surname><given-names>J. W.</given-names></name>; <name><surname>Barnard</surname><given-names>D.</given-names></name>; <name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name>; <name><surname>McKerrow</surname><given-names>J. H.</given-names></name>; <name><surname>Renslo</surname><given-names>A. R.</given-names></name>; <name><surname>Simmons</surname><given-names>G.</given-names></name>
<article-title>Protease inhibitors targeting coronavirus and filovirus
entry</article-title>. <source>Antiviral Res.</source>
<year>2015</year>, <volume>116</volume>, <fpage>76</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id>.<pub-id pub-id-type="pmid">25666761</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Hoffmann</surname><given-names>M.</given-names></name>; <name><surname>Kleine-weber</surname><given-names>H.</given-names></name>; <name><surname>Schroeder</surname><given-names>S.</given-names></name>; <name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name>; <name><surname>Herrler</surname><given-names>T.</given-names></name>; <name><surname>Erichsen</surname><given-names>S.</given-names></name>; <name><surname>Schiergens</surname><given-names>T. S.</given-names></name>; <name><surname>Herrler</surname><given-names>G.</given-names></name>; <name><surname>Wu</surname><given-names>N.-H.</given-names></name>; <name><surname>Nitsche</surname><given-names>A.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>M. A.</given-names></name>; <name><surname>Drosten</surname><given-names>C.</given-names></name>; <name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and
is blocked by a clinically proven protease
inhibitor</article-title>. <source>Cell</source>
<year>2020</year>, <volume>181</volume>, <fpage>271</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>.<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Barnard</surname><given-names>D. L.</given-names></name>; <name><surname>Day</surname><given-names>C. W.</given-names></name>; <name><surname>Bailey</surname><given-names>K.</given-names></name>; <name><surname>Heiner</surname><given-names>M.</given-names></name>; <name><surname>Montgomery</surname><given-names>R.</given-names></name>; <name><surname>Lauridsen</surname><given-names>L.</given-names></name>; <name><surname>Chan</surname><given-names>P. K. S.</given-names></name>; <name><surname>Sidwell</surname><given-names>R. W.</given-names></name>
<article-title>Evaluation of immunomodulators, interferons and known
in vitro SARS-CoV inhibitors for inhibition of SARS-CoV
replication in BALB/c mice</article-title>. <source>Antivir. Chem. Chemother.</source>
<year>2006</year>, <volume>17</volume>, <fpage>275</fpage>&#x02013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1177/095632020601700505</pub-id>.<pub-id pub-id-type="pmid">17176632</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Yao</surname><given-names>X.</given-names></name>; <name><surname>Ye</surname><given-names>F.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Cui</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>B.</given-names></name>; <name><surname>Niu</surname><given-names>P.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>L.</given-names></name>; <name><surname>Dong</surname><given-names>E.</given-names></name>; <name><surname>Song</surname><given-names>C.</given-names></name>; <name><surname>Zhan</surname><given-names>S.</given-names></name>; <name><surname>Lu</surname><given-names>R.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Tan</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>D.</given-names></name>
<article-title>In vitro antiviral activity and projection of optimized
dosing design of hydroxychloroquine for the treatment of severe
acute respiratory syndrome coronavirus 2
(SARS-CoV-2)</article-title>. <source>Clin. Infect. Dis.</source>
<year>2020</year>, <volume>71</volume>, <fpage>732</fpage><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id>.<pub-id pub-id-type="pmid">32150618</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name><surname>Vlietinck</surname><given-names>A. J.</given-names></name>; <name><surname>Vanden Berghe</surname><given-names>D. A.</given-names></name>
<article-title>Can ethnopharmacology contribute to the development of
antiviral drugs?</article-title>. <source>J. Ethnopharmacol.</source>
<year>1991</year>, <volume>32</volume>, <fpage>141</fpage>&#x02013;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1016/0378-8741(91)90112-Q</pub-id>.<pub-id pub-id-type="pmid">1652667</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Jassim</surname><given-names>S. A. A.</given-names></name>; <name><surname>Naji</surname><given-names>M. A.</given-names></name>
<article-title>Novel antiviral agents: a medicinal plant
perspective</article-title>. <source>J. Appl. Microbiol.</source>
<year>2003</year>, <volume>95</volume>, <fpage>412</fpage>&#x02013;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2672.2003.02026.x</pub-id>.<pub-id pub-id-type="pmid">12911688</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name><surname>Liang</surname><given-names>R.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>N.</given-names></name>; <name><surname>Deng</surname><given-names>X.</given-names></name>; <name><surname>Su</surname><given-names>M.</given-names></name>; <name><surname>Su</surname><given-names>Y.</given-names></name>; <name><surname>Hu</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>C.</given-names></name>; <name><surname>Ying</surname><given-names>T.</given-names></name>; <name><surname>Jiang</surname><given-names>S.</given-names></name>; <name><surname>Yu</surname><given-names>F.</given-names></name>
<article-title>Development of small-molecule MERS-CoV
inhibitors</article-title>. <source>Viruses</source>
<year>2018</year>, <volume>10</volume>, <fpage>721</fpage><pub-id pub-id-type="doi">10.3390/v10120721</pub-id>.</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name><surname>Graham</surname><given-names>R. L.</given-names></name>; <name><surname>Sparks</surname><given-names>J. S.</given-names></name>; <name><surname>Eckerle</surname><given-names>L. D.</given-names></name>; <name><surname>Sims</surname><given-names>A. C.</given-names></name>; <name><surname>Denison</surname><given-names>M. R.</given-names></name>
<article-title>SARS Coronavirus replicase proteins in
pathogenesis</article-title>. <source>Virus Res.</source>
<year>2008</year>, <volume>133</volume>, <fpage>88</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.017</pub-id>.<pub-id pub-id-type="pmid">17397959</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name><surname>Keum</surname><given-names>Y.</given-names></name>; <name><surname>Jeong</surname><given-names>Y.</given-names></name>
<article-title>Development of chemical inhibitors of the SARS
coronavirus: viral helicase as a potential
target</article-title>. <source>Biochem. Pharmacol.</source>
<year>2012</year>, <volume>84</volume>, <fpage>1351</fpage>&#x02013;<lpage>1358</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2012.08.012</pub-id>.<pub-id pub-id-type="pmid">22935448</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name><surname>Wen</surname><given-names>C. C.</given-names></name>; <name><surname>Kuo</surname><given-names>Y. H.</given-names></name>; <name><surname>Jan</surname><given-names>J. T.</given-names></name>; <name><surname>Liang</surname><given-names>P. H.</given-names></name>; <name><surname>Wang</surname><given-names>S. Y.</given-names></name>; <name><surname>Liu</surname><given-names>H. G.</given-names></name>; <name><surname>Lee</surname><given-names>C. K.</given-names></name>; <name><surname>Chang</surname><given-names>S. T.</given-names></name>; <name><surname>Kuo</surname><given-names>C. J.</given-names></name>; <name><surname>Lee</surname><given-names>S. S.</given-names></name>; <name><surname>Hou</surname><given-names>C. C.</given-names></name>; <name><surname>Hsiao</surname><given-names>P. W.</given-names></name>; <name><surname>Chien</surname><given-names>S. C.</given-names></name>; <name><surname>Shyur</surname><given-names>L. F.</given-names></name>; <name><surname>Yang</surname><given-names>N. S.</given-names></name>
<article-title>Specific plant terpenoids and lignoids possess potent
antiviral activities against severe acute respiratory syndrome
coronavirus</article-title>. <source>J. Med. Chem.</source>
<year>2007</year>, <volume>50</volume>, <fpage>4087</fpage>&#x02013;<lpage>4095</lpage>. <pub-id pub-id-type="doi">10.1021/jm070295s</pub-id>.<pub-id pub-id-type="pmid">17663539</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name><surname>Stadler</surname><given-names>K.</given-names></name>; <name><surname>Masignani</surname><given-names>V.</given-names></name>; <name><surname>Eickmann</surname><given-names>M.</given-names></name>; <name><surname>Becker</surname><given-names>S.</given-names></name>; <name><surname>Abrignani</surname><given-names>S.</given-names></name>; <name><surname>Klenk</surname><given-names>H. D.</given-names></name>; <name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<article-title>SARS &#x02014; beginning to understand a new
virus</article-title>. <source>Nat. Rev. Microbiol.</source>
<year>2003</year>, <volume>1</volume>, <fpage>209</fpage>&#x02013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro775</pub-id>.<pub-id pub-id-type="pmid">15035025</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name><surname>Kumar</surname><given-names>V.</given-names></name>; <name><surname>Tan</surname><given-names>K.-P.</given-names></name>; <name><surname>Wang</surname><given-names>Y.-M.</given-names></name>; <name><surname>Lin</surname><given-names>S.-W.</given-names></name>; <name><surname>Liang</surname><given-names>P.-H.</given-names></name>
<article-title>Identification, synthesis and evaluation of SARS-CoV
and MERS-CoV 3C-like protease inhibitors</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2016</year>, <volume>24</volume>, <fpage>3035</fpage>&#x02013;<lpage>3042</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2016.05.013</pub-id>.<pub-id pub-id-type="pmid">27240464</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name><surname>Thiel</surname><given-names>V.</given-names></name>; <name><surname>Herold</surname><given-names>J.</given-names></name>; <name><surname>Schelle</surname><given-names>B.</given-names></name>; <name><surname>Siddell</surname><given-names>S. G.</given-names></name>
<article-title>Viral replicase gene products suffice for coronavirus
discontinuous transcription</article-title>. <source>J. Virol.</source>
<year>2001</year>, <volume>75</volume>, <fpage>6676</fpage>&#x02013;<lpage>6681</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.75.14.6676-6681.2001</pub-id>.<pub-id pub-id-type="pmid">11413334</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><name><surname>Thiel</surname><given-names>V.</given-names></name>; <name><surname>Ivanov</surname><given-names>K. A.</given-names></name>; <name><surname>Putics</surname><given-names>&#x000c1;.</given-names></name>; <name><surname>Hertzig</surname><given-names>T.</given-names></name>; <name><surname>Schelle</surname><given-names>B.</given-names></name>; <name><surname>Bayer</surname><given-names>S.</given-names></name>; <name><surname>Wei&#x000df;brich</surname><given-names>B.</given-names></name>; <name><surname>Snijder</surname><given-names>E. J.</given-names></name>; <name><surname>Rabenau</surname><given-names>H.</given-names></name>; <name><surname>Doerr</surname><given-names>H. W.</given-names></name>; <name><surname>Gorbalenya</surname><given-names>A. E.</given-names></name>; <name><surname>Ziebuhr</surname><given-names>J.</given-names></name>
<article-title>Mechanisms and enzymes involved in SARS coronavirus
genome expression</article-title>. <source>J. Gen. Virol.</source>
<year>2003</year>, <volume>84</volume>, <fpage>2305</fpage>&#x02013;<lpage>2315</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.19424-0</pub-id>.<pub-id pub-id-type="pmid">12917450</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name><surname>Anand</surname><given-names>K.</given-names></name>; <name><surname>Ziebuhr</surname><given-names>J.</given-names></name>; <name><surname>Wadhwani</surname><given-names>P.</given-names></name>; <name><surname>Mesters</surname><given-names>J. R.</given-names></name>; <name><surname>Hilgenfeld</surname><given-names>R.</given-names></name>
<article-title>Coronavirus main proteinase (3CLpro) structure: basis
for design of anti-SARS drugs</article-title>. <source>Science</source>
<year>2003</year>, <volume>300</volume>, <fpage>1763</fpage>&#x02013;<lpage>1767</lpage>. <pub-id pub-id-type="doi">10.1126/science.1085658</pub-id>.<pub-id pub-id-type="pmid">12746549</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal" id="cit92"><name><surname>Ryu</surname><given-names>Y. B.</given-names></name>; <name><surname>Park</surname><given-names>S. J.</given-names></name>; <name><surname>Kim</surname><given-names>Y. M.</given-names></name>; <name><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name><surname>Seo</surname><given-names>W. D.</given-names></name>; <name><surname>Chang</surname><given-names>J. S.</given-names></name>; <name><surname>Park</surname><given-names>K. H.</given-names></name>; <name><surname>Rho</surname><given-names>M. C.</given-names></name>; <name><surname>Lee</surname><given-names>W. S.</given-names></name>
<article-title>SARS-CoV 3CLpro inhibitory effects of quinone-methide
triterpenes from Tripterygium Regelii</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2010</year>, <volume>20</volume>, <fpage>1873</fpage>&#x02013;<lpage>1876</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2010.01.152</pub-id>.<pub-id pub-id-type="pmid">20167482</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal" id="cit93"><name><surname>Lin</surname><given-names>C. W.</given-names></name>; <name><surname>Tsai</surname><given-names>F. J.</given-names></name>; <name><surname>Tsai</surname><given-names>C. H.</given-names></name>; <name><surname>Lai</surname><given-names>C. C.</given-names></name>; <name><surname>Wan</surname><given-names>L.</given-names></name>; <name><surname>Ho</surname><given-names>T. Y.</given-names></name>; <name><surname>Hsieh</surname><given-names>C. C.</given-names></name>; <name><surname>Chao</surname><given-names>P. D. L.</given-names></name>
<article-title>Anti-SARS coronavirus 3C-like protease effects of
Isatis Indigotica Root and plant-derived phenolic
compounds</article-title>. <source>Antiviral Res.</source>
<year>2005</year>, <volume>68</volume>, <fpage>36</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.07.002</pub-id>.<pub-id pub-id-type="pmid">16115693</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name><surname>Park</surname><given-names>J. Y.</given-names></name>; <name><surname>Kim</surname><given-names>J. H.</given-names></name>; <name><surname>Kwon</surname><given-names>J. M.</given-names></name>; <name><surname>Kwon</surname><given-names>H. J.</given-names></name>; <name><surname>Jeong</surname><given-names>H. J.</given-names></name>; <name><surname>Kim</surname><given-names>Y. M.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Lee</surname><given-names>W. S.</given-names></name>; <name><surname>Ryu</surname><given-names>Y. B.</given-names></name>
<article-title>Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the
edible brown Algae Ecklonia Cava</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2013</year>, <volume>21</volume>, <fpage>3730</fpage>&#x02013;<lpage>3737</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2013.04.026</pub-id>.<pub-id pub-id-type="pmid">23647823</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal" id="cit95"><name><surname>Zakaryan</surname><given-names>H.</given-names></name>; <name><surname>Arabyan</surname><given-names>E.</given-names></name>; <name><surname>Oo</surname><given-names>A.</given-names></name>; <name><surname>Zandi</surname><given-names>K.</given-names></name>
<article-title>Flavonoids: promising natural compounds against viral
infections</article-title>. <source>Arch. Virol.</source>
<year>2017</year>, <volume>162</volume>, <fpage>2539</fpage>&#x02013;<lpage>2551</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-017-3417-y</pub-id>.<pub-id pub-id-type="pmid">28547385</pub-id></mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><name><surname>Ryu</surname><given-names>Y. B.</given-names></name>; <name><surname>Jeong</surname><given-names>H. J.</given-names></name>; <name><surname>Kim</surname><given-names>J. H.</given-names></name>; <name><surname>Kim</surname><given-names>Y. M.</given-names></name>; <name><surname>Park</surname><given-names>J. Y.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Naguyen</surname><given-names>T. T. H.</given-names></name>; <name><surname>Park</surname><given-names>S. J.</given-names></name>; <name><surname>Chang</surname><given-names>J. S.</given-names></name>; <name><surname>Park</surname><given-names>K. H.</given-names></name>; <name><surname>Rho</surname><given-names>M. C.</given-names></name>; <name><surname>Lee</surname><given-names>W. S.</given-names></name>
<article-title>Biflavonoids from torreya nucifera displaying SARS-CoV
3CLpro inhibition</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2010</year>, <volume>18</volume>, <fpage>7940</fpage>&#x02013;<lpage>7947</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2010.09.035</pub-id>.<pub-id pub-id-type="pmid">20934345</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name><surname>Nguyen</surname><given-names>T. T. H.</given-names></name>; <name><surname>Woo</surname><given-names>H. J.</given-names></name>; <name><surname>Kang</surname><given-names>H. K.</given-names></name>; <name><surname>Nguyen</surname><given-names>V. D.</given-names></name>; <name><surname>Kim</surname><given-names>Y. M.</given-names></name>; <name><surname>Kim</surname><given-names>D. W.</given-names></name>; <name><surname>Ahn</surname><given-names>S. A.</given-names></name>; <name><surname>Xia</surname><given-names>Y.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>
<article-title>Flavonoid-mediated inhibition of SARS coronavirus
3C-like protease expressed in Pichia Pastoris</article-title>. <source>Biotechnol. Lett.</source>
<year>2012</year>, <volume>34</volume>, <fpage>831</fpage>&#x02013;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1007/s10529-011-0845-8</pub-id>.<pub-id pub-id-type="pmid">22350287</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name><surname>Jo</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Shin</surname><given-names>D. H.</given-names></name>; <name><surname>Kim</surname><given-names>M.-S.</given-names></name>
<article-title>Inhibition of SARS-CoV 3CL protease by flavonoids
inhibition of SARS-CoV 3CL protease by
flavonoids</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<year>2020</year>, <volume>35</volume>, <fpage>145</fpage>&#x02013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2019.1690480</pub-id>.<pub-id pub-id-type="pmid">31724441</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Ko</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>D. W.</given-names></name>; <name><surname>Kim</surname><given-names>Y. M.</given-names></name>; <name><surname>Kwon</surname><given-names>H.</given-names></name>; <name><surname>Jeong</surname><given-names>H. J.</given-names></name>; <name><surname>Kim</surname><given-names>C. Y.</given-names></name>; <name><surname>Park</surname><given-names>K. H.</given-names></name>; <name><surname>Lee</surname><given-names>W. S.</given-names></name>; <name><surname>Ryu</surname><given-names>Y. B.</given-names></name>
<article-title>Chalcones isolated from Angelica keiskei inhibit
cysteine proteases of SARS-CoV</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<year>2016</year>, <volume>31</volume>, <fpage>23</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3109/14756366.2014.1003215</pub-id>.</mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Zhu</surname><given-names>H. M.</given-names></name>; <name><surname>Niu</surname><given-names>G. J.</given-names></name>; <name><surname>Shi</surname><given-names>E. Z.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Sun</surname><given-names>B.</given-names></name>; <name><surname>Chen</surname><given-names>W. Q.</given-names></name>; <name><surname>Zhou</surname><given-names>H. G.</given-names></name>; <name><surname>Yang</surname><given-names>C.</given-names></name>
<article-title>Synthesis, modification and docking studies of
5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease
inhibitors</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2014</year>, <volume>22</volume>, <fpage>292</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2013.11.028</pub-id>.<pub-id pub-id-type="pmid">24316352</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name><surname>Kim</surname><given-names>Y.</given-names></name>; <name><surname>Lovell</surname><given-names>S.</given-names></name>; <name><surname>Tiew</surname><given-names>K.-C.</given-names></name>; <name><surname>Mandadapu</surname><given-names>S. R.</given-names></name>; <name><surname>Alliston</surname><given-names>K. R.</given-names></name>; <name><surname>Battaile</surname><given-names>K. P.</given-names></name>; <name><surname>Groutas</surname><given-names>W. C.</given-names></name>; <name><surname>Chang</surname><given-names>K.-O.</given-names></name>
<article-title>Broad-spectrum antivirals against 3C or 3C-like
proteases of picornaviruses, noroviruses, and
coronaviruses</article-title>. <source>J. Virol.</source>
<year>2012</year>, <volume>86</volume>, <fpage>11754</fpage>&#x02013;<lpage>11762</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01348-12</pub-id>.<pub-id pub-id-type="pmid">22915796</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name><surname>Shie</surname><given-names>J.-J.</given-names></name>; <name><surname>Fang</surname><given-names>J.-M.</given-names></name>; <name><surname>Kuo</surname><given-names>C.-J.</given-names></name>; <name><surname>Kuo</surname><given-names>T.-H.</given-names></name>; <name><surname>Liang</surname><given-names>P.-H.</given-names></name>; <name><surname>Huang</surname><given-names>H.-J.</given-names></name>; <name><surname>Yang</surname><given-names>W.-B.</given-names></name>; <name><surname>Lin</surname><given-names>C.-H.</given-names></name>; <name><surname>Chen</surname><given-names>J.-L.</given-names></name>; <name><surname>Wu</surname><given-names>Y.-T.</given-names></name>; <name><surname>Wong</surname><given-names>C.-H.</given-names></name>
<article-title>Discovery of potent anilide inhibitors against the
severe acute respiratory syndrome 3CL protease</article-title>. <source>J. Med. Chem.</source>
<year>2005</year>, <volume>48</volume>, <fpage>4469</fpage>&#x02013;<lpage>4473</lpage>. <pub-id pub-id-type="doi">10.1021/jm050184y</pub-id>.<pub-id pub-id-type="pmid">15974598</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name><surname>Kumar</surname><given-names>V.</given-names></name>; <name><surname>Shin</surname><given-names>J. S.</given-names></name>; <name><surname>Shie</surname><given-names>J. J.</given-names></name>; <name><surname>Ku</surname><given-names>K. B.</given-names></name>; <name><surname>Kim</surname><given-names>C.</given-names></name>; <name><surname>Go</surname><given-names>Y. Y.</given-names></name>; <name><surname>Huang</surname><given-names>K. F.</given-names></name>; <name><surname>Kim</surname><given-names>M.</given-names></name>; <name><surname>Liang</surname><given-names>P. H.</given-names></name>
<article-title>Identification and evaluation of potent middle east
respiratory syndrome coronavirus (MERS-CoV) 3CLPro
inhibitors</article-title>. <source>Antiviral Res.</source>
<year>2017</year>, <volume>141</volume>, <fpage>101</fpage>&#x02013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.02.007</pub-id>.<pub-id pub-id-type="pmid">28216367</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name><surname>Ratia</surname><given-names>K.</given-names></name>; <name><surname>Saikatendu</surname><given-names>K. S.</given-names></name>; <name><surname>Santarsiero</surname><given-names>B. D.</given-names></name>; <name><surname>Barretto</surname><given-names>N.</given-names></name>; <name><surname>Baker</surname><given-names>S. C.</given-names></name>; <name><surname>Stevens</surname><given-names>R. C.</given-names></name>; <name><surname>Mesecar</surname><given-names>A. D.</given-names></name>
<article-title>Severe acute respiratory syndrome coronavirus
papain-like-protease: structure of a viral deubiquitinating
enzyme</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2006</year>, <volume>103</volume>, <fpage>5717</fpage>&#x02013;<lpage>5722</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0510851103</pub-id>.<pub-id pub-id-type="pmid">16581910</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name><surname>Devaraj</surname><given-names>S. G.</given-names></name>; <name><surname>Wang</surname><given-names>N.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Tseng</surname><given-names>M.</given-names></name>; <name><surname>Barretto</surname><given-names>N.</given-names></name>; <name><surname>Lin</surname><given-names>R.</given-names></name>; <name><surname>Peters</surname><given-names>C. J.</given-names></name>; <name><surname>Tseng</surname><given-names>C. T. K.</given-names></name>; <name><surname>Baker</surname><given-names>S. C.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>
<article-title>Regulation of IRF-3-dependent innate immunity by the
papain-like protease domain of the severe acute respiratory
syndrome coronavirus</article-title>. <source>J. Biol. Chem.</source>
<year>2007</year>, <volume>282</volume>, <fpage>32208</fpage>&#x02013;<lpage>32221</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M704870200</pub-id>.<pub-id pub-id-type="pmid">17761676</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Jeong</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>M.</given-names></name>; <name><surname>Park</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Park</surname><given-names>H.</given-names></name>; <name><surname>Lee</surname><given-names>S.</given-names></name>; <name><surname>Ryu</surname><given-names>Y. B.</given-names></name>
<article-title>Hirsutenone diarylheptanoids from Alnus Japonica
inhibit papain-like protease of severe acute respiratory
syndrome coronavirus</article-title>. <source>Biol. Pharm. Bull.</source>
<year>2012</year>, <volume>35</volume>, <fpage>2036</fpage>&#x02013;<lpage>2042</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b12-00623</pub-id>.<pub-id pub-id-type="pmid">22971649</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name><surname>Park</surname><given-names>J.-Y.</given-names></name>; <name><surname>Yuk</surname><given-names>H. J.</given-names></name>; <name><surname>Ryu</surname><given-names>H. W.</given-names></name>; <name><surname>Lim</surname><given-names>S. H.</given-names></name>; <name><surname>Kim</surname><given-names>K. S.</given-names></name>; <name><surname>Park</surname><given-names>K. H.</given-names></name>; <name><surname>Ryu</surname><given-names>Y. B.</given-names></name>; <name><surname>Lee</surname><given-names>W. S.</given-names></name>
<article-title>Evaluation of polyphenols from Broussonetia papyrifera
as coronavirus protease inhibitors</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<year>2017</year>, <volume>32</volume>, <fpage>504</fpage>&#x02013;<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2016.1265519</pub-id>.<pub-id pub-id-type="pmid">28112000</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal" id="cit108"><name><surname>Kim</surname><given-names>D. W.</given-names></name>; <name><surname>Seo</surname><given-names>K. H.</given-names></name>; <name><surname>Curtis-Long</surname><given-names>M. J.</given-names></name>; <name><surname>Oh</surname><given-names>K. Y.</given-names></name>; <name><surname>Oh</surname><given-names>J. W.</given-names></name>; <name><surname>Cho</surname><given-names>J. K.</given-names></name>; <name><surname>Lee</surname><given-names>K. H.</given-names></name>; <name><surname>Park</surname><given-names>K. H.</given-names></name>
<article-title>Phenolic phytochemical displaying SARS-CoV papain-like
protease Inhibition from the seeds of Psoralea
Corylifolia</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<year>2014</year>, <volume>29</volume>, <fpage>59</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.3109/14756366.2012.753591</pub-id>.<pub-id pub-id-type="pmid">23323951</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name><surname>Song</surname><given-names>Y. H.</given-names></name>; <name><surname>Kim</surname><given-names>D. W.</given-names></name>; <name><surname>Curtis-Long</surname><given-names>M. J.</given-names></name>; <name><surname>Yuk</surname><given-names>H. J.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zhuang</surname><given-names>N.</given-names></name>; <name><surname>Lee</surname><given-names>K. H.</given-names></name>; <name><surname>Jeon</surname><given-names>K. S.</given-names></name>; <name><surname>Park</surname><given-names>K. H.</given-names></name>
<article-title>Papain-like protease (PLpro) inhibitory effects of
cinnamic amides from Tribulus Terrestris Fruits</article-title>. <source>Biol. Pharm. Bull.</source>
<year>2014</year>, <volume>37</volume>, <fpage>1021</fpage>&#x02013;<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b14-00026</pub-id>.<pub-id pub-id-type="pmid">24882413</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name><surname>Cho</surname><given-names>J. B.</given-names></name>; <name><surname>Lee</surname><given-names>J. M.</given-names></name>; <name><surname>Ahn</surname><given-names>H. C.</given-names></name>; <name><surname>Jeong</surname><given-names>Y. J.</given-names></name>
<article-title>Identification of a novel mall molecule inhibitor
against SARS coronavirus helicase</article-title>. <source>J. Microbiol. Biotechnol.</source>
<year>2015</year>, <volume>25</volume>, <fpage>2007</fpage>&#x02013;<lpage>2010</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1507.07078</pub-id>.<pub-id pub-id-type="pmid">26387819</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name><surname>Lee</surname><given-names>N. R.</given-names></name>; <name><surname>Kwon</surname><given-names>H. M.</given-names></name>; <name><surname>Park</surname><given-names>K.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Jeong</surname><given-names>Y. J.</given-names></name>; <name><surname>Kim</surname><given-names>D. E.</given-names></name>
<article-title>Cooperative translocation enhances the unwinding of
duplex DNA by SARS coronavirus helicase nsP13</article-title>. <source>Nucleic Acids Res.</source>
<year>2010</year>, <volume>38</volume>, <fpage>7626</fpage>&#x02013;<lpage>7636</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq647</pub-id>.<pub-id pub-id-type="pmid">20671029</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name><surname>Tanner</surname><given-names>J. A.</given-names></name>; <name><surname>Zheng</surname><given-names>B. J.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Watt</surname><given-names>R. M.</given-names></name>; <name><surname>Jiang</surname><given-names>J. Q.</given-names></name>; <name><surname>Wong</surname><given-names>K. L.</given-names></name>; <name><surname>Lin</surname><given-names>Y. P.</given-names></name>; <name><surname>Lu</surname><given-names>L. Y.</given-names></name>; <name><surname>He</surname><given-names>M. L.</given-names></name>; <name><surname>Kung</surname><given-names>H. F.</given-names></name>; <name><surname>Kesel</surname><given-names>A. J.</given-names></name>; <name><surname>Huang</surname><given-names>J. D.</given-names></name>
<article-title>The adamantane-derived bananins are potent inhibitors
of the helicase activities and replication of SARS
coronavirus</article-title>. <source>Chem. Biol.</source>
<year>2005</year>, <volume>12</volume>, <fpage>303</fpage>&#x02013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2005.01.006</pub-id>.<pub-id pub-id-type="pmid">15797214</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name><surname>Lee</surname><given-names>J. M.</given-names></name>; <name><surname>Cho</surname><given-names>J. B.</given-names></name>; <name><surname>Ahn</surname><given-names>H. C.</given-names></name>; <name><surname>Jung</surname><given-names>W.</given-names></name>; <name><surname>Jeong</surname><given-names>Y. J.</given-names></name>
<article-title>A novel chemical compound for inhibition of SARS
coronavirus helicase</article-title>. <source>J. Microbiol. Biotechnol.</source>
<year>2017</year>, <volume>27</volume>, <fpage>2070</fpage>&#x02013;<lpage>2073</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1707.07073</pub-id>.<pub-id pub-id-type="pmid">28910865</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name><surname>Yu</surname><given-names>M. S.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Lee</surname><given-names>J. M.</given-names></name>; <name><surname>Kim</surname><given-names>Y.</given-names></name>; <name><surname>Chin</surname><given-names>Y. W.</given-names></name>; <name><surname>Jee</surname><given-names>J. G.</given-names></name>; <name><surname>Keum</surname><given-names>Y. S.</given-names></name>; <name><surname>Jeong</surname><given-names>Y. J.</given-names></name>
<article-title>Identification of myricetin and scutellarein as novel
chemical inhibitors of the SARS coronavirus helicase,
NsP13</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2012</year>, <volume>22</volume>, <fpage>4049</fpage>&#x02013;<lpage>4054</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id>.<pub-id pub-id-type="pmid">22578462</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name><surname>Xiao</surname><given-names>S.</given-names></name>; <name><surname>Tian</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Si</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Zhou</surname><given-names>D.</given-names></name>
<article-title>Recent progress in the antiviral activity and mechanism
study of pentacyclic triterpenoids and their
derivatives</article-title>. <source>Med. Res. Rev.</source>
<year>2018</year>, <volume>38</volume>, <fpage>951</fpage>&#x02013;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1002/med.21484</pub-id>.<pub-id pub-id-type="pmid">29350407</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name><surname>Shibata</surname><given-names>S.</given-names></name>
<article-title>A drug over the millennia: pharmacognosy, chemistry,
and pharmacology of licorice</article-title>. <source>Yakugaku Zasshi</source>
<year>2000</year>, <volume>120</volume>, <fpage>849</fpage>&#x02013;<lpage>862</lpage>. <pub-id pub-id-type="doi">10.1248/yakushi1947.120.10_849</pub-id>.<pub-id pub-id-type="pmid">11082698</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name><surname>Hoever</surname><given-names>G.</given-names></name>; <name><surname>Baltina</surname><given-names>L.</given-names></name>; <name><surname>Michaelis</surname><given-names>M.</given-names></name>; <name><surname>Kondratenko</surname><given-names>R.</given-names></name>; <name><surname>Baltina</surname><given-names>L.</given-names></name>; <name><surname>Tolstikov</surname><given-names>G. A.</given-names></name>; <name><surname>Doerr</surname><given-names>H. W.</given-names></name>; <name><surname>Cinatl</surname><given-names>J.</given-names></name>
<article-title>Antiviral activity of glycyrrhizic acid derivatives
against SARS - coronavirus</article-title>. <source>J. Med. Chem.</source>
<year>2005</year>, <volume>48</volume>, <fpage>1256</fpage>&#x02013;<lpage>1259</lpage>. <pub-id pub-id-type="doi">10.1021/jm0493008</pub-id>.<pub-id pub-id-type="pmid">15715493</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name><surname>Cinatl</surname><given-names>J.</given-names></name>; <name><surname>Morgenstern</surname><given-names>B.</given-names></name>; <name><surname>Bauer</surname><given-names>G.</given-names></name>; <name><surname>Chandra</surname><given-names>P.</given-names></name>; <name><surname>Rabenau</surname><given-names>H.</given-names></name>; <name><surname>Doerr</surname><given-names>H. W.</given-names></name>
<article-title>Glycyrrhizin, an active component of Liquorice Roots,
and replication of SARS-associated coronavirus</article-title>. <source>Lancet</source>
<year>2003</year>, <volume>361</volume>, <fpage>2045</fpage>&#x02013;<lpage>2046</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13615-X</pub-id>.<pub-id pub-id-type="pmid">12814717</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name><surname>Sui</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Murakami</surname><given-names>A.</given-names></name>; <name><surname>Tamin</surname><given-names>A.</given-names></name>; <name><surname>Matthews</surname><given-names>L. J.</given-names></name>; <name><surname>Wong</surname><given-names>S. K.</given-names></name>; <name><surname>Moore</surname><given-names>M. J.</given-names></name>; <name><surname>Tallarico</surname><given-names>A. S. C.</given-names></name>; <name><surname>Olurinde</surname><given-names>M.</given-names></name>; <name><surname>Choe</surname><given-names>H.</given-names></name>; <name><surname>Anderson</surname><given-names>L. J.</given-names></name>; <name><surname>Bellini</surname><given-names>W. J.</given-names></name>; <name><surname>Farzan</surname><given-names>M.</given-names></name>; <name><surname>Marasco</surname><given-names>W. A.</given-names></name>
<article-title>Potent neutralization of severe acute respiratory
syndrome (SARS) coronavirus by a human MAb to S1 protein that
blocks receptor association</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2004</year>, <volume>101</volume>, <fpage>2536</fpage>&#x02013;<lpage>2541</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0307140101</pub-id>.<pub-id pub-id-type="pmid">14983044</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name><surname>Yuan</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>R.</given-names></name>; <name><surname>Ma</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>
<article-title>A systematic review of the active saikosaponins and
extracts isolated from Radix Bupleuri and their
applications</article-title>. <source>Pharm. Biol.</source>
<year>2017</year>, <volume>55</volume>, <fpage>620</fpage>&#x02013;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2016.1262433</pub-id>.<pub-id pub-id-type="pmid">27951737</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name><surname>Cheng</surname><given-names>P.</given-names></name>; <name><surname>Ng</surname><given-names>L.</given-names></name>; <name><surname>Chiang</surname><given-names>L.</given-names></name>; <name><surname>Lin</surname><given-names>C.</given-names></name>
<article-title>Antiviral effects of saikosaponins on human coronavirus
229E in vitro</article-title>. <source>Clin. Exp. Pharmacol. Physiol.</source>
<year>2006</year>, <volume>33</volume>, <fpage>612</fpage>&#x02013;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1681.2006.04415.x</pub-id>.<pub-id pub-id-type="pmid">16789928</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name><surname>Kim</surname><given-names>D. E.</given-names></name>; <name><surname>Min</surname><given-names>J. S.</given-names></name>; <name><surname>Jang</surname><given-names>M. S.</given-names></name>; <name><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name><surname>Shin</surname><given-names>Y. S.</given-names></name>; <name><surname>Park</surname><given-names>C. M.</given-names></name>; <name><surname>Song</surname><given-names>J. H.</given-names></name>; <name><surname>Kim</surname><given-names>H. R.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Jin</surname><given-names>Y. H.</given-names></name>; <name><surname>Kwon</surname><given-names>S.</given-names></name>
<article-title>Natural bis-benzylisoquinoline alkaloids-tetrandrine,
fangchinoline, and cepharanthine, inhibit human coronavirus Oc43
infection of Mrc-5 human lung cells</article-title>. <source>Biomolecules</source>
<year>2019</year>, <volume>9</volume>, <fpage>696</fpage><pub-id pub-id-type="doi">10.3390/biom9110696</pub-id>.</mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal" id="cit123"><name><surname>Ng</surname><given-names>A. W. T.</given-names></name>; <name><surname>Poon</surname><given-names>S. L.</given-names></name>; <name><surname>Huang</surname><given-names>M. N.</given-names></name>; <name><surname>Lim</surname><given-names>J. Q.</given-names></name>; <name><surname>Boot</surname><given-names>A.</given-names></name>; <name><surname>Yu</surname><given-names>W.</given-names></name>; <name><surname>Suzuki</surname><given-names>Y.</given-names></name>; <name><surname>Thangaraju</surname><given-names>S.</given-names></name>; <name><surname>Ng</surname><given-names>C. C. Y.</given-names></name>; <name><surname>Tan</surname><given-names>P.</given-names></name>; <name><surname>Pang</surname><given-names>S. T.</given-names></name>; <name><surname>Huang</surname><given-names>H. Y.</given-names></name>; <name><surname>Yu</surname><given-names>M. C.</given-names></name>; <name><surname>Lee</surname><given-names>P. H.</given-names></name>; <name><surname>Hsieh</surname><given-names>S. Y.</given-names></name>; <name><surname>Chang</surname><given-names>A. Y.</given-names></name>; <name><surname>Teh</surname><given-names>B. T.</given-names></name>; <name><surname>Rozen</surname><given-names>S. G.</given-names></name>
<article-title>Aristolochic acids and their derivatives are widely
implicated in liver cancers in Taiwan and throughout
Asia</article-title>. <source>Sci. Transl. Med.</source>
<year>2017</year>, <volume>9</volume>, <fpage>eaan6446</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aan6446</pub-id>.<pub-id pub-id-type="pmid">29046434</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><name><surname>Zeng</surname><given-names>Z. P.</given-names></name>; <name><surname>Jiang</surname><given-names>J. G.</given-names></name>
<article-title>Analysis of the adverse reactions induced by natural
product-derived drugs</article-title>. <source>Br. J. Pharmacol.</source>
<year>2010</year>, <volume>159</volume>, <fpage>1374</fpage>&#x02013;<lpage>1391</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00645.x</pub-id>.<pub-id pub-id-type="pmid">20233209</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name><surname>Fugh-Berman</surname><given-names>A.</given-names></name>
<article-title>Herb-drug interactions</article-title>. <source>Lancet</source>
<year>2000</year>, <volume>355</volume>, <fpage>134</fpage>&#x02013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(99)06457-0</pub-id>.<pub-id pub-id-type="pmid">10675182</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name><surname>Sutton</surname><given-names>T. C.</given-names></name>; <name><surname>Subbarao</surname><given-names>K.</given-names></name>
<article-title>Development of animal models against emerging
coronaviruses: from SARS to MERS coronavirus</article-title>. <source>Virology</source>
<year>2015</year>, <volume>479&#x02013;480</volume>, <fpage>247</fpage>&#x02013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2015.02.030</pub-id>.</mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name><surname>Sun</surname><given-names>J.</given-names></name>; <name><surname>Zhuang</surname><given-names>Z.</given-names></name>; <name><surname>Zheng</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Wong</surname><given-names>R. L.-Y.</given-names></name>; <name><surname>Liu</surname><given-names>D.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>A.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Xi</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Alshukairi</surname><given-names>A. N.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>F.</given-names></name>; <name><surname>Lai</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>D.</given-names></name>; <name><surname>Wen</surname><given-names>L.</given-names></name>; <name><surname>Zhuo</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>S.</given-names></name>; <name><surname>Dai</surname><given-names>J.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>K.</given-names></name>; <name><surname>Leidinger</surname><given-names>M. R.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Zhong</surname><given-names>N.</given-names></name>; <name><surname>Meyerholz</surname><given-names>D. K.</given-names></name>; <name><surname>McCray</surname><given-names>P. B.</given-names><suffix>Jr.</suffix></name>; <name><surname>Perlman</surname><given-names>S.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>
<article-title>Generation of a broadly useful model for COVID-19
pathogenesis, vaccination, and treatment</article-title>. <source>Cell</source>
<year>2020</year>, <volume>182</volume>, <fpage>734</fpage>&#x02013;<lpage>743</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.06.010</pub-id>.<pub-id pub-id-type="pmid">32643603</pub-id></mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Ren</surname><given-names>L.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Fan</surname><given-names>G.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>W.</given-names></name>; <name><surname>Xie</surname><given-names>X.</given-names></name>; <name><surname>Yin</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Xiao</surname><given-names>Y.</given-names></name>; <name><surname>Gao</surname><given-names>H.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Xie</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>; <name><surname>Jiang</surname><given-names>R.</given-names></name>; <name><surname>Gao</surname><given-names>Z.</given-names></name>; <name><surname>Jin</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Cao</surname><given-names>B.</given-names></name>
<article-title>Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China</article-title>. <source>Lancet</source>
<year>2020</year>, <volume>395</volume>, <fpage>497</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Hou</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Pan</surname><given-names>W.</given-names></name>; <name><surname>Ma</surname><given-names>Q.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Jia</surname><given-names>Z.</given-names></name>; <name><surname>Jiang</surname><given-names>H.</given-names></name>; <name><surname>Kui</surname><given-names>Z.</given-names></name>; <name><surname>Zheng</surname><given-names>K.</given-names></name>; <name><surname>Huang</surname><given-names>S.</given-names></name>; <name><surname>Dai</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Hou</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Zhong</surname><given-names>N.</given-names></name>; <name><surname>Yang</surname><given-names>Z.</given-names></name>
<article-title>Lianhuaqingwen exerts anti-viral and anti-inflammatory
activity against novel coronavirus (SARS-CoV-2)</article-title>. <source>Pharmacol. Res.</source>
<year>2020</year>, <volume>156</volume>, <fpage>104761</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104761</pub-id>.<pub-id pub-id-type="pmid">32205232</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><name><surname>Ledford</surname><given-names>H.</given-names></name>
<article-title>Coronavirus breakthrough: dexamethasone is first drug
shown to save lives</article-title>. <source>Nature</source>
<year>2020</year>, <volume>582</volume>, <fpage>469</fpage><pub-id pub-id-type="doi">10.1038/d41586-020-01824-5</pub-id>.<pub-id pub-id-type="pmid">32546811</pub-id></mixed-citation></ref></ref-list></back></article>